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ABSTRACT

Carbon Monoxide on Demand: Light-Induced CO Release of Flavonols

by

Stacey N. Anderson, Doctor of Philosophy
Utah State University, 2018
Major Professor: Lisa M. Berreau
Department: Chemistry and Biochemistry
The research herein outlines the development of flavonol-based
compounds that when triggered, release carbon monoxide using visible light. Use
of 1) microenvironment effects; 2) modifications to the core structure of 3hydroxyflavone; and 3), zinc stabilization of the anionic form of flavonols, enabled
the development of a family of novel compounds that exhibit a wide array of CO
release reactivity
An initial study of zinc 3-hydroxyflavone compounds provided evidence
that modulation of the microenvironment surrounding the 3-hydroxyflavonolato
moiety influences the quantum yield for light-induced CO release. A hydrophobic
microenvironment gives the highest quantum yield for CO release whereas a
hydrophilic microenvironment slows light-induced CO release. These properties
mimic those found for light-induced CO-release from free flavonols in organic
versus aqueous environments.

iii

A new family of extended flavonols containing an additional fused
aromatic ring were prepared, characterized and evaluated for CO release
reactivity. Members of this family of compounds were tuned to absorb light from
400-600 nm using substituent and heavy atom effects. Notable attributes of this
family of compounds include: 1) ease and high yield of synthesis; 2) solubility in
aqueous dimethyl sulfoxide (DMSO); 3) thermal stability in aqueous, aerobic
media in the absence of light; 4) quantitative CO release reactivity upon
exposure to visible light in air; 5) low toxicity, including for the CO release
product; and 5) fluorescence prior to CO release, which enables tracking of the
compounds within cells. Anaerobic CO release reactivity was also discovered for
the derivative that absorbs lowest energy visible light. Overall, this family of
compound has many properties that make them desirable for use in biological
applications.
Stabilization of the monoanionic form of the extended flavonols via zinc
coordination results in compounds that exhibit red-shifted absorption spectra,
enhanced quantum yields for quantitative CO release, and most notably, solid
state CO release reactivity. Notably, zinc complexes containing two deprotonated
extended flavonols exhibit visible-light induced release of two equivalents of CO
in the presence of air as either solutions in pyridine or as solids. A compound of
this type can be used as an in-situ solid-state source for CO in a palladiumcatalyzed carbonylation reaction.

(326 pages)
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PUBLIC ABSTRACT
Carbon Monoxide on Demand: Light-Induced CO Release of Flavonols
Stacey N. Anderson
Carbon monoxide (CO) is an extremely useful molecule with applications
in industrial manufacturing, synthetic procedures as a C1 building block, and as a
potential pharmaceutical to produce anti-inflammatory effects and vasodilation.
However, the toxicity associated with CO has prevented its full utilization. In
order to safely handle CO, compounds and molecules have been developed that
act as storage materials for the gas. Ideal storage platforms only release CO
upon stimulation via a trigger. Light activation is the most desirable trigger as it
can be regulated in terms of the intensity and the wavelength of light used. The
majority of light-induced CO-storage platforms that have been reported to date
consist of metal carbonyl compounds where CO is bound directly to a metal
center. However, disadvantages inherent to this motif, such as potential toxicity
associated with the metal and lack of characterization of CO release remnant(s),
has pushed the research community to search for alternative CO storage
structures.
The research presented in this dissertation outlines our approach toward
the development of safe-to-handle, light-induced CO release platforms. We use a
flavonol structure similar to those found in fruits and vegetables, such as
quercetin, as a light-induced CO release unit. Through changes in the structure
of the flavonol and its surrounding environment in chemical compounds, we have
found ways to strategically control the light-induced CO release reactivity of the
flavonol. Chemical compounds developed in this project are of interest for
studying the effects of CO in biological systems and applications in synthetic
processes.
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CHAPTER 1

INTRODUCTION

Carbon Monoxide – Overview
Carbon monoxide (CO) (Figure 1-1) is a colorless, odorless, diatomic gas
with a molecular weight of 28.0 g/mol, making it slightly lighter than the average
molecular weight of air (28.8 g/mol). The boiling point of CO is 82 K and the
melting point is 68 K. The bond dissociation energy of this diatomic molecule is
1072 kJ/mol, making it the strongest chemical bond known.1

Figure 1-1. Structural representation of carbon monoxide.

The History of Carbon Monoxide
The toxic properties of carbon monoxide have been known for centuries.
Aristotle (384-322 BC) was the first to record that burning coals produced a toxic
gas. It wasn’t until 1800 that the Scottish chemist William Cumberland
Cruikshank, collecting gases produced by burning charcoal over red-hot metal
oxides, identified an inflammable gas containing carbon and oxygen, CO.2
Exploitation of the poisonous effect of this gas has occurred from antiquity, when
convicts were enclosed in rooms with burning coals to modern times where it

2

was used in large scale at Nazi extermination camps.3 While CO is no longer
utilized as a means of execution, CO poisoning is the most common type of fatal
poisoning in many countries.4 From 1999-2010, there were 5,149 fatalities in the
United States resulting from unintentional CO inhalation.5 The commonality in
everyday life of processes that produce CO, such as the incomplete combustion
of fossil fuels used to heat homes and power automobiles, has caused CO
poisoning to remain relevant.
It is the chemical properties of CO that make it a potent poison. It is
colorless, odorless, and tasteless, earning it the moniker of “silent killer.”
However, its toxicity truly arises from the ability of this gas to irreversibly bind to
metal centers. CO binds to metal centers through σ donation from the highest
occupied molecular orbital (HOMO) on CO (σ*) to an empty d orbital of a metal
and through π back-bonding from a filled d orbital on a metal to the lowest
occupied molecular orbital (LUMO) on CO (π*) (Figure 1-2). For example, this
strong binding of CO to a metal center results in a 230-times stronger affinity for
CO than molecular oxygen (O2) in hemoglobin, the iron-containing metalloprotein
responsible for oxygen-transport.7-9 Since 1921, it has been thought that the
irreversibility of the binding between CO and the iron-center in hemoglobin, which
disrupts O2 delivery to tissues, causes the toxicity of CO. While the binding of CO
to hemoglobin has long been touted as the root of its harmfulness, a subsequent
study reported in 1976 has cast some doubt onto this theory. In this study, dogs
were administered similar concentrations of carbon monoxide through inhalation
or by transfusing the blood with carboxyhemoglobin saturated blood.

3

Figure 1-2. (top) Bonding scheme of carbon monoxide to a metal center;
(bottom) Molecular orbital diagram of carbon monoxide.

Unfortunately, all of the dogs from the inhalation trials died, while none of the
dogs with carboxyhemoglobin saturated blood passed away.6 These results
indicate that the harmfulness of CO is not entrenched in its ability to bind
hemoglobin.

4

Beneficial Biology of Carbon Monoxide
Compared to the long known history of carbon monoxide as a lethal gas,
its beneficial effects were only recently discovered in the 20th century. Seminal
work by Swedish physician Torgny Sjöstrand demonstrated that not only is CO
endogenously produced in humans, but that the oxidative decomposition of heme
was the source.7 Additional work by Coburn and associates demonstrated that
the concentration of CO exhaled was greater than the concentration inhaled,
particularly under physiologically stressful conditions.8 These initial findings
indicated that CO might serve in a beneficial capacity.

Heme Oxygenase
The oxidation catalyzed by the enzyme heme oxygenase (HO) is the ratelimiting step in the degradation of heme in mammals.9 HO catalyzes the oxidation
of the ɑ-meso carbon of the protoporphyrin ring leading to the formation of
carbon monoxide, free iron in the +2 oxidation state, and biliverdin, which is
rapidly converted to bilirubin by biliverdin reductase (Figure 1-3).9-10 Originally
characterized in 1969, this enzyme has two isoforms.11 The isoform constitutively
expressed in tissues, heme oxygenase-2 (HO-2; ~36 kDa, enzyme classification
(EC) 1.14.99.39) functions mainly to regulate necessary levels of free heme.12
The other isoform, heme oxygenase-1 (HO-1; ~32 kDa, EC 1.14.99.3), is
inducible and its regulation and expression is modulated in response to oxidative
stress. Notably, an increasing number of reports demonstrate that HO-1 is over

5

Figure 1-3. Proposed mechanism of COrelease from heme via heme
oxygenase. Adapted from Ref 10 with permission of The Royal Chemical
Society.

6

expressed in a variety of diverse disease states such as cardiovascular,
neurodegenerative, and immune diseases.12-13 The over-expression of HO-1 in a
number of disease states led to the hypothesis that instead of heme being merely
catabolized, that there exists a dynamic equilibrium between destructive and
constructive metabolism of heme.14 In destructive metabolism, the end products
of heme degradation are simply eliminated from the organism, whereas in
constructive metabolism, CO and bilirubin are purposely produced to modulate
vital biological activities.14 This hypothesis is supported by multiple reports of
bilirubin acting as an antioxidant and antinitrosative agent and the ever
increasing body of literature demonstrating the efficacy of CO in the treatment of
numerous disease states in animal models (Table 1.1).15

Cellular Targets of Carbon Monoxide
Carbon monoxide, as a small, gaseous molecule, is freely diffusible
across membranes and does not require transporters.25 Therefore, CO can
rapidly facilitate transformations in the cell. Due to the ease with which CO can
move across membranes, multiple targets both on or near the cellular surface
and within cells have been proposed. The targets proximal to the cellular surface
include heme-containing potassium channels, caveolar nitric oxide synthase
(NOS; the endothelial isoform of NO synthase), surface NADPH oxidase, and
soluble guanylyl cyclase (sGC).26 Distal cellular targets are thought to include
heme-containing transcription factors such as BACH1 and NPAS2 and
mitochondria.26-27 All of the aforementioned targets of CO contain transition
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Table 1-1. Preclinical efficacy of inhaled carbon monoxide. Reprinted by
permission from Macmillan Publishers Ltd: Nature Reviews Drug Discovery (Ref
16), copyright 2010.
Models of disease

CO gas effect

Bacterial infection in
mice

250 ppm improves survival and prevents multipleorgan failure when administered after gram-positive or
gram-negative bacterial infection.16

Sepsis and
endotoxemia in mice,
rats, and pigs

50-250 ppm has anti-inflammatory effects; 250 ppm
improved lung derangement by endotoxin; 10-250
ppm as a pretreatment or as a post-treatment
improves survival, and lung and liver injury in
response to lipopolysaccharides.17
Pulmonary hypertension 250 ppm for 1 hour per day beginning at peak
in rats and mice
hypertension reverses right heart size and pulmonary
arterial pressure; 50 ppm for 21 days prevents
pulmonary hypertension.18
Cardiac graft rejection in 20 ppm prolongs survival; 250-400 ppm for 5-6 days
mice and rats; mouse to prevents rejection.19
rat xenografts
Myocardial infarction in
250-1,000 ppm after injury prevents infarct mass
mice; cardiac ischemia- induced by left anterior descending artery ligation.20
reperfusion injury in rats
Hemorrhagic shock in
250 ppm after resuscitation prevents organ failure.21
mice
Model of acute
250 ppm prevents hypoxia-induced lung inflammation
inflammation in mice;
and injury.22
acute lung injury
Aortic allograft rejection 250-400 ppm prevents transplant vascular stenosis.23
in mice and rats
Lung allograft rejection
250 ppm prevents chronic rejection, ischemia
in mice and rats
reperfusion injury, and apoptosis.24
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metals and while it has been postulated that CO binds to many targets, direct
evidence of CO interaction with cellular components that do not contain transition
metals is lacking.17a, 28 It has been demonstrated that the binding of CO to heme
in proteins alters their conformation and thereby controls activity. In the case of
sGC and NOS, the interaction of CO with the heme moiety leads to an increased
production of cyclic guanosine monophosphate (cGMP) and nitric oxide (NO),
respectively. cGMP and NO are both potent regulators of vascular tone and
neurotransmission.26 CO can also have an inhibitory effect such as with NADPH
oxidase where it interferes with the production of superoxide and in cytochrome c
oxidase in mitochondria, where it is thought to interfere with electron transport
and oxidative phosphorylation thus increasing the production of reactive oxygen
species (ROS).29 While there is a significant amount of evidence implicating
potential cellular targets of carbon monoxide, a clear understanding of the
molecular mechanisms by which CO imparts its biological effects is lacking.
Compounds capable of releasing discrete quantities of CO in a directed manner
have the potential to expand the current working knowledge of this potentially
therapeutic molecule.

Carbon Monoxide-Releasing Molecules (CORMS)
The numerous health benefits observed for administration of low doses of
carbon monoxide, coupled with the dangers of exposure to large amounts of
carbon monoxide, led researchers to develop safe-to-handle storage platforms
for CO. Metal carbonyl compounds (coordination complexes of transition metals
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with CO as ligands) have been utilized in synthetic organic chemistry as CO
sources, such as in palladium-catalyzed carbonylation reactions.30 For this
reason and the commercial availability of metal carbonyls, the first reported
CORMs belong to this class of compounds. CORM-1 (Mn2(CO)10) (Figure 1-4
(left)) and CORM-2 ([Ru(CO)3Cl]2) (Figure 1-4 (middle)) were the first reported
metal carbonyl compounds that exhibited biological effects similar to gaseous
CO.31 Both of these highly lipophilic compounds exhibit CO release upon
dissolution in dimethylsulfoxide (DMSO) albeit through different mechanisms.
CORM-1 was observed to liberate CO only upon illumination while CO was
displaced from CORM-2 through ligand exchange with DMSO and the formation
of tricarbonyl and dicarbonyl monomers. Due to the poor solubility of CORM-1
and CORM-2 in aqueous media, for initial biological studies a cell line was
chosen that displayed resistance to toxic insult, bovine vascular smooth muscle
cells (2% DMSO had no effect on cell viability).32 While the originally reported
IC50 values for CORM-1 and CORM-2 were > 100 μM and > 400 μM respectively,
in subsequent studies, CORM-2 induced cell death at concentrations as low as
10 nM in HL-1 heart cells.33 The CO released from CORM-1 and CORM-2
produced a vasodilatory effect (CORM-2; using isolated aortic ring model;
CORM-1; using isolated rat heart) and the ability to modulate mean arterial
carbonyl compound could deliver CO in vivo and evoke biological responses
spurred the further development of metal carbonyl CORMs by derivatization of
supporting ligands in order to impart desirable characteristics, such as aqueous
solubility.

10

Compounds need to be able to move across lipid bilayers of cell
membranes before entering the blood stream and distributing throughout the
body. Lipophilic compounds, such as CORM-2, are generally able to diffuse
across cell membranes whereas hydrophilic compounds are usually unable to
penetrate the lipid bilayer.34 A method used to overcome the potential toxicity
associated with lipophilic CORM-2, was to increase the hydrophilicity of the
compound through the introduction of a supporting ligand. A little more than a
year after the initial report of CORM-2 was published, the same authors
described a tricarbonylchloro(glycinato)ruthenium(II) compound, CORM-3 (Figure
1-4 (right)).35 The use of deprotonated glycine as a supporting ligand imparted
aqueous solubility to the CORM. Introduction of CORM-3 produced no change in

Figure 1-4. Selected properties of CO-releasing molecules CORM-1, CORM-2
and CORM-3.
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the cell viability of porcine aortic endothelial cells or primate peripheral blood
mononuclear cells in vitro at concentrations up to 500 μM.36 CORM-3 releases
approximately one equivalent of carbon monoxide per equivalent of compound.
In vitro and in vivo experiments using CORM-3 have revealed a host of beneficial
health effects, such as the protection of cardiac cells against oxidative stress,
cardioprotective effects against myocardial ischemia-reperfusion injury, and the
prevention of allograft rejection.35, 37 These findings propelled CORM-3 into use
to probe the biological effects of CO.38 The excellent biological properties
coupled with the low toxicity of CORM-3 indicated that this compound had
potential to enter clinical trials; however, complicated aqueous chemistry in both
the synthesis and its CO release mechanism limited its potential (Figure 1-5(a)).
While the synthesis of CORM-3 is straight forward, with [Ru(CO)3Cl2]2 (CORM-2)
and glycine combined with sodium ethoxide in methanol under nitrogen, the
purification is problematic.39 The IR spectrum of each preparation of CORM-3
displayed stretches at 2137, 2072, and 2058 cm-1, consistent for a fac-Ru(CO)3
group lacking C3 symmetry.39 However, another IR stretch at 1985 cm-1 was
observed consistent with a cis- Ru(CO)2 impurity.39 It was initially assumed that
this impurity was a result of CO loss, until it was realized that
[Ru(CO)3Cl(glycinato)] was reacting with water in the solvent to form
[Ru(CO)2(CO2H)Cl(glycinato)]-.39 This was additionally confirmed through the
observation that CORM-3, upon dissolution in neutral water, lowered the pH to
approximately 3.40 The original report of CORM-3 indicated that despite the
complex having three carbonyl ligands, only 1 equivalent of CO was released per
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equivalent of compound.35 Subsequent studies demonstrated that in addition to
the formation of CO, CORM-3 also released carbon dioxide (CO2), indicating the
presence of other isomer(s) at physiological pH (Figure 1-5(a)).40 It was
subsequently determined that in the pH range of 6-10 one of the carbonyl ligands
has been transformed into CO2 (Figure 1-5(b)).40

A

B

Figure 1-5. Aqueous reactivity of CORM-3: (a) The most probable species
formed at equilibrium at different pHs involving CORM-3, and (b) Water-gas
shift reaction of CORM-3 in solution to rapidly release CO2, creating an open
site at the ruthenium center which enables coordination to histidine residues.
Adapted with permission from Mann, B. E. Organometallics 2012, 31, 57285735. Copyright 2012 American Chemical Society.
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The formation of a metal coordinated CO2 and subsequent loss had an
unintended side-effect for the biological reactivity of this compound. As CO2 has
a much lower affinity towards metal centers as compared to CO, this ligand was
readily lost leaving an open coordination site that was readily filled by binding
with protein residues. In biological environments, the protein bound ruthenium
carbonyl is the actual CO-releasing molecule.38e While CORM-3 remains the
compound of choice for elucidating the biological effects of CO, the complicated
aqueous chemistry has hindered further development as a pharmaceutical.
Ruthenium complexes, in addition to being utilized as CORMs, have been
widely explored as anticancer agents.41 Due to potential of biological activity of
the metal remnants left after CO release occurs from CORM-2 and CORM-3,
various other metal centers have been explored. The majority of CORMs
reported thus far contain iron or manganese, with a few featuring chromium,
rhenium, iridium, tungsten, cobalt, molybdenum, or rhodium.42 However, none of
these compounds have achieved the same level of widespread application as
CORM-2 or CORM-3. These subsequent CORMs all display disadvantages that
have hampered continued development. Metal carbonyl CORMs have two
potential environments that can be tuned for the effective development of a
pharmaceutical candidate; the “CORM sphere,” defined by the number of
carbonyl ligands and the “drug sphere,” defined by the supporting ligands which
can modulate the pharmacological profiles of the compounds (Figure 1-6).43 Key
parameters of the “CORM sphere” are the number of CO molecules that can be
released from the compounds, the kinetics of CO release, and the mechanism
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Figure 1-6. The ligand environment surrounding the metal center in a metalcarbonyl CORM is divided into the “drug sphere” and the “CORM sphere”. The
“drug sphere” is defined by the supporting ligands which can be modulated for
pharmacokinetics. The “CORM sphere” is defined by the stoichiometry and
kinetics of CO release from the metal center. Adapted by permission from
John Wiley and Sons: British Journal of Pharmacology (Ref 42). Copyright
2014.

that leads to CO release. It is important to note that there is no current
consensus in the scientific community as to whether a large or small number of
carbonyl ligands is desirable and whether the CO release rate should be slow or
fast. Rather, it is likely that there is no single answer to these questions and
instead a variety of CORMs should be developed to address specific
pharmacological applications. However, the majority of CORMs reported have
focused almost exclusively on the development of the “CORM sphere” with the
“drug sphere” largely neglected. The development of the “drug sphere” is vital to
the progression of CORMs beyond simply compounds capable of studying the
biological effects of CO to the end goal of real pharmaceuticals. The lack of
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progress on the “drug sphere” of CORMs is likely due to other undesirable
characteristics present in metal carbonyl CORMs. These complexes release CO
through ligand exchange (Figure 1-7). Most have been tested for CO release in
aqueous solution using

Figure 1-7. Metal carbonyl carbon monoxide-releasing molecules (CORMs).
(a) CO release from metal carbonyl CORMs through ligand exchange, where
L’ is either solvent or a biologically relevant coordinating species such as a
histidine residue, and (b) selected examples of metal carbonyl CORMs that
release CO via ligand exchange.

what is known as the myoglobin assay. This assay relies on the different
absorption features of deoxymyoglobin and dicarboxymyoglobin and the reported
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CO release from CORMs using this method was reproducible. However, using
alternative methods to test for CO release, such as gas chromatography or COspecific electrodes, it has been determined that CORMs release very little CO in
solution and it was the presence of an additional component in the myoglobin
assay solution, sodium dithionite, that induced CO release.44 The small amount
of CO release detected for CORMs using gas chromatography or CO-specific
electrodes is thought to be due to the reversibility of the ligand exchange reaction
liberating CO from the metal center.45 The reversibility of the CO release reaction
is an undesirable characteristic of metal carbonyl compounds and has hindered
their further development as CORMs.
While CO release from CORMs in solution via ligand exchange is slow it is
not controllable in terms of location and timing. The spontaneity of the CO
release calls into question the numerous reports of the biological activity of CO
derived from CORMs as the response could have been due to the presence of
CO, the CORM, the metal-containing fragment remaining after CO release, or a
combination of all of these things. Additionally, for the majority of CORMs
reported no information regarding the product(s) remaining after CO release is
available. The majority of CORMs contain redox active metal centers. Once CO
has been fully liberated, an open coordination site at the metal center is formed.
These remnants have the potential to be extremely toxic via the formation of
reactive radical species from components common to biological environments,
such as O2. However, as the metal-containing compound(s) formed post CO
release are rarely characterized or their toxicity examined, biologically adverse
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reactions can only be estimated at this point. The numerous disadvantages
associated with metal carbonyl CORMs have hindered their development as
pharmaceutical pro-drugs.

Triggered Carbon Monoxide-Releasing Molecules
Since CORMs serve as a storage platform for the biologically active agent
CO, the trigger mechanism is a fundamental aspect of the compounds. As noted
above, CORMs, such as CORM-3, liberate CO through ligand exchange, which
imparts the disadvantage of the lack of temporal control and site-specific delivery
of CO. In order to side-step this problem, CORMs have been developed that are
stable in solution and only release CO upon stimulation via either an internal
(enzyme triggered; ET-CORMs) or external source (magnetic heating or
photoexcitation; photoCORM). The CORMs reported to date that are able to
release CO when supplied with certain triggers are still almost exclusively metal
carbonyl compounds.

Enzyme Triggered Carbon Monoxide-Releasing Molecules (ET-CORMs)
ET-CORMs (Figure 1-8) were developed as a means of slowing down the
rate of CO release from metal carbonyl CORMs.46 The ET-CORMs developed to
date utilize supporting ligands susceptible to enzymatic degradation and an
Fe(CO)3 “CORM sphere”.46-47 Prior to incubation in the presence of appropriate
enzymes (i.e. esterase or phosphatase), ET-CORMs are stable with respect to
hydrolysis.
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Figure 1-8. Enzyme triggered CO-releasing molecules (ET-CORMs). (A) The
ET-CORMs reported to date, and (B) Proposed CO release mechanism from
ET-CORMs. Adapted by permission from John Wiley and Sons: British Journal
of Pharmacology (Ref 42). Copyright 2014.

The enzymes transform the compounds into highly unstable intermediates that
readily decompose and release CO.48 While it is known that these compounds
release CO, the other products of the reaction are less well defined. The
proposed reaction mechanism involves release of the transformed supporting
ligand as well as Fe3+.46 The potential release of Fe3+ is problematic for the
development of these compounds into pharmaceuticals in that while iron is
essential to life, the storage and regulation is tightly controlled due to its redox
capabilities. Additionally, the classes of enzymes used for these transformations
tend to be ubiquitous and therefore targeting to specific biological sites is
currently unavailable.
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Magnetic Heat Triggered Carbon Monoxide-Releasing Molecules
An alternative and interesting approach to triggering CO release from
CORMs is the use of magnetic heating. Ruthenium carbonyl compounds were
attached to the surface of iron oxide nanoparticles (Figure 1-9).49 These types of

Figure 1-9. Magnetic heat triggered carbon monoxide-releasing molecule. CO
release from ruthenium carbonyl moieties appended to iron oxide
nanoparticles. CO release is triggered using an alternating current magnetic
field (AC field).

compounds seem promising in that magnetic nanoparticles would allow the
compounds to be directed to specific physiological locations by magnetic control.
CO release from the CORM-appended nanoparticle increased two-fold upon
magnetic heating.49 Unfortunately, due to the type of CORM used in this report
(CORM-3 derivative), magnetic heating of the nanoparticle was not necessary for
CO release to occur and acted more as an aid rather than a trigger.49
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Photoinduced Carbon Monoxide-Releasing Molecules (photoCORMs)
The most popular type of trigger used to initiate CO release from CORMs
is light. The use of light as a trigger is popular because it would allow for site
directed CO release. While the photoCORM itself would be systemic, CO release
has the potential to be confined simply by limiting illumination to certain areas of
the body. The earliest CORMs tested, Fe(CO)5 and Mn2(CO)10, fall into this
category, now known as photoCORMs, with CO release occurring only upon
illumination. Due to the strength of the CO-metal bonding interaction, these
photoCORMs required UV-light to initiate CO liberation. The requirement of UVlight is problematic not only due to the harmful nature of UV-light on living
organisms, but also due to its inability to penetrate tissues. The penetration depth
of light is wavelength dependent with visible light having greater penetration
depth as well as being less harmful than UV-light. However, compounds capable
of undergoing photoinduced CO release upon illumination with red light would be
the most desirable as wavelengths in the range of 620 - 910 nm have the
greatest penetration depth due to the lack of biologically relevant species
absorbing in this window (Figure 1-10). Utilizing supporting ligands with specific
properties, metal carbonyl photoCORMs have been developed that are capable
of undergoing photoinduced CO release at wavelengths ≥ 520 nm.51 The design
strategy for the supporting ligands in these compounds employs a combination of
a strong σ-donating ligand like Br-, to destabilize occupied orbitals, and a highly
conjugated ligand with low-lying π* molecular orbitals to further destabilize the
metal carbonyl bonds through a metal-to-ligand (MLCT) charge transfer.52 While
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Figure 1-10. The absorption spectrum of a human hand. The best
transmission through a hand is between approximately 670 nm and 910
nm and from approximately 1050 nm and higher.50 Optical density is
abbreviated O.D. unpublished data of Karl H. Norris, from The Science of
Photobiology, KC Smith, ed., Plenum Press, 1977; p. 400.

these compounds release CO upon illumination with low energy light, as a
consequence of destabilizing the metal carbonyl bonds enough to allow for the
use of red light, they are not entirely stable in solution and will also release CO
through ligand exchange over time (Figure 1-11(b1)).53
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Figure 1-11. Photoinduced carbon monoxide-releasing molecules
(photoCORMs). (a) CO release from metal carbonyl photoCORMs via
illumination where L’ is proposed to be solvent, and (b) selected examples of
metal carbonyl photoCORMs.

Upconverting Nanoparticles (UCNP)
A different method to obtaining compounds capable of using low energy
red light for CO release is the use of an upconverting nanoparticle (UCNP)
together with a photoCORM that requires high-energy visible light (i.e. blue-light).
UCNPs are NaGdF4 nanoparticles doped with ytterbium (20%) as the red-light
absorber and thulium (0.1%) as the blue light emitter (Figure 1-12).54 UCNPs
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Figure 1-12. Electronic absorption spectrum (yellow) of a Mn(I) carbonyl
photoCORM and emission spectrum (blue) of an upconverting nanoparticle.
Reproduced (Ref. 54) with permission of The Royal Society of Chemistry
(RSC) on behalf of the European Society for Photobiology, the European
Photochemistry Association and the RSC.

generate high-energy visible light when multiple Yb3+ ions absorb low energy red
light or near infrared light and transfer energy to Tm3+ thereby populating excited
states that emit higher energy light. The high energy emitted light can then be
absorbed by a photoCORM tethered to the nanoparticle and undergo CO
liberation. UNCPs offer an exciting alternative to achieve CO release from
photoCORMs using low energy light without compromising the stability of the
photoCORM itself, although the biological compatibility of UCNPs has yet to be
determined.
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Organic PhotoCORMs
PhotoCORMs offer a distinct advantage over traditional CORMs in that
CO release can be controlled with the use of photoexcitation. However, in
retaining the metal carbonyl framework as the CORM sphere, photoCORMs
retain the same disadvantage as their earlier predecessors in the potentially toxic
and often uncharacterized metal containing fragments left after CO release. In
reaction to the perceived toxicity of metal carbonyl photoCORMs, CORMs,
and/or the metal-containing byproduct(s) of the photoreaction, several purely
organic compounds capable of undergoing CO release either through
photoreaction or some other mechanism have been recently reported (Figure 113).55 These compounds represent a significant divergence from traditional metal
carbonyl CORMs. Wowever, fundamental disadvantages have hampered their
significant development as well.
The diketone compound (Figure 1-13(a)) exhibits photoinduced COrelease using visible light (λirr = 470 nm) with two equivalents of CO liberated per
equivalent of compound and the production of a fluorescent photoproduct which
could enable tracking of CO liberation in cellular environments.55b However, the
synthesis of the compound requires multiple steps with an overall yield of 19%.
Additionally, the toxicity of the photoCORM and the organic photoproduct has not
been evaluated, and importantly, the diketone moiety, necessary for CO release,
has been shown to hydrate in aqueous media thereby deactivating the COrelease capability.
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Figure 1-13. Proposed mechanism for CO release from the four reported
organic CORMs. (a) photoinduced CO release from a diketonate moiety, (b)
photoinduced CO release from a carboxylate, (c) photoinduced CO release
from a carboxylate BODIPY compound, and (d) the formation of an unstable
intermediate through a Diels-Alder reaction which decomposes to release CO.

The carboxylate compound (Figure 1-13(b)) undergoes photoreaction to
liberate one mole of CO per mole of molecule and is fluorescent.55a While the
toxicity of neither the photoCORM nor the photoproduct has been determined,
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the main disadvantage to this compound is the synthesis needed to produce the
photoCORM. It is generated using a photoreaction; therefore, isolating the
photoCORM before it can undergo further reaction to release CO is problematic
and results in an extremely low yield.
A third organic photoCORM has recently been reported that relies on a
boron dipyrromethene (BODIPY; Figure 1-13(c)) framework.56 Derivatives using
this framework undergo photoinduced CO-release at wavelengths greater than
500 nm with an extended conjugation derivative capable of CO release upon
activation with near-IR light. Additionally, this compound is fluorescent whereas
the photoproduct(s) are not allowing for the potential to track CO release in a
cellular environment. Minimal toxicity was observed for cells (cell viability did not
drop below 50%; neuroblastoma and SH-SY5Y cell lines) at all concentrations
tested (up to 100 μM). An almost quantitative amount of CO was produced from
the photoreaction of the BODIPY carboxylate under anaerobic conditions (87%
yield). However, in aerated solution, the quantity of CO produced decreases
dramatically (44% yield). This is thought to be due to the formation of 1O2, which
then reacts with the starting material, forming a heretofore unidentified species
that is unable to undergo CO release. The efficacy of the lead compound was
also tested on hairless mice which displayed increased carboxyhemoglin levels,
particularly in the liver and kidneys. Unfortunately, the toxicity of the organic
photoproducts was not tested. This was probably due to the fact that a mixture of
products is generated, only two of which have been identified as 2-methylpyrrole
and 2H-pyrrole-4-carbaldehyde.
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A fourth compound that doesn’t require an external trigger to release CO
has also been reported (Figure 1-13(d)). This organic CORM is produced in situ
via a Diels-Alder reaction and subsequently decomposes to produce CO and an
aromatic organic product.55c Cytotoxicity assays of the reactants necessary to
form the CORM and the CO release product were examined and one of the
reactants displayed a relatively high toxicity (IC50 12.5 μM) while the other
reactant was minimally toxic (IC50 1 mM). The organic CO release product was
non-toxic at all concentrations tested (0.78 - 100 μM). Unfortunately, this CO
release system utilizes an in situ bimolecular process that could be severely
hampered in the complex environments of biological organisms. While organic
compounds may represent the future of CO-releasing materials for use as
possible therapeutics, those described above have limitations that hamper their
continued development.

Alternative Platforms for Carbon Monoxide Release
A notable alternative to metal carbonyl or organic compounds capable of
undergoing CO release reactions either triggered or through ligand exchange is
CORM-A1 and derivatives thereof (Figure 1-14(a)).57 CORM-A1 is a water
soluble sodium boranocarbonate compound (Na2[H3BCO2]) that decomposes to
release CO upon interaction with protons. The slow, pH-dependent liberation of
CO (t½ 27.06 min. at pH 7.4, 37 °C) has been considered key for the therapeutic
effects observed in a variety of in vitro tests and in vivo animal disease models.58
Prior to its use as a CORM, CORM-A1 was utilized as a key component of the
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Figure 1-14. Alternative CO release platforms to metal carbonyl complexes
and organic compounds. (a) pH-dependent CO release from sodium
boranocarbonate (CORM-A1), and (b) Iron(III) terephthalate metal organic
framework (MOF) utilized for CO storage; viewed along the a axis (left), c axis
(middle), and one of the μ3-oxo-bridged timeric unit made of iron octahedrons
and terephthalate linkers (right). Empty circles represent terminal ligands, iron
atoms are displayed as light gray spheres, oxygen atoms as gray spheres and
carbon atoms as black spheres. Reproduced by permission from John Wiley
and Sons: Chemistry - A European Journal (Ref. 62). Copyright 2013.

IsoLink kit that in situ, reduces [99mTc(O4)]- to [99mTc(CO)3]+ for use in
radiopharmaceutical diagnostics.59 Additionally, the first biological studies of this
compound were performed in the 1990s well before the beneficial health effects
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of CO were recognized.60 While the CO release from CORM-A1 cannot be
controlled in terms of location and timing, the main disadvantage of this
compound likely comes from its hydride donor character, with a reducing
capability equivalent to that of sodium borohydride (Na[BH4]).61
An additional alternative to traditional CORMs has been reported in the
form of two metal organic frameworks (MOFs). MOFs are porous coordination
polymers constructed from metal nodes and organic linkers. The MOFs reported
as CO storage and release platforms are comprised of iron in the +3 oxidation
state and dicarboxylate, terephthalate linkers (Figure 1-14b).62 In order to load
CO into the MOF, an activation process is required to remove non-bridging
ligands, such as water and chloride, from the iron centers. This process involves
heating the MOF above 100 °C in a CO gas stream. CO is released from the
platforms via decomposition of the MOF in physiological media. Neither the
toxicity of the MOFs nor the decomposition products were reported. However, it
is particularly troubling that the decomposition products were not characterized at
all. While iron is a biologically required metal ion, its storage is highly controlled
as free iron ions are capable of undergoing reactions to produce compounds that
are extremely damaging, such as through Fenton reactions. Additionally, the
amount of CO loaded and released from the MOFs is unknown, which is
extremely problematic for a compound that is therapeutic in low doses and
extremely toxic at high concentrations.
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The Future of CORMs
Since discovering the potential health benefits of low doses of CO, a
considerable number of storage and release platforms for this small gaseous
molecule have been developed. However, none of the compounds or materials
developed to date represents viable constructs for further development into
pharmaceuticals. It is clear that the field of CORMs needs a revolutionary future
direction verses a continued investment in the evolutionary development of the
previously described CORMs. Nature has the potential to serve as inspiration for
a new direction. In higher organisms, the enzyme heme oxygenase
endogenously produces CO through the breakdown of hemoglobin. This process
can be visually monitored through bruise healing. The utilization of hemoglobin or
hemoglobin-like compounds as CORMs could be problematic as it would rely on
pre-existing enzymes for CO release and could potentially lead to the destruction
of naturally occurring hemoglobin to restore homeostasis. Bacteria and fungi
utilize enzymes known as quercetin dioxygenases (QDOs) to produce CO
(Figure 1-15). QDOs make use of a class of naturally occurring compounds
called flavonols to yield CO. Flavonols are potent antioxidants found in a variety
of fruits and vegetables and can serve as inspiration for a revolutionary new
class of CORMs.63
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Figure 1-15. Proposed mechanism of CO release from a flavonol in copper
containing quercetin dioxygenase.

Industrial Significance of Carbon Monoxide
Carbon monoxide is used in the production of a wide variety of products
from the purification of metals to the synthesis of chemicals.65 Well known
compounds manufactured using CO include drugs, such as ibuprofen, and
familiar household products such as vinegar, detergents, and plastics.66 It is also
routinely used by workers in small-scale drug discovery companies and in
academic laboratories. Additionally, CO is utilized in atmospheric packaging
systems for meats in order to lower microbial load and extend shelf life.67 The
use of CO gas in industrial processes have become incredibly pervasive to its
low cost and excellent atom economy and is produced (Figure 1-16) by the
megaton (Mt) each year for its multiple applications. The dangers of carbon
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monoxide are well documented and can result in fatal poisoning. The symptoms
of CO poisoning - headache, nausea, vomiting, and dizziness - can be difficult to
recognize as they may be accredited to other maladies (e.g. virus, food

Figure 1-16. Common methods for large-scale industrial production of carbon
monoxide.64

poisoning). In large-scale industrial environments, elaborate and expensive gas
handling systems are incorporated to minimize the risk of workers being exposed
to CO. However, smaller scale facilities and academic environments lack the
resources to invest in such an infrastructure and as such the gas is used under
much less rigorous safety conditions. Recognition by the chemical community
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that this is a severe hazard has led to the consideration of alternative means of
delivering CO into chemical reactions. A general approach has been to develop
molecules that will release CO when triggered.68 To date, the majority of these
compounds are used in an ex situ fashion, meaning that gaseous CO is
produced and then transferred into the reaction chamber.
The most commercially significant CO-release system for use in chemical
synthesis reported to date is the “COgen”/”COware” system (Figure 1-17).

“COgen”/”COware”
• Special two-chamber system
required (non-standard
glassware)
• CO generated via palladium
catalysis in one side;
palladium-catalyzed
carbonylation in other side

COgen

Other CO-release agents used with “COware”:

COware

Figure 1-17. “COgen”/”COware”. Listed on the right are compounds that are
also patented for use as CO-release agents using COware.

This approach involves using chemical compounds to generate CO ex situ and
deliver the gas via diffusion into the catalytic reaction using a two chambered
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system. The utility of this system has been examined on palladium-catalyzed
carbonylation reactions. Reactions of this type were first discovered by Richard
Heck (2010 Nobel Prize winner) and can be visualized as shown in Figure 1-18.

Figure 1-18. Proposed catalytic cycle of a carbonylative Heck reaction
where L is a triphenyl phosphine ligand.

Using a palladium catalyst, two molecules are joined via the formation of two new
bonds on either side of an inserted C=O unit. The broad generality of this
reaction in terms of the compounds that can be coupled make this synthetic
approach incredibly powerful. For example, a palladium-catalyzed carbonylation
reaction is used in the synthesis of ibuprofen.66 However, due to size limitations
with the required glassware, the primary users of “COgen”/”COware” are likely
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small-scale synthetic laboratories (academic and industrial). Notably, this system
is able to deliver stoichiometric quantities of CO and has the ability to incorporate
carbon isotopes in the CO unit.68a-ab, 69
“COgen”/ ”COware” has also demonstrated some drawbacks. These
include: (1) the requirement of the two-chamber glassware that is not common in
most synthetic organic laboratories and must be specially purchased; (2) both
sides of the chamber are heated at the same temperature; and (3) the use of
expensive palladium catalysts in both chambers as both the release of CO from
COgen and the incorporation of CO into the product require palladium catalysts.
A few other compounds have been reported to date that can be used as in situ
CO-release agents (formamides68ai-ap, CHCl3/CsOH68aq, 68as, 70, Mo(CO)668ar, 68atba

), however all require the presence of additional reagents or heat to induce CO

release, which can be problematic with regard to reactivity of substrates. For
example, Mo(CO)6 acts as a reducing agent toward nitro-substituted substrates
and thus limits the substrate scope that can be examined using this CO-release
agent in situ.71
A significant advance for the use of carbon monoxide for the production of
value added compounds would be the development of a safe-to-handle,
heterogeneous, triggered CO-release material that could be used in situ in a
broad array of reactions under a variety of reaction conditions. The importance of
a material that is safe-to-handle cannot be understated as it could expand the
synthetic utility of carbon monoxide to small chemical companies and academic
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environments that may not have the capital to invest in the expensive and
elaborate infrastructure to use CO safely. The heterogeneous nature would
differentiate such a material from CO release agents currently employed and
would be especially advantageous as reaction work-up would only involve
separation of the CO release material via simple filtration. If such a material could
be prepared at low cost and used in standard laboratory glassware, it would be
uniquely useful relative to all other reported CO release compounds.

Conclusions
Carbon monoxide is a small gaseous molecule with a long history of
toxicity. More recently, the importance of CO in human health as well as in a
wide variety of chemical processes has been demonstrated. Due to the everincreasing significance of this small molecule, the development of safe-to-handle,
storage platforms that have properties desirable to the specific application is vital
to the continued advancement of CO both as a pharmaceutical and in the
production of value-added compounds. In the Berreau group, we are interested
in the development and evaluation of novel compounds capable of undergoing
photoinduced CO-release based on the framework of naturally occurring
flavonols. We hypothesized that flavonols could be developed into a new family
of tunable visible light-triggered photoCORMs. In the subsequent chapters of this
dissertation, the following topics will be presented: (1) the effect of
microenvironment on the photoinduced CO release reactivity of zinc-bound 3hydroxyflavonolato ligand; (2) the development and biological properties of a new
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family of flavonols capable of CO release upon illumination with visible light; (3)
the optimization of photochemical efficiency and solid state photoreactivity of zinc
bound flavonolato compounds utilizing a hydrophobic microenvironment; and (4)
the development of zinc bis-flavonolato compounds for use as heterogeneous in
situ CO sources in oxidative palladium catalyzed carbonylation reactions.
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CHAPTER 2
INFLUENCE OF SUPPORTING LIGAND MICROENVIRONMENT ON THE
AQUEOUS STABILITY AND VISIBLE LIGHT INDUCED CO RELEASE
REACTIVITY OF ZINC FLAVONOLATO SPECIES‡

Abstract
The visible light induced CO release reactivity of the zinc flavonolato
complex [(6-Ph2TPA)Zn(3-Hfl)]ClO4 (1) has been investigated in 1:1 H2O:DMSO.
Additionally, the effect of ligand secondary microenvironment on the aqueous
stability and visible light-induced CO release reactivity of zinc flavonolato species
has been evaluated through the preparation, characterization, and examination
of the photochemistry of compounds supported by chelate ligands with differing
secondary appendages, [(TPA)Zn(3-Hfl)]ClO4 (3; TPA = tris-2(pyridylmethyl)amine) and [(bnpapa)Zn(3-Hfl)]ClO4 (4; bnpapa = N,N-bis((6neopentylamino-2-pyridyl)methyl)-N-((2-pyridyl)methyl)amine)). Compound 3
undergoes reaction in 1:1 H2O:DMSO resulting in the release of the free neutral
flavonol. Irradiation of acetonitrile solutions of 3 and 4 at 419 nm under aerobic
conditions results in quantitative, photoinduced CO release. However, the
reaction quantum yields under these conditions are lower than that exhibited by
‡

Coauthored with Mark Nobel, Katarzyna Grubel, Brooks Marshall, Atta M. Arif,
Lisa M. Berreau. Reproduced in a modified format with permission from J. Coord.
Chem., 2014, 67, 4061-4075.
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1, with 4 exhibiting an especially low quantum yield. Overall, the results of this
study indicate that positioning a zinc flavonolato moiety within a hydrophobic
microenvironment is an important design strategy toward further developing such
compounds as CO release agents for use in biological systems.

Introduction
The development of carbon monoxide releasing molecules (CORMs) for
use in biological systems is of significant current interest.[1-7] This is due to the
identification of several beneficial health effects associated with the controlled
administration of small amounts of CO. These include anti-inflammatory and
antiapoptotic effects, as well as the promotion of vasodilation and protection of
tissues against reperfusion injury.[4] To date, the vast majority of CORMs
reported are low-valent metal carbonyl compounds. These compounds, while
exhibiting a number of favorable properties for biological use, also have
limitations, including the fact that many cannot be controlled in terms of the
location and timing of the CO release. In this regard, metal-carbonyl based
CORMs that exhibit photoinduced CO release reactivity (photoCORMs) using low
energy visible light are of particular current interest.[1, 2, 8-13] However, an
important unresolved issue for these compounds is the potential for toxicity
resulting from the remaining metal/ligand fragment following CO release.
We are interested in developing new types of photoinduced CO-releasing
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molecules that are not based on the metal-carbonyl unit. In this regard, it is
known that metalloenzymes termed quercetin dioxygenases (QDOs) catalyze the
oxidative breakdown of flavonols to give CO and an O-benzoylsalicylic acid (Obs) derivative as products.[14] In studies of synthetic complexes of relevance to
the enzyme/substrate (ES) adducts of QDOs, we discovered stoichiometric, UVlight induced CO-release reactivity for a family of divalent metal complexes ([(6Ph2TPA)M(3-Hfl)]X, M = Zn(II), Co(II) Cu(II), Ni(II), Mn(II); X = ClO4- or OTf-)
containing a deprotonated 3-hydroxy-4-flavonolato ligand (3-Hfl) and supported
by a tetradentate N4-donor chelate ligand (6-Ph2TPA, N,N-bis((6-phenyl-2pyridyl)methyl)-N-((2-pyridyl)methyl)amine).[15,16] For these complexes, CO
release occurs via a photoinduced, dioxygenase-type reaction akin to the thermal
reaction catalyzed by QDOs. The reaction observed for [(6-Ph2TPA)Zn(3Hfl)]ClO4 (1) in CH3CN under O2 is shown in Scheme 2-1. The quantum yield for
this reaction with irradiation at 300 nm (ɸ = 0.09(1)) [16] is an order of magnitude
higher than that exhibited by structurally similar Mn(II), Co(II), Ni(II), Cu(II)
complexes (ɸ = 0.005-0.008).[16] This is the result of quenching of the excited
state in the complexes containing an open-shell dn metal ion. The photoinduced
reaction pathway for O2-dependent CO-release from [(6-Ph2TPA)Zn(3-Hfl)]ClO4
(1) likely involves either the coordinated flavonolato ligand acting as a
photosensitizer to generate singlet oxygen (1O2), which can then react with
ground-state 1, or an excited state singlet to triplet conversion of the zinc-bound
flavonolato anion, which may then undergo reaction with 3O2.
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Scheme 2-1. Photoinduced CO release from zinc-bound flavonolato.

The initial studies outlined above have led us to further examine the
chemistry of zinc flavonolato species. In the results described herein, we have
evaluated the visible light induced CO release reactivity of 1 in 1:1 H2O:DMSO.
Additionally, we have evaluated how the nature of the supporting chelate ligand,
particularly with respect to the secondary microenvironment surrounding the zinc
flavonolato moiety, influences the aqueous stability and visible light induced COrelease reactivity of this unit. These combined results provide evidence that
maintaining a hydrophobic microenvironment surrounding the zincflavonolato
moiety is key toward further developing such compounds for use in biological
systems.
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Experimental

Chemicals and reagents
All chemicals and reagents were obtained from commercial sources and
used as received unless otherwise noted. Anaerobic procedures were performed
under N2 in either a VAC Atmospheres or an MBRAUN Unilab glovebox.
Solvents for glovebox use were dried according to published methods and
distilled under N2.[17] The preparation of the chelate ligands tris(2pyridylmethyl)amine (TPA) [18] and N,N-bis((6-neopentylamino-2-pyridyl)methyl)N-((2-pyridyl)methyl)amine (bnpapa) [19] was accomplished as previously
reported. [(6-Ph2TPA)Zn(3-Hfl)]ClO4 (1) was prepared as previously described.[20]

Physical methods
1

H NMR spectra were collected using a JEOL ECX-300 or Bruker ARX-

400 spectrometer. Chemical shifts (in ppm) are referenced to the residual solvent
peaks in CD2HCN (1H: 1.94 (quintet) ppm; 13C: 1.39 (quintet) ppm). J values are
given in Hz. IR spectra were recorded on a Shimadzu FTIR-8400 spectrometer
as KBr pellets. UV-vis spectra were recorded at ambient temperature using a
Hewlett-Packard 8453A diode array spectrophotometer. Emission spectra were
collected using a Shimadzu RF-5301PC spectrofluorophotometer using a slit
width of 4 nm with the excitation wavelength corresponding to the absorption
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maximum of the complex above 400 nm. A Rayonet photoreactor equipped with
RPR-4190A lamps was used for all photochemical reactions. Quantum yields
were determined using potassium ferrioxalate actinometry as a standard to
measure photon flux.[21-23] Carbon monoxide was quantified as previously
described.[16] Mass spectral data was collected at the Mass Spectrometry
Facility, University of California, Riverside. Elemental analyses were performed
by Atlantic Microlab, Inc., Norcross, GA using a PE2400 automatic analyzer.
Caution! Perchlorate salts of metal complexes with organic ligands are
potentially explosive. Only small amounts should be prepared and these should
be handled with great care.[24]

Photoreactivity of 1 in 1 : 1 H2O : DMSO using visible light
A solution of 1 (0.1 mmol in 10 mL 1:1 H2O:DMSO) was placed in a 100
mL round bottom flask under air. This solution was irradiated at 419 nm until the
reaction was determined to be complete as evidenced by loss of the 420 nm
absorption band. CO release was determined to be quantitative by GC.
Performing the same reaction in 1:1 D2O:d6-DMSO confirmed the formation of 2
via comparison of the 1H NMR features with those previously reported for this
compound.[15]
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Preparation of zinc flavonolato complexes
[(TPA)Zn(3-Hfl)]ClO4 (3). Under a N2 atmosphere, a methanol solution (2
mL) of Zn(ClO4)2×6H2O (40 mg, 0.11 mmol) was added to solid TPA (39 mg, 0.13
mmol) and the solution was stirred until the chelate ligand had dissolved. The
resulting mixture was combined with a methanol solution (2 mL) containing 3hydroxyflavone (32 mg, 0.13 mmol) and Me4NOH×5H2O (24 mg, 0.13 mmol). This
mixture was stirred for 4 hours at ambient temperature. The solvent was then
removed under reduced pressure and the residual solid dissolved in CH2Cl2. The
CH2Cl2 solution was filtered through a Celite/glasswool plug and the product was
precipitated via the addition of excess hexanes (40 mL). The isolated solid was
dried under reduced pressure. Recrystallization via Et2O diffusion into CH3CN
yielded yellow crystals suitable for X-ray crystallography (74 mg, 80%). Anal.
Calcd. for C33H27ClN4O7Zn (%): C, 57.24; H, 3.93; N, 8.09. Found: C, 57.55; H,
4.00; N, 7.84. 1H NMR (CD3CN, 300 MHz) δ 8.9 (br, 2H), 8.80-8.45 (br, 4H),
8.03-7.77 (br, 3H) 7.76-7.59 (m, 4H), 7.58-7.20 (m, 8H), 4.79-4.02 (bs, 6H) ppm;
UV-vis (CH3CN), nm (ε, M-1cm-1) 415 (19000), 313 (7600); FTIR (KBr, cm-1) 1558
(nC=O), 1088 (νClO4), 619 (νClO4); MALDI-MS, m/z (relative intensity)
C33H27N4O3Zn: Calcd: 591.1369; Found: 591.1385 ([M-ClO4]+, 100).
[(bnpapa)Zn(3-Hfl)]ClO4 (4). Prepared using a synthetic procedure similar
to that employed for the preparation of [(6-Ph2TPA)Zn(3-Hfl)]ClO4.[20]
Recrystallization of the crude product via slow Et2O diffusion into CHCl3 yielded
yellow crystals suitable for single crystal X-ray crystallography (87 mg, 75%).
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Anal. Calcd. for C43H49ClN6O7Zn(%): C, 59.86; H, 5.72; N, 9.74. Found: C, 60.05;
H, 6.02; N, 9.38. 1H NMR (CD3CN, 300 mHz) δ 8.87 (br, 2H, N-H), 8.73 (d, J =
7.9 Hz, 1H), 8.10 (d, J = 7.9 Hz, 1H), 7.82-7.63 (m, 5H), 7.61-7.52 (m, 2H), 7.507.32 (m, 4H), 7.30-7.18 (m, 2H), 6.49 (d, J = 7.2 Hz, 2H), 6.36 (d, J = 8.6 Hz,
2H), 4.52 (d, J = 14.3 Hz, 2H), 4.31 (s, 2H), 4.23 (d, J = 14.3 Hz, 2H), 2.87 (d, J =
7.2 Hz, 1H), 2.83 (d, J = 7.5 Hz, 1H), 2.62 - 2.48 (m, 2H), 0.63 (s, 18H) ppm; UVvis (CH3CN), nm (ε, M-1cm-1) 401 (16500), 321 (18400); FTIR (KBr, cm-1) 3307
(br, νN-H), 1560 (nC=O), 1085 (νClO4), 620 (νClO4); MALDI-MS, m/z (relative
intensity) C43H49N6O3Zn: Calcd: 761.3152; Found: 761.3120 ([M-ClO4]+, 100).

Photoreactivity of [(L)Zn(3-Hfl)]ClO4 (L = TPA (3) or bnpapa (4))

Identification of [(L)Zn(O-bs)]ClO4 products (O-bs = O-benzoylsalicylato)
A solution of each complex ([(L)Zn(3-Hfl)]ClO4 (L = TPA (3) or bnpapa (4);
0.1 mmol in 10 mL CH3CN) was placed in a 100 mL round bottom flask under air.
Each solution was irradiated at 419 nm until the reaction was determined to be
complete as evidenced by loss of the ~400-415 nm absorption band. The solvent
was then removed under reduced pressure and the residual solid was
redissolved in a minimal amount of CH3CN (ca. 2 mL). Addition of excess Et2O
(~20 mL) resulted in the deposition of a beige solid that was dried in vacuo to
give the reported yields for [(TPA)Zn(O-bs)]ClO4 (5) and [(bnpapa)Zn(O-bs)]ClO4
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(6). 18O2-labeled samples were prepared by transferring aliquots of 18O2 into
frozen CH3CN solutions of 3 and 4 in 100 mL solvent transfer flasks, followed by
irradiation and work-up as described above.
[(TPA)Zn(O-bs)]ClO4 (5). Yield: 91%. 1H NMR (CD3CN, 300 MHz) δ 8.74
(s, 3H), 8.02 (td, J1= 7.8, J2 = 1.5, 4H), 7.73-7.23 (m, 14 H), 4.13 (s, 6H); FTIR
(KBr, cm-1) 1761 (νC=O); 18O2 sample: MALDI-MS, m/z (relative intensity);
C32H27N416O218O2Zn: Calcd. 599.1403. Found: 599.1407 ([M-ClO4]+; 27).
[(bnpapa)Zn(O-bs)]ClO4 (6). Yield: 88%. 1H NMR (CD3CN, 300 MHz) δ
8.57 (s, 1H), 8.19 - 7.00 (m, 14H), 6.65 (s, 2H), 6.47 (d, J = 6.4 Hz, 2H), 4.06 (s,
2H), 3.81-3.62 (m, 4H), 3.12-2.87 (m, 6H), 0.85 (s, 18H); FTIR (KBr, cm-1) 1743
(νC=O); MALDI, m/z (relative intensity); C42H49N616O4Zn: Calcd: 765.3101.
Found: 765.3124 ([M-ClO4]+, 30). 18O2 sample: MALDI-MS, m/z (relative
intensity); C42H49N616O218O2Zn: Calcd. 769.3186. Found: 769.3196 ([M-ClO4]+,
58).

Dark control reactions
Solutions of 3 and 4 in CD3CN (~0.02 M) were prepared in air under
minimal red light and placed in NMR tubes. Each NMR tube was then covered
with foil and irradiated at 419 nm for a specific amount of time (3: 24 h; 4: 96 h)).
For both, evaluation of the solution by 1H NMR indicated that no reaction had
occurred. These results indicate that the CO-release reactions of 3 and 4 are
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photoinduced and not thermal processes.

Anaerobic control reactions
Solutions of 3 and 4 in CD3CN (~0.02 M) were prepared under N2 in a
glove box and placed in NMR tubes. Each NMR tube was then irradiated at 419
nm for a specific amount of time (3: 24 h; 4: 96 h)). For both, evaluation of the
solution by 1H NMR indicated that no reaction had occurred. These results
indicate that the CO release reactions of 3 and 4 require O2.

X-ray crystallography

Data collection and refinement
Single crystals of 3×CH3CN and 4×CHCl3 were each mounted on a glass
fiber using viscous oil and then transferred to a Nonius Kappa CCD
diffractometer for data collection using Mo Ka radiation (l = 0.71073 Å). Methods
of unit cell refinement and determination of final cell constants have been
previously reported.[25] The data collected for each compound was corrected for
Lorentz, polarization, and absorption effects using DENZO-SMN and
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SCALEPAC.[26] Each structure was solved using a combination of direct methods
and heavy atoms using SIR 97.

Structure solution
Complexes 3×CH3CN and 4×CHCl3 crystallize in the space groups P21/n
and P-1, respectively. All non-hydrogen atoms were refined with anisotropic
displacement coefficients. All hydrogen atoms were assigned isotropic
displacement coefficients (U(H) = 1.2U(C) or = 1.5U(Cmethyl)) and their
coordinates were allowed to ride using SHELXL97.[27] In 3×CH3CN the
perchlorate anion exhibits disorder of three of the oxygen atoms. In 4×CHCl3,
hydrogen bonding interactions are found between the secondary amine NH units
of O(1) of the coordinated flavonolato ligand.

Results and discussion

Spectroscopic features and photoinduced CO-release reactivity of 1 in 1:1
H2O:DMSO

Absorption and emission properties

63

Compound 1 is not soluble in water, but exhibits good solubility in 1:1
H2O:DMSO. As shown in Figure 2-1(a), 1 exhibits a ~420 nm absorption band in
this solvent mixture which is similar to the spectrum produced in CH3CN.
Evaluation of this solution after 24 h of storage at ambient temperature in the
dark revealed no spectral changes. Hence, the compound is stable in an
aqueous environment under dark, aerobic conditions.

Figure 2-1. (a) Absorption spectra of 1 in CH3CN and 1:1 DMSO:H2O. (b)
Fluorescence emission spectra of 1 in CH3CN and 1:1 DMSO:H2O generated
upon excitation at 420 nm.
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Photoinduced CO-release reactivity of 1 using visible light
Irradation of 1 in 1:1 H2O:DMSO using visible light (419 nm) under air
results in the release of one equivalent of CO (Table 2-1) and the formation of
[(6-Ph2TPA)Zn(O-bs)]ClO4 (2). The quantum yield for this reaction (ɸ = 0.006) is
only two-fold lower than that observed in acetonitrile under similar conditions.

Table 2-1. Reaction quantum yields and CO quantification for the visible light
induced aerobic CO release reactions of 1, 3, and 4.
Solvent
ɸa,b
CH3CN
0.012(2)
1:1 H2O/DMSO
0.006(1)
3
CH3CN
0.0060(9)
4
CH3CN
0.000269(8)
a
b
lirr = 419 nm; Average of three independent determinations.
Compound
1

Eq. COb
0.99(2)
0.977(6)
0.99(1)
1.00(4)

Synthesis and characterization of 3 and 4
To investigate the influence of the chelate ligand on the aqueous stability
and photoinduced CO release reactivity of 1, analogs were prepared and
characterized using tetradentate chelate ligands that either lacked secondary
appendages (TPA) or contained hydrogen bond donor moieties (bnpapa).
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Synthesis of 3 and 4.
Admixture of the appropriate chelate ligand (TPA or bnpapa) with
Zn(ClO4)2×6H2O, followed by treatment with a solution containing a mixture of 3hydroxyflavone (3-HflH) and Me4NOH×5H2O, respectively, produced yellow
reaction mixtures. After workup, each complex was isolated as a crystalline solid
(Scheme 2-2) in 75-80% yield. The zinc flavonolato complexes [(TPA)Zn(3Hfl)]ClO4 (3) and [(bnpapa)Zn(3-Hfl)]ClO4 (4) were characterized by elemental
analysis, X-ray crystallography, absorption and emission spectroscopy, IR, 1H
NMR, and mass spectrometry.

Scheme 2-2. Synthesis of 3 and 4.
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Elemental analysis
The elemental analysis data for bulk samples of 3 and 4 is consistent with
the dried powder form of each complex having an analytical formulation that
lacks the CH3CN and CHCl3 solvate molecules, respectively, that are found in the
X-ray structures of these complexes (vide infra).

X-ray crystallography
Representations of the cationic portions of 3·CH3CN and 4·CHCl3 are
shown in Figure 2-2. Details of the X-ray data collection and refinement are
givenin Table A-1. Bond distances and angles within the cationic portions of
these structures are given in Table A-2. The Zn(II) centers in the cationic portions
of 3·CH3CN and 4·CHCl3 have a coordination number of six and exhibit a
distorted psuedoctahedral geometry. This differentiates the solid-state structures
of these cations from that found for 1×2CH2Cl2, which exhibits an overall
coordination number of five, a distorted square pyramidal geometry (t = 0.35) [28],
and a dissociated phenyl-appended pyridyl donor. All three complexes exhibit
bidentate coordination of the flavonolato ligand, with the shorter zinc-oxygen
distance in each involving the deprotonated hydroxyl donor (1×2CH2Cl2: 1.951(2)
Å; 3·CH3CN: 1.9834(17) Å; 4·CHCl3: 2.020(2) Å) and a longer bond to the ketone
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Figure 2-2. Thermal ellipsoid (50%) representations of the cationic portions of (a)
3 and (b) 4. Hydrogen atoms except those of the N-H units have been omitted for
clarity.

oxygen (1×2CH2Cl2: 2.1175(19) Å; 3·CH3CN: 2.1373(17) Å; 4·CHCl3: 2.159(2) Å).
The DZn-O value is similar in this family of compounds, with all being found in the
range of 0.14-0.17 Å. Generally, the observed bond lengths and DZn-O values for
the complexes described herein fall within the ranges of other previously reported
zinc flavonolato complexes (1.98-2.24 Å; DZn-O = 0.16-0.26 Å).[29-31] Notably, both
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Zn-O distances elongate across the supporting chelate ligand series in the order
6-Ph2TPA < TPA < bnpapa. The same trend is found in the average Zn-Npy
distance, which increases from 2.11 Å in the 6-Ph2TPA-ligated complex to 2.16
and 2.17 Å in the TPA- and bnpapa-ligated complexes, respectively. This latter
trend is likely due to the effect of overall coordination number, as well as the
presence of the secondary amine donor appendages in the bnpapa-ligated
system, which introduces additional steric hindrance.
Examination of the bond lengths within the coordinated flavonolato ligand
shows that all three complexes exhibit a similar slight elongation (~0.02 Å) of the
ketone carbonyl C-O bond and a slight contraction (~0.02-0.04 Å) of the C-O
bond of the hydroxyl donor relative the distances found in the free flavonol
(1.232(3) and 1.357(3) Å, respectively).[32] The C=C bond distance within the
flavonolato chelate ring is similar in all three complexes (1×2CH2Cl2: 1.458(4) Å;
3·CH3CN: 1.439(3) Å; 4·CHCl3; 1.460(4) Å) and is elongated relative to that
found in the free flavonol (1.363(4) Å).[32] Overall, the bond lengths within the
flavonolato ligands of this series of complexes are only minimally affected by the
nature of the supporting chelate ligand.
In 4·CHCl3, hydrogen bonds are found between the two secondary amine
NH units of the bnpapa chelate ligand and O(1) of the coordinated flavonolato
ligand. The heteroatom distances (2.93 and 3.01 Å) and corresponding N-H…O
angles (136.5° and 155.2°) associated with these interactions suggest that these
are moderate hydrogen bonds with individual energies of 4-14 kcal/mol.[33]
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Spectroscopic characterization
Powdered samples of 3 and 4 were characterized by solid state IR
spectroscopy, and solutions of these complexes were examined using 1H NMR,
mass spectrometry, and absorption and emission spectroscopy.

Infrared spectra
The solid-state FTIR spectra of 1, 3 and 4 contain a nC=O vibration at
~1550-1560 cm-1 for the coordinated ketone moiety, as well as vibrations for the
perchlorate counterion. For 4, a broad vibration at ~3300 cm-1 is consistent with
the presence of the secondary amine appendages and their involvement in
hydrogen bonding interactions with the coordinated flavonolato ligand.

1

H NMR
Complex 1 exhibits a 1H NMR spectrum with the appropriate number of

signals for Cs symmetry in CD3CN (Figure A-1). This is consistent with
coordination of all of the nitrogen donors of the 6-Ph2TPA ligand in the solution
structure of the complex. Complex 3 exhibits broadened 1H NMR signals
suggestive of fluxional behavior when dissolved in CD3CN (Figure A-2) or CD2Cl2
(Figure A-3(a)) at 25 oC. The broadened benzylic methylene resonance at ~4.4
ppm suggests that the fluxionality could involve dissociation and reassociation of
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pyridyl donors (Figure A-3). This type of behavior has been previously identified
in d10 Cu(I) complexes of TPA.[34] Cooling of a CD2Cl2 solution of 3 from 25 oC to 53.5 oC (Figure A-3(a-h)) produced a sharpening of some of the resonances that
was reversible upon returning the sample to room temperature. Further
evaluation of the 1H NMR properties of 3 are underway. Complex 4 exhibits 1H
NMR features (Figure A-4) consistent with the cationic portion having Cs
symmetry. 1H NMR spectra of photoproducts 5 (Figure A-5) and 6 (Figure A-6)
were as expected.

Mass spectrometry
Complexes 3 and 4 as well as their photoproducts, 5 and 6, respectively,
were evaluated by MALDI mass spectrometry (Figures A-7 – A-12). Each
exhibits an isotopic cluster molecular ion that is consistent with the proposed
cationic formulation. 18O2 incorporation into 5 and 6 was evaluated by MALDI
mass spectrometry. Each exhibits an isotopic cluster molecular ion consistent
with the incorporation of both atoms of 18O2 into the compounds.

Absorption and emission spectra in CH3CN and 1:1 H2O:DMSO
Free 3-hydroxyflavone (3-HflH) exhibits absorption bands at 304 and 343 nm,
respectively, when dissolved in methanol.[35,36] The lower energy feature (Band I)
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is assigned to a π®π* HOMO to LUMO transition, while the higher energy Band
II corresponds to a HOMO-1 to LUMO transition. The absorption spectra of 3 and
4 in CH3CN are shown in Figure 2-3. The Band I absorption feature for 1, 3 and 4
is red-shifted relative to the neutral flavonol, with the degree of shift depending

Figure 2-3. (a) Absorption spectra of 3 in CH3CN and 1:1 DMSO:H2O and the
absorption spectrum of 3-hydroxyflavone in 1:1 DMSO:H2O. (b) Absorption
spectra of 4 in CH3CN and 1:1 DMSO:H2O.

on the nature of the supporting chelate ligand. Specifically, the most red-shifted
Band I absorption is found for the 6-Ph2TPA-ligated complex 1 (lmax = 420 nm
(21,000 M-1cm-1))[16], followed by those of 3 (lmax = 415 nm (16,500 M-1cm-1))
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and 4 (lmax = 401 nm (16,500 M-1cm-1)). In 1:1 DMSO:H2O, the TPA-supported
complex 3 exhibits spectral changes consistent with protonation of the
coordinated flavonolato ligand and displacement from the Zn(II) center (Figure 23(a)). A new absorption feature at ~350 nm is consistent with the presence of
free 3-hydroxyflavone (Figure 2-3(a)). The UV-vis absorption spectrum of 4 in 1:1
DMSO:H2O is similar to that found in CH3CN (Figure 2-3(b)) albeit with
significantly lower molar absorptivity values. Excitation into the ~400-415 nm
absorption maximum of 3 and 4 dissolved in anaerobic CH3CN (5 x 10-5 M)
produced the emission spectra shown in Figure 2-4. Compound 3 exhibits a
similar Stokes shift (~72 nm) to that found for 1, but with an overall lower intensity
fluorescent emission. Essentially no fluorescent emission is observed for 4 upon
excitation at its absorption maximum (401 nm). Thus, the fluorescence intensity
decreases in the order of 1 > 3 > 4 in CH3CN. We propose that this difference
relates to the microenvironment in the 6-Ph2TPA chelate in 1, resulting in the
phenyl appendages surrounding the coordinated flavonolato ligand. Specifically,
the presence of the phenyl appendages in the 6-Ph2TPA chelate in 1 result in the
flavonolato ligand being positioned in a hydrophobic microenvironment. This
motif more limits solvent access to the flavonolato ligand relative to that in 3
thereby reducing collisional quenching. That being said, in 1:1 H2O:DMSO, the
emission of 1 decreases in intensity relative to that found in CH3CN (Figure 21(b)), suggesting that there is some solvent access to the flavonolato moiety. For
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Figure 2-4. Fluorescence emission spectra of 1, 3, and 4 in CH3CN. All spectra
were obtained with λex at the absorption maximum at ~400-420 nm.

complex 4, the presence of the rigid intramolecular hydrogen bond donors, which
may undergo excited state lengthening or shortening, results in significant
fluorescence quenching. [37]
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Visible light induced reactivity of 3 and 4
As 3 undergoes reaction in 1:1 H2O:DMSO to produce free 3hydroxyflavone, we have only examined the visible light induced CO release
reactivity of this compound in aerobic CH3CN using 419 nm irradiation. Complex
4 was also examined in aerobic CH3CN and was found to exhibit such low
photochemical efficiency (vide infra) that further studies in 1:1 H2O:DMSO were
not performed. Each reaction was irradiated until judged to be complete by the
disappearance of the ~400-415 nm absorption band.

Product Identification
GC headspace gas analysis, 1H NMR, IR, and mass spectrometry were
used to characterize the products generated upon photoirradiation of 3 and 4 in
CH3CN at 419 nm. For each complex, the photoreaction resulted in the formation
of one equivalent of CO (Table 2-1) as well as a [(L)Zn(O-bs)]ClO4 complex
(TPA: 5; bnpapa: 6). The latter complexes were identified by their 1H NMR
spectral features (Figures 2-7 and 2-8), molecular ions in MALDI mass spectral
experiments (Figures 2-11, 2-12, 2-13 and 2-14), and by their characteristic nC=O
ester vibration at 1740-1770 cm-1 for the O-benzoysalicylate ligand. Quantitative
18

O incorporation from 18O2 for the reactions of 3 and 4 provides conclusive

evidence for a dioxygenase-type reaction. Appropriate dark and anaerobic
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control reactions demonstrate that the observed reactions for 3 and 4 are O2
dependent photoinduced processes.

Reaction Quantum Yields
The quantum yields for the visible light induced CO release reactions of 3
and 4 in CH3CN are shown in Table 2-1. The structure of the supporting chelate
ligand has a significant effect on the photochemical efficiency of the CO release
reactions, with the quantum yield for 1 being two-fold higher than that of 3, and
both of these values being >20 fold higher than the quantum yield for the reaction
of 4. These results demonstrate that positioning a zinc flavonolato moiety within a
rigid hydrogen bond donor environment significantly stabilizes the compound with
respect to light induced reactivity.

Conclusions
In the studies outlined herein, we have examined the aqueous, visible light
induced CO release reactivity properties of 1. The results indicate that this
complex is stable in an aqueous, aerobic environment in the dark, but will exhibit
quantitative, visible light induced CO release to generate a single zinc-containing
product. The quantum yield for CO release in 1:1 H2O:DMSO is only of factor of
two lower than that observed in organic solvent.
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We have also examined how the supporting chelate ligand influences the
aqueous stability and visible light induced CO-release reactivity of zinc
flavonolato species. We were particularly interested in examining the influence of
the aryl appendages of the 6-Ph2TPA ligand in 1 as it is well known that the
photochemical reactivity of organic and inorganic molecules can be modulated
via encapsulation within a confined microenvironment such as a cyclodextrin
cavity, hydrogen-bonded capsules, or hollow molecular structure [38,39]. Our
results demonstrate that the secondary environment introduced by the
tetradentate chelate ligand influences the chemistry of zinc flavonolato
complexes in multiple ways. First, the presence of the hydrophobic
microenvironment in 1 stabilizes the zinc flavonolato moiety with respect to water
and differentiates the chemistry of 1 from that of 3 in aqueous DMSO solution.
The observation of flavonol displacement from 3 in water is noteworthy not only
to this study, but also to investigations being performed in other laboratories
wherein simple zinc flavonolato species such as [Zn(3-Hfl)(acetate)] are being
evaluated in aqueous media for their antidiabetic and DNA binding properties
[40-42]. Second, the lower quantum yields observed for photoinduced CO
release from 3 and 4 in CH3CN relative to 1 is likely a consequence of the
enhanced accessibility of solvent to the flavonolato moiety and/or secondary
hydrogen bonding. These interactions offer additional pathways for non-radiative
decay thus leading to the observed excited state quenching and less efficient
CO-release processes relative to 1.
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Overall, these investigations revealed that the presence of a hydrophobic
microenvironment is important toward providing aqueous stability and maximizing
the photochemical efficiency of the CO-release reaction of a zinc flavonolato
moiety. Therefore, if zinc flavonolato species are to be advanced for use as
photoinduced CO release agents in biological systems, careful consideration will
need to be given to the supporting microenvironment within the compound.
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CHAPTER 3

A STRUCTURALLY-TUNABLE 3-HYDROXYFLAVONE MOTIF FOR VISIBLE
LIGHT-INDUCED CO-RELEASING MOLECULES (CORMS)‡

Abstract
Molecules that can be used to deliver a controlled amount of CO have the
potential to facilitate investigations of the roles of this gaseous molecule in
biology and advance therapeutic treatments. This has led to the development of
light-induced carbon monoxide-releasing molecules (photoCORMs). A goal in
this field is the development of molecules that exhibit a combination of controlled
CO release, favorable biological properties (e.g. low toxicity and trackability in
cells), and structural tenability to affect CO release. Herein we report a new
biologically-inspired organic photoCORM motif that exhibits several features that
are desirable in a next generation photoCORM. We show that 3-hydroxyflavonebased compounds are easily synthesized and modified to impart changes in
absorption features and quantum yield for CO release, exhibit low toxicity, are
trackable in cells, and can exhibit both O2-dependent and –independent CO
release reactivity.

‡

Coauthored by Jason M. Richards, Hector J. Esquer, Abby D. Benninghoff,
Prof., Atta M. Arif, Dr., and Lisa M. Berreau, Prof. Reproduced in a modified
format with permission from Chemistry Open 2015, 4(5), 590-594.
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Introduction
Carbon monoxide-releasing molecules (CORMs) are of significant current
interest due to the potential of CO as a therapeutic molecule.[1] The vast majority
of CORMs developed to date are based on a metal-carbonyl unit as the COreleasing moiety.[2] Many molecules of this type, including protein-bound
derivatives of [RuCl(glycinato)(CO)3] (CORM-3, Figure 3-1) and analogs,

Figure 3-1. Structural motifs of selected previously reported CORMs.

release CO spontaneously through ligand exchange in an aqueous
environment.[3] The lack of temporal control for CO release in such systems has
led to the use of metal carbonyl complexes that release CO only when
triggered.[4,5] Examples of such complexes include photoCORMs, which release
CO from a metal carbonyl unit upon illumination with UV or visible light.[4] Recent
advances in the field of metal carbonyl photoCORMs demonstrate that CO
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release can be tuned to occur upon illumination with low-energy red or NIR light
through modification of supporting ligands or through approaches using
nanoparticles.[4] However, a concern associated with some metal-carbonyl based
photoCORMs are side effects related to the metal-containing photoproducts.[6] A
limited number of organic photoCORMs (1-3, Figure 3-1) have also been recently
reported.[7] However, these molecules also have limitations. For example, 1 and
2 are derived from relatively low-yield, multistep synthetic routes that have not
been shown to be amenable to structural modification for the tuning of physical
properties or biological targeting. The Diels-Alder product 3 can be generated in
good yield and subsequently undergoes CO release. However, this compound
cannot be isolated and stored.
Desirable features in a next generation organic photoCORM motif include:
(1) a high-yield synthesis that enables the preparation of gram quantities of
analytically pure compound; (2) solubility in water or aqueous DMSO; (3) thermal
stability in aerobic, aqueous environments; (4) controllable, triggered CO release,
preferably using light at wavelengths that do not have the potential to impart
cellular damage; (5) low toxicity of the photoCORM and its post-CO-release
byproducts; (6) ease of structural modification to modulate aqueous solubility,
photochemical properties (e.g. light absorption properties), and biocompatibility,
and (7) exhibits fluorescence so as to enable tracking of the localization and CO
release reactivity of the molecule within cells.[8] In the results reported herein, we
describe a new class of biologically-inspired photoCORMs that exhibit all of the
desirable features noted above. The parent structure contains a 3-
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hydroxyflavone motif, which is found in naturally-occurring molecules that are
already known to exhibit several types of biological activity, including antioxidant,
anti-inflammatory, and anti-cancer activity, as well as protection against
cardiovascular disease.[9] The new flavones reported herein all exhibit visible
light-induced CO-release in O2-containing environments, with one derivative also
exhibiting O2-independent CO release reactivity.

Discussion
Naturally-occurring 3-hydroxyflavone derivatives, such as quercetin
(Scheme 3-1(top)), are known to undergo O2-dependent, enzyme-catalyzed
degradation to produce CO in bacteria and fungi.[10] In the absence of enzyme,
quercetin is known to undergo various types of oxidative reactions, including UV
light-induced reactions, which can result in CO release.[11] It is known that
unsubstituted 3-hydroxyflavone (3-HflH) will undergo incorporation of both atoms
of O2 and expulsion of CO in the presence of a photosensitizer, or via direct
illumination using UV light (Scheme 3.1(middle)).[12] These reactions are
proposed to proceed from the normal and tautomeric excited state forms of 3HlfH, respectively. We have reexamined the photoinduced (l = 300 nm) reactivity
of 3-HflH under O2 and found that while a nearly quantitative amount of CO is
generated (0.95 eq), multiple organic products are detected by GC-MS. Finally,
3-HflH is also known to undergo UV light-induced rearrangement resulting in CO
release under anaerobic conditions (Scheme 3-1(bottom)).[13] These combined
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Scheme 3-1. Top) O2-dependent CO release reactivity of quercetin and 3-HflH.
Bottom) O2-independent, UV-light induced isomerization reactivity of 3-HflH.

results indicate that 3-hydroxyflavone derivatives have multiple reaction
pathways by which light-induced CO-release reactivity can occur.
We hypothesized that the 3-hydroxyflavone structural motif could be tuned
to undergo visible light-induced CO release. With this strategy in mind, the new
3-hydroxyflavone 4 was designed and prepared using Alger-Flynn-Oyamada
methodology (Figure 3-2(top)).[14] X-ray quality crystals of 4 were obtained via
slow evaporation of a CH2Cl2 solution. Compound 4 was additionally

86

characterized by elemental analysis, spectroscopic methods (Figures B-1 and B3 – B-5), and mass spectrometry (Figure B-2). Compound 4 is readily soluble in
organic solvents and is also soluble in aqueous DMSO at concentrations suitable
for spectroscopic measurements (1:1 H2O:DMSO) and biological experiments
(1% DMSO). Compound 4 crystallizes in the monoclinic space group C2/c.[15] A
representation of the molecular structure of 4 is shown in Figure 3-2(bottom).

Figure 3-2. Top) Synthetic route for the preparation of 4. Bottom left) A
representation of the molecular structure of 4 as determined by X-ray
crystallography. Bottom right) Side-on structural view.

In the solid state, the 3-hydroxy-4-pyrone units from two molecules form
centrosymmetric hydrogen bonded dimers with two identical intermolecular OH..O hydrogen bonds (O…O 2.69 Å; 145.3°).[16] The naphthyl-fused 3-hydroxy-4pyrone ring structure is nearly planar, and the phenyl appendage twists only

87

slightly out of this plane. This overall structure favors conjugation of the two
electronic systems. Compound 4 has bond lengths and angles very similar to
those of 3-hydroxyflavone (3-HflH).[16]
The extended conjugation in 4 produces a red-shift of the absorption
features relative to those found for 3-HflH in CH3CN (Figure B-3).[13] The lowest
energy band for 4 is found in the visible region with maximum intensity at 409 nm
(e = 16,600 M-1cm-1) in CH3CN, whereas there is no absorption feature above
400 nm for 3-HflH. In 1:1 H2O:DMSO, 4 exhibits similar absorption features but
with overall lower intensity (Figure B-3). Excitation into any of the absorption
features exhibited by 4 in CH3CN produces a single broad emission feature
centered at 582 nm (Figure B-4). Based on literature precedent for 3-HflH, the
large Stokes shift (³ 177 nm) suggests the formation of an excited state
tautomeric form wherein intramolecular proton transfer has occurred to give a
zwitterionic species. [17] When dissolved in 1:1 H2O:DMSO and excited in the
lowest energy absorption band, 4 exhibits two emission bands at 475 and 582
nm, respectively (Figure B-5). The former is of relatively low intensity and likely
represents emission from an excited state normal form of the molecule, whereas
the latter matches the emission feature produced in organic solvent.[17]
Solutions of 4 in acetonitrile, 1:1 H2O:DMSO, or cell culture media (RPMI1640; pH = 7.4) are stable in the presence of ambient O2 for >2 weeks when
protected from light. Exposure of an aerobic CH3CN solution of 4 to visible light
(419 nm) results in quantitative CO release (0.96(2) eq) as determined by GC
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headspace analysis and the formation of 3-(benzoyloxy)-2-naphthoic acid (5,
Scheme 3-2; Figures B-6 – B9). This organic product is pale yellow in color and

Scheme 3-2. Photoinduced CO release reactivity of 4.

does not exhibit any emission features in the visible region (Figure B-10). The
quantum yield for the CO-release reaction of 4 is 0.007(3). The same reaction
occurs in methanol (Figure B-8) and 1:1 H2O:DMSO as determined by 1H NMR
and GC head space gas analysis. Control reactions indicate that both O2 and
visible light are needed for the CO release reaction of 4. An 18O2 labeling
experiment demonstrates that both oxygen atoms from O2 are incorporated into
the organic photoproduct. Compound 4 exhibits several features that suggest
that it could be a useful CO release agent in biological systems. First, it exhibits
minimal toxicity, as determined by MTT cell viability assays using A549 cells (IC50
= 41.5 μM; Figure B-11), and the organic product remaining following CO release
is non-toxic. Importantly, the fluorescent nature of 4 makes it trackable in cells
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prior to CO release. The cellular uptake properties of 4 were evaluated in A549
cells, which were exposed to Hoechst stain for 10 minutes (to enable
visualization of nuclei), followed by incubation with 4 for 1 hour in the dark.
Fluorescence microscopy images (Figure 3-3; Figure B-12) of the cells were
collected after 30 seconds, 3 minutes, and 10 minutes of visible light exposure.[18]
The observed green emission at the first two time points provides
evidence that 4 is taken up by almost all cells. The compound is not associated
with the plasma membrane, but is distributed throughout the cytoplasm and
appears to concentrate around the nucleus. Importantly, continued exposure of
the cells to visible light results in a decrease in the observed green fluorescence
of the compound after three minutes, with complete loss after ten minutes. This
observation provides strong evidence for the photoinduced cleavage of the 3hydroxy-4-pyrone ring and CO release reactivity within the cells as the
photoproduct does not display any emission. It should be noted that use of the
intracellular CO probe COP-1 is not feasible in this system because the emission
of 4, which disappears upon CO release, overlaps with the emission feature of
CO-incorporated COP-1. [19]
A key feature of the structural motif of 4 that distinguishes it from all
previously described organic photoCORMs is the ease with which structural
modifications can be introduced to tune its physical properties. For example, a
dialkylamino substituent can be incorporated on the phenyl ring or the carbonyl
oxygen can be substituted with sulphur to red-shift absorption features toward
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the therapeutic window. Dialkylamino-substituted flavonols have been previously
used as

Figure 3-3. Fluorescence microscopy images of human lung cancer (A549) cells
treated with 4 for 1 hr, then exposed to visible light (X-Cite 120 LED light source
(Lumen Dynamics) with a 120-watt lamp used at 18% power (~4 x 1016
photons/sec) and 38HE filter) for a) 30 sec, b) 3 min, and c) 10 min.[18] Pictures
represent overlay images for fluorescence detection of 4 (green) and the nuclear
Hoechst stain (blue). Loss of fluorescence with increasing length of exposure to
visible light is consistent with photoinduced CO release from 4. See Figure B-12
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for separate images of each detection channel and the complete field of view
observed.
environment-sensitive probes in biological systems.[20] However, neutral flavonols
of this type have not been previously shown to exhibit photoinduced COreleasing reactivity. Flavothiones, have been reported to undergo O2-dependent
photodegradation to give non-toxic byproducts, but these reactions have not
been fully explored in terms of product identification.[21] Molecules 6-8 (Figure 34) were easily prepared using standard synthetic methods and were isolated in
analytically pure forms via precipitation. Each compound was characterized by
elemental analysis, UV-vis, fluorescence, IR, and mass spectrometry (Figure B13 – B-21). These molecules exhibit red-shifted absorption features and higher
molar absorptivity values than were observed for 4 (Figure 3-4). Quantitative CO
release occurs when aerobic CH3CN solutions of 6-8 are exposed to visible light
(6,7: 419 nm; 8: >546 nm) (Table 3-1). For 6 and 7, O2-incorporated organic
products akin to that found in the reaction of 4 were identified by 1H NMR, IR,
and mass spectral analysis (Figures B-22 – B-26). The quantum yield associated
with the reaction of 7 is significantly enhanced relative to that found for 4. The
reaction involving 8 is noteworthy in that, while a full equivalent of CO is released
under aerobic conditions, significant light-induced CO release reactivity (0.32(7)
eq) also occurs under anaerobic conditions. Both the aerobic and anaerobic
pathways for CO release from 8 result in the production of a mixture of products,
including some that appear to result from photoisomerization reactivity (Figures
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B-27 – B28). Photoinduced CO-release also occurs when 6-8 are dissolved in
other solvents, including DMSO and 1:1 H2O:DMSO.

Figure 3-4. (top) Synthetic procedures for 6-8. (bottom) Absorption spectra of 4
and 6-8 in CH3CN.
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Table 3-1. CO quantification and quantum yields for the reactions of 4 and 6-8
with O2 upon illumination with visible light in CH3CN.
Compound

eq. CO[c]

F[c]

4[a]

0.96(2)

0.007(3)

6[a]

0.99(1)

0.006(1)

7[a]

1.00(1)

0.426(3)

8[b]

1.00(1)

[d]

8[b]

0.32(7)[e]

[d]

[a]

Measured using 419 nm light. [b] Measured using >546 nm light. [c]Reported
values are the average of three independent trials. [d]Not reported due to
mixture of products. [e]Anaerobic conditions.

Conclusion
The use of a 3-hydroxyflavone-based structural motif offers many
advantages in terms of photoCORM design. Compounds of this type can be
prepared and isolated in analytically pure form using simple organic chemistry.
Compounds 4 and 6-8 are soluble in organic solvents as well as aqueous DMSO.
Solutions of these compounds are stable with respect to O2 for weeks when
protected from light. CO release is triggered under aerobic conditions by the
introduction of visible light, the wavelength of which can be tuned through
structural modification of the molecule. A representative example of this family of
compounds (4) exhibits minimal toxicity and its organic byproduct following CO
release is non-toxic. The fluorescent nature of 4 and analogs makes these
molecules trackable in cells up to the point of CO-release. The observed
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photoinduced reactivity of 6-8 demonstrates that structural modifications can be
made without loss of the CO-release reactivity, and that both aerobic and
anaerobic CO-release reaction pathways can be accessed. Overall, this family of
compounds thus meets key criteria set forth for next generation photoCORMs.
Further evaluation of the applications of these novel molecules and analogs for
CO-release in biological systems are in progress.

Experimental Section

Chemicals and Reagents
All chemicals and reagents were obtained from commercial sources and
used as received unless otherwise noted. Anaerobic procedures were performed
under N2 in a VAC Atmosphere glovebox. Solvents for glovebox use were dried
according to published methods and distilled under N2.[22]

Physical Methods
1

H and 13C{1H} NMR spectra (in ppm) were collected using JEOL ECX-

300 MHz spectrometer and are referenced to the residual solvent peak in CDCl3
(1H: 7.26 (singlet) ppm; 13C 77.16 (singlet) ppm). J values are given in Hz. IR
spectra were collected using a Shimadzu FTIR-8400 spectrometer. UV-vis
spectra were recorded at ambient temperature using a Hewlett-Packard 8453A
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diode array spectrophotometer. Fluorescence emission spectra were collected
using a Shimadzu RF-530XPC spectrometer in the range of 400-800 nm, with
the excitation wavelength corresponding to the absorption maxima of the
molecules. The excitation and emission slit widths were set at 1.5 nm for all
molecules. Mass spectral data was collected at the Mass Spectrometry Facility,
University of California, Riverside. ESI/APCI mass spectra were recorded on an
Agilent LCTOF (2006) with a Windows XP based operating system. Elemental
analyses were performed by Atlantic Microlab, Inc., Norcross, GA, using a
PE2400 automatic analyzer. A Rayonett photoreactor equipped with either RPR4190A or white light lamps with 546 nm cutoff filters were used for all
photochemical reactions. Quantum yields were determined using potassium
ferrioxalate or potassium reinekate as standards to measure photon flux.[23]
Carbon monoxide was quantified as previously described.[24]
1-(3-hydroxynaphthalen-2-yl)ethenone. 2-hydroxynaphthoic acid
(1.8818 g, 10 mmol) was dissolved in dry, freshly distilled THF (40 mL). This
solution was purged with N2 and subsequently cooled to 0 °C using an ice bath.
Methyllithium (30 mmol, 18.7 mL, 1.6 M in hexanes) was then slowly added in
aliquots via air-tight syringe. The reaction was allowed to stir at 0 °C for 3 hours
and then quenched with 0.5 M HCl dropwise until any frothing ceased. The THF
was then removed under reduced pressure and 0.5 M HCl (60 mL) was added to
the residue. The acidic aqueous solution was then extracted using
dichloromethane (50 mL x 3). The combined organic fractions were dried over
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sodium sulfate, filtered, and the solvent was then removed under reduced
pressure yielding the product as a bright yellow solid (1.84 g, 99%). 1H NMR
(CDCl3, 300 MHz) δ 11.54 (s, 1H), 8.35 (s, 1H), 7.79 (d, J = 6.0 Hz, 1H), 7.65 (d,
J = 6.0 Hz, 1H), 7.50 (t, J = 5.1 Hz, 1H), 7.32 (t, J = 5.1 Hz, 1H), 7.24 (s, 1H),
2.78 (s, 3H) ppm. 13C NMR (CDCl3, 100 MHz) 204.9, 157.3, 138.4, 133.7, 129.8,
129.5, 127.0, 126.4, 124.2, 121.5, 112.4, 27.1 ppm (12 signals expected and
observed). Melting point 111-113 °C. The 13C NMR and melting point data are
consistent with reported literature values.[25]
3-Hydroxy-2-phenyl-benzo[g]chromen-4-one (4). Sodium hydroxide (21
mL. 5M, 104 mmol) was added to a suspension of 1-(3-hydroxynaphthalen-2yl)ethanone (3.90 g, 21 mmol) in ethanol (60 mL) and allowed to stir for 30
minutes at room temperature. Benzaldehyde (2.14 mL, 21 mmol) was added to
the reaction and the resulting mixture was stirred for 5 hours resulting in the
formation of a dark red solution. The reaction was then cooled to 0 °C in an ice
bath, hydrogen peroxide (7.6 mL, 30%) was added drop-wise, and the resulting
mixture was stirred overnight while warming to room temperature. Acidification of
the solution to pH = 6.5 with 0.5 M HCl resulted in the formation of a bright yellow
precipitate which was isolated by filtration and washed with ethanol (3.74 g,
62%). 1H NMR (CDCl3, 300 MHz) δ 8.88 (s, 1H), 8.35 (d, J = 5.4 Hz, 2H), 8.08 (t,
J = 3.6 Hz, 2H), 7.95 (d, J = 6.3 Hz, 1H), 7.67 – 7.45 (m, 5H), 6.93 (s, 1H) ppm.
13

C NMR (CDCl3, 100 MHz) 174.6, 151.7, 145.8, 137.3, 136.1, 131.4, 130.5,

130.0, 129.6, 129.0, 128.8, 128.2, 127.4, 126.7, 126.0, 120.1, 114.4 ppm (17
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signals expected and observed). FTIR (KBr, cm-1) 3290 (νO-H), 1596 (νC=O). UVvis (CH3CN, nm) (ε, M-1cm-1) 409 (16,600), 392 (15,900), 345 (22,800). Melting
point 208-210 °C. Anal. Calc. C19H12O3: C, 79.16; H, 4.20. Found: C, 78.96; H,
4.23. ESI/APCI-MS (relative intensity) calcd. for C19H13O3 [MH]+: 289.0859;
found: 289.0866 (100%).
Photoreactivity of 4 in the presence of O2. Production of 3(benzoyloxy)-2-naphthoic acid (5). A solution of 4 (~0.05 mmol) in 5.0 mL
CH3CN was placed in a 50 mL round bottom flask under air. The solution was
then placed in a Rayonette photoreactor equipped with 419 nm lamps and was
irradiated until the reaction was determined complete as evidenced by the
disappearance of the lowest energy absorption band. The solvent was then
removed under reduced pressure yielding an off-white solid (100%). 1H NMR
(CDCl3, 300 MHz) δ 8.73 (s, 1H), 8.25 (d, J = 7.5, 2H), 7.98 (d, J = 7.8, 1H), 7.86
(d, J = 7.8, 1H), 7.72 - 7.46 (m, 6H) ppm. FT-IR (KBr, cm-1) 1743 (νC=O).
ESI/APCI-MS (relative intensity) calcd. for C18H13O4 [MH]+: 293.0808; found:
293.0811 (83%).
18

O-labeling studies. Aliquots of 18O2 were transferred into a frozen

CH3CN solution of 4 in a 100 mL solvent transfer flask followed by irradiation at
419 nm and removal of the solvent under reduced pressure. ESI/APCI-MS
(relative intensity) calcd. for C18H13O218O2 [MH]+: 297.0892; found: 297.0899
(18%).
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Dark Control Reaction. A solution of 4 in CD3CN (~3 mM) was prepared
in air under minimal red light and placed in an NMR tube. The NMR tube was
then covered with foil, placed in a photo reactor, and irradiated using 419 nm
lamps for 24 hours. Evaluation of the solution by 1H NMR indicated that no
reaction had occurred.
Anaerobic Control Reaction. A solution of 4 in CD3CN (~3 mM) was
prepared under N2 in a glove box and placed in an NMR tube. The NMR tube
was then placed in a photo reactor and irradiated using 419 nm lamps for 24
hours. Evaluation of the solution by 1H NMR indicated that no reaction had
occurred.
Cell Culture and Viability Assays. Jurkat (JM) cells were maintained as
previously described by Shorey et al.[26] A549 human adenocarcinoma cells
(ATCC, Manassas, VA) cells were grown in DMEM/Ham’s F-12 1:1 mixture
medium supplemented with 10% charcoal-stripped, heat-inactivated fetal bovine
serum (FBS; Caisson Laboratories, Logan, UT) in a humidified incubator at 37°C
with 5% CO2. Cytotoxicity was determined by the colorimetric MTT [3-(4,5dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazoluim bromide] assay as previously
described.[26] Briefly, 2.1 x 103 cells/ml for A549 cells or 1 x 105 cells/ml for Jurkat
cells. Test compounds were prepared in DMSO, then added to culture media for
a maximum final DMSO concentration not greater than 0.1% (v/v). After addition
of test compounds at concentrations ranging from 80 nM to 100 μM, cells were
incubated for 24 h in the dark, then treated with MTT to assess cell viability as
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outlined previously.[26] All experiments were independently replicated three times,
and each experimental treatment was performed in triplicate.
Fluorescence microscopy. A549 cells were maintained in culture as
described above, then seeded into Millicell E-Z-Slide culture chambers (EMD
Millipore, Billerica, MA) at an initial density of 7.5 × 104 cells/cm3 and allowed to
adhere to the chamber slides for 24 hr. The cells were then treated for 1 hr with
the nuclear dye Hoechst 33342 (0.5% v/v) for 10 min, followed by three washes
with plain culture media to remove residual dye. All of incubation and wash steps
described below were performed under minimal red light. A 100 mM stock
solution of compound 4 was prepared in DMSO and then diluted to a working
concentration of 2 mM in culture media (DMEM/Ham’s F-12). The compound 4
working stock was diluted again to a final concentration of 50 μM in the culture
chamber media, and the cells were incubated for 1 hr. The culture chamber was
then gently washed thrice with plain culture media. Cells were fixed with a 1:10
(v/v) solution of formaldehyde fixative (Immunochemistry Technologies,
Bloomington, MN) and culture media for 5 min, then washed twice with plain
culture media. Finally, cells were imaged using a Zeiss Axio Observer inverted
microscope (Carl Zeiss Microscopy, Thornwood, NY) equipped with fluorescence
detection. Images were acquired using a 10x objective with excitation λ of 450490 nm (BP 470/40 filter) and emission λ of 500-550 nm (BP 525/50 filter) for
detection of compound 4 in A549 cells following 30 sec, 3 min or 10 min
exposure to visible light. Also, for localization of the Hoechst dye, a single
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fluorescence image was acquired at excitation λ at 365 nm; emission λ of 420470nm (BP 445/50 filter). Acquired images were universally adjusted to enhance
contrast levels (same settings for all acquired images for each detection channel)
using Adobe Photoshop CS6 (Adobe, San Jose, CA).
2-(4-(diethylamino)phenyl)-3-hydroxy-4H-benzo[g]chromen-4-one (6).
Sodium hydroxide (4.0 mL, 5M, 20 mmol) was added to a suspension of 1-(3hydroxynaphthalen-2-yl)ethanone (0.931 g, 5 mmol) in ethanol (14 mL) and the
resulting mixture was allowed to stir for 30 minutes at room temperature. 4diethylaminobenzaldehyde (0.886 g, 5 mmol) was added to the mixture and the
solution stirred for 24 hours. The reaction mixture was then cooled to 0 °C in an
ice bath, hydrogen peroxide (3 mL, 30%) added drop-wise, and the solution was
stirred overnight. Acidification of the solution to pH = 6.5 with 0.5 M HCl caused
the formation of an orange precipitate. The solid was filtered from solution and
washed with ethanol (0.754 g, 42% yield). 1H NMR (CDCl3, 300 MHz) δ 8.83 (s,
1H), 8.27 (d, J = 9.27 Hz, 2H), 8.06 (d, J = 8.22 Hz, 1H), 8.02 (s, 1H), 7.93(d, J =
8.22 Hz, 1H), 7.60 (t, J = 7.89 Hz, 1H), 7.51 (t, J = 7.89 Hz, 1H), 6.9 – 6.76 (m,
3H), 3.48 (q, J = 7.2 Hz, 4H), 1.26 (t, J = 7.2 Hz, 6H) ppm. 13C NMR (CDCl3, 100
MHz) 173.2, 151.7, 149.4, 147.9, 135.8, 135.7, 130.1, 129.6, 128.6, 127.4,
126.2, 125.8, 120.6, 117.6, 114.1, 111.2, 44.7, 12.8 ppm (19 signals expected
and observed). FT-IR (KBr, cm-1) 3270 (νO-H), 1588 (νC=O). UV-vis (CH3CN), nm
(ε, M-1cm-1) 442 (51,000), 301 (22,100). Melting point 191-192 °C. Anal. Calc.
C23H21NO3: C, 76.86; H, 5.89; N, 3.90. Found: C, 76.77; H, 5.80; N, 3.96.
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ESI/APCI-MS (relative intensity) calcd. for C23H22NO3 [MH]+: 360.1594; found:
360.1594 (100%).
Synthesis of 7 and 8. Lawsson’s Reagent (1.01 g, 2.5 mmol) was added
to a solution of 4 or 6 in toluene (120 mL), thoroughly purged with N2, and
refluxed for 4 hours producing a dark red solution. The solution was cooled to
room temperature, filtered, and the solvent removed under reduced. The residual
solid was washed with methanol and hexanes yielding 7 (61% yield) or 8 (60%
yield) as a dark orange and dark purple solid respectively.
3-Hydroxy-2-phenyl-4H-benzo[g]chromene-4-thione (7). 1H NMR
(CDCl3, 300 MHz) δ 9.15 (s, 1H), 8.61 (bs, 1H), 8.49 (d, J = 8.1 Hz, 2H), 8.178.07 (m, 2H), 7.94 (d, J = 8.4 Hz, 1H), 7.70-7.45 (m, 5H) ppm. 13C NMR (CDCl3,
100 MHz) δ 189.7, 147.5, 145.4, 142.1, 135.8, 131.4, 131.2, 129.8, 129.6, 129.3,
129.1, 129.0, 127.3, 126.7, 126.4, 114.8 ppm (17 signals expected, 16
observed). UV-vis (CH3CN), nm (ε, M-1cm-1) 478 (36,700), 456 (29,600), 376
(40,300). Melting Point 151-152 °C. Anal. Calc. C19H12O2S·0.1H2O: C, 74.54; H,
4.02. Found: C, 74.42; H, 4.09. The presence of 0.1 eq H2O was confirmed by
integration of the peak at 1.56 ppm in the 1H NMR spectrum. ESI/APCI-MS
(relative intensity) calcd. for C19H13O2S [MH]+: 305.0631; found: 305.0638
(100%).
2-(4-(diethylamino)phenyl)-3-hydroxy-4H-benzo[g]chromene-4-thione
(4).1H NMR (CDCl3, 300 MHz) δ 9.10 (s, 1H), 8.75 (bs, 1H), 8.46 (d, J = 9.0 Hz,
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2H), 8.08 (d, J = 8.1 Hz, 1H), 8.03 (s, 1H), 7.91 (d, J = 8.4 Hz, 1H), 7.57 (t, J =
7.5 Hz, 1H), 7.49 (t, J = 7.5 Hz, 1H), 6.82 (d, J = 9.0, 2H), 3.49 (q, J = 7.2 Hz,
4H), 1.27 (t, J = 7.2 Hz, 6H) ppm. 13C NMR (CDCl3, 100 MHz) 182.6, 150.3,
147.4, 145.0, 134.9, 131.8, 131.0, 129.6, 129.0, 128.3, 127.2, 126.4, 125.9,
116.8, 114.0, 111.5, 44.9, 12.8 ppm (19 signals expected, 18 observed). UV-vis
(CH3CN), nm (ε, M-1cm-1) 544 (85,800), 400 (19,500), 320 (22,800). Melting
point: 176-177 oC. Anal. Calc. C23H21NO2S: C, 73.57; H, 5.64; N, 3.73. Found:
C, 73.30; H, 5.79; N, 3.70. ESI/APCI-MS (relative intensity) calcd. for
C23H22NO2S [MH]+: 376.1366; found: 376.1364 (100%).
Photoreactivity of 6-8. Identification of 9-11. A solution of each
molecule 6, 7 and 8 (~0.05 mmol) in 5.0 mL CH3CN was placed in a 50 mL round
bottom flask under air. The solution was then placed in a Rayonette photoreactor
equipped with lamps of appropriate wavelength (6,7: 419 nm lamps; 8: white light
lamps with 546 nm cutoff filters) and irradiated until the reaction was determined
complete as evidenced by the loss of the lowest energy absorption band (409 544 nm). The solvent was then removed under reduced pressure yielding
molecules 9-11.
3-((4-(diethylamino)benzoyl)oxy)-2-naphthoic acid (9). 1H NMR
(CDCl3, 300 MHz) 8.69 (s, 1H), 8.07 (d, J = 9.0 Hz, 2H), 7.96 (d, J = 8.4 Hz, 1H);
7.84 (d, J = 8.1 Hz, 1H), 7.68 (s, 1H), 7.61 (t, J = 8.4 Hz, 1H), 7.53 (t, J = 8.1 Hz,
1H), 6.70 (d, J = 9.0, 1H), 6.61 (d, J = 9.0 Hz, 1H), 3.27 (q, J = 6.9 Hz, 4H), 1.31
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(t, J = 6.9 Hz, 6H) ppm. FT-IR (KBr, cm-1) 1716 (νC=O). ESI/APCI-MS (relative
intensity) calcd. for C22H22NO4 [MH]+: 364.1543; found: 364.1544 (100%).
3-(benzoyloxy)naphthalene-2-carbothioic-O-acid (10). 1H NMR (CDCl3,
300 MHz) 8.67 (s, 1H), 8.24 (d, J = 7.8 Hz, 2H), 7.99 (d, J = 8.7 Hz, 1H), 7.85 (d,
J = 7.8 Hz, 1H), 7.76 (s, 1H), 7.72 - 7.39 (m, 5H) ppm. FT-IR (KBr, cm-1) 1704
(νC=O). ESI/APCI-MS (relative intensity) calcd. for C36H22O6S2Na [2M+Na]+:
637.0750; found: 637.0757 (37%).
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CHAPTER 4

SOLUTION OR SOLID - IT DOESN’T MATTER: DIOXYGENASE-TYPE VISIBLE
LIGHT-INDUCED CO RELEASE CHEMISTRY OF ZINC FLAVONOLATO
COMPLEXES

Abstract
A family of zinc flavonolato complexes, [(6-Ph2TPA)Zn(flavonolato)]X, of
four extended flavonols has been prepared, characterized, and evaluated for
visible light-induced CO release reactivity. Zinc coordination of each flavonolato
anion results in a red-shift of the lowest energy absorption feature and in some
cases enhanced molar absoptivity. The zinc-coordinated flavonolato ligands
undergo visible light-induced CO release with enhanced reaction quantum yields
relative to the neutral flavonols. Most notable is the disovery that zinc flavonolato
derivatives undergo similar visible light-induced CO release reactivity in solution
and in the solid state. This discovery suggests the possible application of solid
zinc flavonolato species in applications requiring controlled, light-triggered CO
release in biological and synthetic applications.

Introduction
Delivery of controlled amounts of carbon monoxide (CO) is of significant
current interest both in biology and synthetic chemistry. In humans, CO is
produced endogenously via the enzyme-catalyzed breakdown of heme.1 Studies
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of the effects of CO have demonstrated its potential to produce a variety of
beneficial health effects including anti-inflammatory, anti-apoptotic, vasodilation,
and anti-bacterial effects.2,3 To explore the biology of CO and its possible uses
as a therapeutic, CO-releasing molecules (CORMs) have been developed for the
delivery of controlled amounts of CO.4 To date, the majority of CORMs
investigated have been metal carbonyl compounds (MCCs), with the most
extensively studied being [Ru(CO)3(glycinate)Cl] (CORM-3).5 This compound
coordinates to histidine residues of proteins and spontaneously releases CO via
ligand exchange.6-8 Other MCC CORMs release CO via enzyme-induced
reactivity9,10, magnetic heating11, or via visible light-induced reactivity
(photoCORMs).12-14 CORMs that can be controlled in terms of their CO release
reactivity are especially attractive as they offer the opportunity for localized
release of CO at specific sites for biological studies or therapeutic purposes.
To address issues of solubility and concerns regarding the use of redoxactive and heavy metals in MCCs, efforts to encapsulate these compounds in
micelles, dendrimers, and solid supports have been reported.11,15-19 Efforts to
develop metal-free organic photoCORMs have also advanced.20-23 The
development of organic photoCORMs holds significant promise as standard
approaches employed in medicinal chemistry for tuning and targeting could be
possible.24-26
CO-releasing molecules are also of significant current interest for
applications in synthetic organic chemistry. For example, because of the health
hazards of handling CO gas, efforts in recent years have focused on the
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development of molecules that release CO on demand for synthetic applications,
such as palladium-catalyzed carbonylation reactions.27-32 The majority of the COrelease compounds currently being used in synthetic organic applications either
are used in an ex situ fashion or are used in situ but require the introduction of
additional reagents, microwave irradiation, or heating to induce CO release.
An area that has seen little development is that of solid-state coordination
compounds capable of visible light-induced CO release. Such compounds offer
the possibility of CO release materials with no soluble byproducts, which could
have tremendous advantages for both biological and synthetic applications.
Mascharak recently reported two visible light induced MCC photoCORMs that
are reported to undergo solid-state CO release.33 However, the quantity of CO
released and the other products of this reactivity have not been reported.
Our laboratory is developing CO release compounds based on the 3hydroxy-4-flavone moiety found in naturally occurring flavonols. We recently
reported a new family of flavonol derivatives (1-4, Figure 4-1) that undergo visible
light-induced quantitative CO release when dissolved in organic solvents or
organic/aqueous mixtures in the presence of O2.34 As shown in Table 4-1, this
class of compounds can be structurally tuned to undergo quantitative CO release
under aerobic or anaerobic conditions. These flavonol derivatives are fluorescent
and therefore are trackable in cells. Compound 1 has been demonstrated to
penetrate cells and then undergo CO release upon exposure to visible light. The
structural framework in 1-4 also offers the opportunity for chelation to a metal
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Fig 4-1 Structures of flavonol-based CO releasing molecules.

Table 4-1 Properties of 1-4.

Compound

lmax (nm)a

Aerobic

e (M-1cm-1)

CO-

Anaerobic
Fc

CO-release

releaseb
1

409
Yes
0.007(3)
No
(16,600)
2
442
Yes
0.006(1)
No
(51,000)
3
478
Yes
0.426(3)
No
(36,700)
4
544
Yes
d
Yes
(85,500)
a
Most red-shifted absorption feature. bMeasured in acetonitrile in the presence of
air. cAverage of three independent trials; values in parenthesis represent
standard error. dQuantum yield for CO release not reported due to concurrent
aerobic and anaerobic CO release reactions.

113

center as a means of tuning the reactivity of the CO-releasing moiety. In the
studies reported herein, we have used a structural template from our laboratory
that has been employed in studies of other metal flavonolato compounds35-37 to
evaluate how zinc stabilization of 1-4 affects their CO-release reactivity. Key
findings include that zinc coordination: (1) red shifts the absorption spectral
features of the compounds, with some being in the therapeutic window (>650
nm), (2) significantly enhances the quantum yield for visible-light induced CO
release, and (3) enables solid-state CO release activity that is identical to the
reactivity seen in solution. The discovery of light-induced solid-state release
reactivity is particularly significant as it suggests that solid-state CO-release
materials based on a zinc flavonolato motif can be developed. Overall, our
results suggest that the structural motif in 1-4 is a highly versatile CO release unit
that can be developed for various CO release applications.

Experimental Section

General

Chemicals and reagents. All chemicals and reagents were obtained from
commercial sources and used as received unless otherwise noted. The synthesis
of the extended flavonols 1-4 proceeded as previously reported.34 The 6-Ph2TPA
(N,N-bis(((6-phenyl-2-pyridyl)methyl)-N-((2-pyridyl)methyl)amine) ligand was
prepared and purified as previously described.35
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Physical Methods. Anaerobic procedures were performed in a Vacuum
Atmospheres glovebox under N2. Solvents for glovebox use were dried according
to published methods and distilled under N2.36 UV-vis spectra were recorded at
room temperature using a Hewlett-Packard 8453A diode array
spectrophotometer. Fluorescence emission spectra were collected using a
Shimadzu RF-530XPC spectrometer in the range of 400-800 nm with the
excitation wavelength corresponding to the most red-shifted absorption maximum
of the compound. Infrared spectra were recorded using a Shimadzu FTIR-8400
as KBr pellets. 1H NMR spectra (in ppm) are referenced to the residual solvent
peaks in acetonitrile-d3 (1H: 1.94 (quintet) ppm). J values are given in Hz. Mass
spectral data was collected at the Mass Spectrometry Facility, University of
California, Riverside. Elemental analyses were performed by Atlantic Microlab,
Inc., Norcross, GA, or by Robertson Microlit Laboratories, Ledgewood, NJ.
Photochemical experiments were performed using a Luzchem photoreactor
equipped with either RPR-4190A, RPR-5750A, or Sylvania cool white lamps.
Carbon monoxide quantification was performed by gas chromatography as
previously described.37 Quantum yields were determined by ferrioxalate or
potassium reineckate actinometry using an integrative analysis method.38-40 The
output measured during the quantum yield determination for 5 was 1.46091 x
1017 photons/sec when illuminated with RPR-4190A lamps and for 6, 7, and 8
was 6.87824 x 1015 photons/sec when illuminated with white light lamps
equipped with 546 nm cut off filters.
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Caution! Perchlorate salts of metal complexes with organic ligands are
potentially explosive. Only small amounts of material should be prepared, and
these should be handled with great care.42
Synthesis of 5-8. In a N2-filled glovebox, a methanolic solution (2 mL) of
Zn(ClO4)2.6H2O (0.0500 g, 0.134 mmol) was added to solid 6-Ph2TPA (0.0594 g,
0.134 mmol) and the resulting mixture was stirred until all of the chelate ligand
dissolved. The solution was then added to a methanolic solution (2 mL)
containing 1, 2, 3, or 4 (0.134 mmol) and Me4NOH.5H2O (0.0243 g, 0.134 mmol).
The mixture was allowed to stir for 4 hours at ambient temperature. The solvent
was then removed under reduced pressure and the residual solid was dissolved
in CH2Cl2. The solution was then filtered through a Celite/glasswool plug and the
final product was precipitated by the addition of excess hexanes. Each solid
product was dried under reduced pressure.
[(6-PhTPA)Zn(1-)]ClO4 (5). Orange solid (89%). 1H NMR (CD3CN, 300
MHz) δ 8.62 (d, J = 5.1, 1H), 8.27 (t, J = 1.5, 1H), 8.25 (t, J = 1.5, 1H), 8.21 (d, J
= 21.6, 2H), 8.03 (m, 2H), 7.96 (t, J = 7.5, 1H), 7.78 (t, J = 7.8, 2H), 7.66 - 7.37
(m, 9H), 7.33 (d, J = 7.8, 2H), 7.16 - 6.88 (m, 10H), 4.92 (d, J = 14.7, 2H), 4.57
(d, J = 14.7, 2H), 4.43 (s, 2H) ppm. FTIR (KBr, cm-1) 1094 (νClO4), 622 (νClO4).
UV-vis (CH3CN) nm (ε, M-1cm-1) 480 (6300), 384 (1700). ESI/APCI-MS, m/z
(relative intensity) 793.2152, calc. 793.2157 ([M-ClO4]+, 34%). Anal Calc.
C49H37N4O7ClZn·0.7CH2Cl2: C, 62.56; H, 4.06; N, 5.87. Found: C, 62.62; H, 4.26;
N, 6.16. The presence and quantity of dichloromethane in the solid sample was
confirmed through integration of the CH2Cl2 resonance in the 1H NMR spectrum.
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[(6-Ph2TPA)Zn(2-)]ClO4 (6).Orange-red solid (93%). 1H NMR (CD3CN,
300 MHz) δ 8.50 (d, J = 4.8 Hz, 1H), 8.31 (d, J = 9.3 Hz, 2H), 8.22 (s, 1H), 8.09
(s, 1H), 8.05 - 7.93 (m, 2H), 7.85 (t, J = 7.8 Hz, 1H), 7.78 (t, J = 7.5 Hz, 2H), 7.64
- 7.45 (m, 4H), 7.44 - 7.34 (m, 3H), 7.31 - 7.21 (m, 5H), 7.11 (t, J = 7.5 Hz, 2H),
7.01 (t J = 7.5 Hz, 4H), 6.80 (d, J = 9.0 Hz, 2H), 4.93 (d, J = 14.4 Hz, 2H), 4.54
(d, J = 14.4 Hz, 2H), 4.37 (s, 2H), 3.51 (q, J = 7.2 Hz, 4H), 1.24 (t, J = 7.2 Hz,
6H) ppm. FT-IR (KBr, cm-1) 1088 (νClO4), 618 (νClO4). UV-vis (CH3CN) nm (ε, M1

cm-1) 524 (80,000). ESI/APCI-MS, m/z (relative intensity) 864.2887, calc.

864.2882 ([M-ClO4]+, 7%). Anal Calc. C53H46N5O7ClZn.H2O: C, 64.70; H, 4.92; N,
7.12. Found: C, 64.84; H, 4.63; N, 6.52. The presence and quantity of water in
the elemental analysis sample was confirmed through integration of the H2O
resonance in the 1H NMR spectrum.
[(6-Ph2TPA)Zn(3-)]ClO4 (7).Dark red solid (93%). 1H NMR (CD3CN, 300
MHz) δ 8.80 (s, 1H), 8.47 - 8.39 (m, 2H), 8.38 - 8.30 (m, 2H), 8.13 (d, J = 9.0 Hz,
1H), 8.05 (d, J = 9.0 Hz, 1H), 7.85 (t J = 7.8 Hz, 1H), 7.79 (t, J = 7.8 Hz, 2H),
7.64 (t, J = 6.6 Hz, 1H), 7.60 - 7.52 (m, 4H), 7.43 (t, J = 6.6 Hz, 5H), 7.28 (d, J =
6.9 Hz, 5H), 7.08 (t, J = 7.2 Hz, 2H), 6.99 (t, J = 7.2 Hz, 4H), 4.82 (bd, J = 14.4
Hz, 2H), 4.49 (bd, J = 14.4 Hz, 2H), 4.41 (s, 2H) ppm. FT-IR (KBr, cm-1) 1086
(νClO4), 619 (νClO4). UV-vis (CH3CN) nm (ε, M-1cm-1) 550 (9,300), 396 (7,200).
ESI/APCI-MS, m/z (relative intensity) 809.1930, calc. 809.1923 ([M-ClO4]+, 25%).
Anal Calc. C49H37N4O6ClSZn . 0.5H2O . 1CH2Cl2: C, 59.77; H, 4.01; N, 5.58.
Found: C, 59.29; H, 3.51; N, 5.57. The presence and quantity of water and
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dichloromethane in the elemental analysis sample was confirmed through
integration of the respective resonances in the 1H NMR spectrum.
[(6-Ph2TPA)Zn(4-)]ClO4 (8).Dark blue solid (91%). 1H NMR (CD3CN, 300
MHz) δ 8.69 (s, 1H), 8.58 (d, J = 9.3 Hz, 2H), 8.43 (d, J = 5.4 Hz, 1H), 8.21 (s,
1H), 8.10 (d, J = 8.1 Hz, 1H), 8.00 (d, J = 8.1 Hz, 1H), 7.89 - 7.77 (m, 3H), 7.64 7.42 (m, 10H), 7.38 (t, J = 7.2 Hz, 1H), 7.29 (d, J = 7.8 Hz, 1H), 7.24 - 7.17 (m,
2H), 7.16 - 7.07 (m, 4H), 6.86 (d, J = 9.3 Hz, 2H), 4.83 (d, J = 13.8 Hz, 2H), 4.49
(d, J = 13.8 Hz, 2H), 4.41 (s, 2H), 3.54 (q, J = 7.2 Hz, 4H), 1.23 (t, J = 7.2 Hz,
6H) ppm. FT-IR (KBr, cm-1) 1084 (νClO4), 622 (νClO4). UV-vis (CH3CN) nm (ε, M1

cm-1) 600 (111,700). ESI/APCI-MS, m/z (relative intensity) 880.2659, calc.

880.2658 ([M-ClO4]+, 15%). Anal Calc. C53H46N5O6ClSZn.H2O: C, 63.67; H, 4.84;
N, 7.00. Found: C, 63.37; H, 4.57; N, 6.75. The presence and quantity of water in
the elemental analysis sample was confirmed through integration of the H2O
resonance in the 1H NMR spectrum.
Photoinduced Reactivity of 5-8 in CH3CN. Illumination of aerobic
CH3CN solutions of 5-8 using visible light (5: 419 nm; 6, 7, 8: >546 nm) results in
the release of one equivalent of CO (Table 4-2) and the formation of the
carboxylate derivatives [(6-Ph2TPA)Zn(carboxylate)]ClO4 (9-12) which were
characterized by 1H NMR, IR, and ESI/MS.
[(6-Ph2TPA)Zn(((3-benzoyl)oxy)-2-naphthanoate)]ClO4. (9). 1H NMR
(CD3CN, 300 MHz) δ 8.22 (d, J = 4.5 Hz, 1H), 8.14-7.99 (m, 3H), 7.93-7.78 (m,
4H), 7.66 (d, J = 7.5 Hz, 2H), 7.64-7.51 (m, 6H), 7.50 - 7.37 (m, 5H), 7.34-7.23
(m, 2H), 7.20-7.05 (m, 9H), 4.58-4.26 (m, 6H) ppm. FT-IR (KBr, cm-1) 1724
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(nC=O). ESI/APCI-MS, m/z (relative intensity), 797.2113, calc. 797.2201 ([MClO4]+, 35%).

Table 4-2 Properties of 5-8.
Compound lmax (nm)a
e (M-1cm-1)
5

480
(6300)
524
(80,000)
550
(9300)
600
(111,700)

6
7
8

Solution COrelease (eq
CO)b
0.94(4)

Fc

0.98(1)

0.583(4)e 0.93(2)

0.92(3)

0.951(4)e 0.97(1)

0.97(2)

0.947(7)e 0.94(1)

Solid-state CO
release (eq CO)f

0.651(2)d 0.96(3)

[(6-Ph2TPA)Zn(3-((4-(diethylamino)benzoyl)oxy)-2-naphthoate)]ClO4
(10). 1H NMR (CD3CN, 300 MHz) δ 8.24 (d, J = 5.4 Hz, 1H), 8.15-7.97 (m, 3H),
7.88-7.77 (m, 2H), 7.68 (t, J = 9.0 Hz, 4H), 7.61-7.50 (m, 4H), 7.49-7.39 (m, 3H),
7.34-7.24 (m, 2H), 7.21 - 6.84 (m, 9H), 6.60 (d, J = 9.0 Hz, 2H), 4.65-4.27 (m,
6H), 3.41 (q, J = 7.2 Hz, 4H), 1.15 (t, J = 7.2 Hz, 6H) ppm. FT-IR (KBr, cm-1)
1722 (νC=O). ESI/APCI-MS, m/z (relative intensity), 868.2870, calc. 868.2836 ([MClO4]+, 3%).
[(6-Ph2TPA)Zn(3-((benzoyloxy)naphthalene-2-carbothiolate)]ClO4 (11).
1

H NMR (CD3CN, 300 MHz) 8.46 (d, J = 5.4 Hz, 1H), 8.15-7.84 (m, 6H), 7.83-

7.74 (m, 3H), 7.70 (t, J = 7.5 Hz, 1H), 7.65-7.32 (m, 13H), 7.27 (t, J = 7.8 Hz,
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4H), 7.09 (d, J = 7.8 Hz, 3H), 4.60-4.16 (m, 6H) ppm. FT-IR (KBr, cm-1) 1742
(νC=O). ESI/APCI-MS, m/z (relative intensity), 813.1889, calc. 813.1872 ([MClO4]+, 100%).
[(6-Ph2TPA)Zn(3-((4-diethylamino)benoyl)oxy)naphthalene-2carbothiolate)]ClO4 (12). 1H NMR (CD3CN, 300 MHz) 8.46 (d, J = 5.1 Hz, 1H),
8.00 - 7.88 (m, 4H), 7.85 - 7.75 (m, 2H), 7.65 (d, J = 9.3 Hz, 2H), 7.61 - 7.52 (m,
4H), 7.48 - 7.35 (m, 7H), 7.25 (t, J = 7.8 Hz, 4H), 7.10 (d, J = 7.5 Hz, 4H), 6.68
(d, J = 9.3 Hz, 2H), 4.62 - 4.28 (m, 6H), 3.51 (q, J = 6.9 Hz, 4H), 1.25 (t, J = 6.9
Hz, 6H) ppm. FT-IR (KBr, cm-1) 1739 (nC=O). ESI/APCI-MS, m/z (relative
intensity), 884.2641, calc. 884.2607 ([M-ClO4]+, 50%).
Control reactions. Solutions of 5-8 (~10 mM) in d3-acetontirile were
prepared in air under minimal red light and placed in NMR tubes. The tubes were
then covered with foil and illuminated with white light for 24 hours. Evaluation of
each solution by 1H NMR indicated that no reaction had occurred.
Anaerobic control reactions. Solutions of 5-8 (~10 mM) in d3-acetontrile
were prepared in a Vacuum Atmospheres glovebox under N2 and placed in NMR
tubes. The caps of the NMR tubes were wrapped securely with Parafilm and the
tubes were illuminated with white light lamps for 24 hours. Evaluation of the
samples by 1H NMR indicated that no reaction had occurred.
CO release quantification of 5-8 in acetonitrile. 50 mL round bottom
flasks were loaded with 5-8 (ca. 10 mg) dissolved in acetonitrile (5.0 mL). The
flask was then sealed with a septum, purged with O2 for 45 seconds, and
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illuminated with white light for 24 hours resulting in bleaching of each solution to
colorless. A sample (10 mL) of the headspace gas was then analyzed by gas
chromatography and the area of the peak associated with CO applied to a
calibration curve created specifically for reactions done in acetonitrile. The
solvent was then removed under reduced pressure and the residual solid
analyzed by 1H NMR for completeness of reaction.
Photoinduced Reactivity of 5-8 as Solids. Compounds 5-8 (ca. 10 mg)
were loaded into 50 mL round bottom flasks under O2. Exposure of solid 5-8 to
white light for 48 hours results in clean conversion to 9-12 as determined by 1H
NMR of the final product. Additionally, the color of the solid compounds changed
to beige.
Results
The development of CO-releasing structural motifs that can be easily
prepared and tuned via multiple strategies (e.g. organic synthesis and/or metal
coordination) offers advantages toward the development of compounds that can
be applied in biology and synthesis. Our approach focuses on the use of
extended 3-hydroxy-4-pyrone based frameworks which are easily structurally
modified to modulate spectroscopic and CO release properties. The presence of
the 3-hydroxy-4-pyrone unit also offers the possibility of metal coordination.
Compounds 5-8 were prepared via the approach shown in Scheme 4-1. Each
was obtained in high yield as an analytically pure solid following precipitation
from hexanes. Although X-ray quality crystals could not be obtained for a

121

Scheme 4-1 Synthesis of 5-8.

member of this family of compounds, the 1H NMR spectral features of 5-8
(Figures C-1, C-6, C-11, and C-16) suggest a mononuclear pseudo-octahedral
Zn(II) center with the flavonolato ligand positioned between the phenyl-appended
pyridyl donors of the 6-Ph2TPA ligand. Evidence for this type of structure is the
1

H NMR features of the benzylic hydrogens which are consistent with Cs (mirror

plane) symmetry in the cation. When dissolved in CH3CN, each compound
exhibits a molecular ion consistent with the proposed mononuclear formulation
(Figures C-5, C-10, C-15, and C-20). The outer sphere ClO4- is evidenced in the
solid state IR spectra of the compounds (Figures C-2, C-7, C-12, and C-17).
Each compound 5-8 exhibits a ~60-90 nm red-shift for the lowest energy
absorption feature relative to neutral 1-4 (Tables 4-1 and 4-2; Figures C-3, C-8,
C-13, C-18). While 5 and 7 exhibit lower molar absorptivity values for the lowest
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energy absorption band than the neutral flavonols, those of the NEt2-substituted
6 and 8 are enhanced relative to the neutral flavonols. In terms of previously
reported photoCORMs, the molar absorptivity values of 6-8 at >500 nm exceed
those exhibited by molecular metal carbonyl photoCORMs that absorb above
500 nm.12 aMost red-shifted absorption feature.b Compound dissolved in
acetonitrile in the presence of O2. CO quantification performed by GC after
illumination with 419 nm lamps (5) or white light lamps equipped with 546 nm cut
off filters (6, 7, 8) for 24 h. Average CO release of three independent samples;
values in parentheses represent standard error. cAverage of three independent
trials; values in parenthesis represent standard error. dF obtained for solution
(CH3CN) CO release via illumination using 419 nm lamps and potassium
ferrioxalate actinometer. eF obtained for solution (CH3CN) CO release via
illumination with white light lamps equipped with 546 nm cut off filters and
potassium reineckate actinometer. fPowdered compound in the presence of O2.
CO quantification performed by GC after illumination with 419 nm light (5) or
white light lamps equipped with 546 nm cut off filters (6, 7, 8) for 48 h. Average
CO release of two independent samples; values in parentheses represent
standard error.
Compounds 6 and 8 have molar absorptivity values at >500 nm that
exceed all organic photoCORMs20-23, including recently reported BODIPY
derivatives.20 Illumination into the lowest energy absorption band of 5-8 produces
a fluorescent emission with a Stokes shift of 30-72 nm (Figures C-4, C-9, S14,
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and C-19). The sulfur-containing 7 and 8 exhibit smaller Stokes shifts relative to
the oxygen analogs.

Photoinduced O2 reactivity of 5-8 in CH3CN
Illumination of CH3CN solutions of 5-8 with visible light results in the
release of one equivalent of CO and the clean formation of a single zinc
carboxylate compound (9-12; Scheme 4-2) as determined by 1H NMR, IR, and
ESI-MS. The1H NMR spectra of 9-12 again exhibit features for the benzylic
hydrogens consistent with Cs symmetry (Figures C-21, C-25, C-28, C-31).
Infrared and ESI/APCI mass spectral data also supports to proposed formulation

Scheme 4-2 Visible light induced CO release reactivity of 5-8 in CH3CN or the
solid state.
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of mononuclear carboxylate compounds that have resulted from dioxygenasetype reactivity and CO-release (IR: Figures C-22, C-26, C-29, C-32; ESI/APCI:
Figures C-23, C-27, C-30, C-33). The incorporation of two oxygen atoms from O2
into the product is also evidenced by the reaction of 5 in the presence of 18O2,
which yields 9 containing two labeled oxygen atoms (ESI/APCI MS Figure C-24).
The reaction quantum yields for CO-release from 9-12 (Table 4-2) in CH3CN
significantly exceed those exhibited by the neutral flavonols 5-7, metal carbonyl
photoCORMs12, and all reported neutral organic photoCORMs20-23.

Solid-state photoinduced CO release reactivity of 5-8
Light induced CO release compounds offer the possibility of control over
the temporal and spatial release of CO. To date, compounds developed for
biological and in situ synthetic applications have focused on soluble species.
However, insoluble solid-state materials or compounds that release CO upon
introduction of visible light could also be very useful in various applications
including in implantable systems and for CO release within reaction mixtures.
Visible and near infra-red light-driven NO-releasing solid-state materials
(photoNORMs) have been previously developed for biological applications.43-51 A
current limitation in terms of photoCORM development is the almost complete
lack of availability of compounds that exhibit solid state CO release reactivity
upon illumination with visible light. Recently, Mascharak, et al. reported two Mn(I)
tricarbonyl compounds that will release CO upon illumination of the crystals with
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microscope light. However, these compounds were not characterized in terms of
the amount of CO released or the products remaining following CO release.33
To our knowledge, solid-state light-induced CO release has not been
previously reported for flavonol or metal flavonolato complexes.52 Notably, we
have discovered that exposure of powders of 5-8 to visible light in the presence
of O2 for 48 h results in quantitative CO release (Table 4-2). Analysis of the
remaining beige powders following light illumination via 1H NMR in CD3CN
indicates the clean formation of 9-12. Thus, the same reactivity is observed for 58 both in solution and in the solid state. It is essential to note that the neutral
flavonols 1-4 are unreactive as solids upon extended illumination (one week) with
visible light. Both the neutral flavonols (1-4) and the zinc flavonolato derivatives
(5-8) are also unreactive as solids under anaerobic conditions.

Conclusions
The dioxygenase-type CO release chemistry of metal complexes of 3hydroxy-4-pyrone derivatives (flavonols) has received considerable attention due
to its relevance to quercetin dioxygenase enzymes.53-60 Our discovery of lightinduced CO release chemistry for divalent metal flavonolato compounds37,38 has
spurred us to further evaluate the light-induced CO release reactivity of flavonol
and flavonolato species for applications as photoCORMs. Construction of the
extended 3-hydroxy-4-pyrone derivatives 1-4 led to the discovery that unlike
neutral 3-hydroxyflavone52, which undergoes multiple types of reactions upon
illumination with UV light, the neutral extended flavonols undergo clean
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dioxygenase-type visible-light induced CO release in the presence of O2.34 In this
contribution we have evaluated how stabilizing the flavonolato anion of 1-4 via
zinc coordination affects the CO release chemistry. Importantly, we have
discovered that zinc coordination results in a red-shift of the absorption features,
with 8 exhibiting a large absorption feature that extends into the therapeutic
window (>650 nm). The reaction quantum yields for CO release are enhanced in
the flavonolato derivatives relative to the neutral flavonols, in some cases by two
orders of magnitude. Perhaps most importantly, the flavonolato derivatives
exhibit CO release both in solution and in the solid state. Overall, these results
demonstrate that 3-hydroxy-4-pyrone (flavonol) derivatives are tunable using
both organic and inorganic approaches for the development of light-driven COreleasing molecules. The ease with which structural modifications can be made
positions this family of CO release molecules to contribute to various goals in
understanding the biological effects of CO. Specifically, the tunability of the
quantum yield in flavanol/flavonolato derivatives suggests that such compounds
could be used to deliver various fluxes of CO under site and temporal control.
The discovery of light-induced solid-state release reactivity in 9-12 also opens up
the opportunity for the development of metal flavonolato-based solid-state COreleasing materials that can be triggered using visible light. Such materials could
be useful for antibacterial applications61 and well as CO release in synthesis (e.g.
carbonylation chemistry). We note that replacement of the 6-Ph2TPA ligand with
other supporting ligands dramatically affects the organic and aqueous solubility
of the zinc flavonolato compounds while light-induced CO release reactivity is
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retained. Studies of applications of various compounds of this class are currently
in progress in our laboratory.
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CHAPTER 5

SOLUTION OR SOLID - IT DOESN’T MATTER: VISIBLE-LIGHT INDUCED CO
RELEASE REACTIVITY OF ZINC FLAVONOLATO COMPLEXES

Abstract
Zinc flavonolato complexes, Zn(flavonolato)2, of four extended flavonols
have been prepared, characterized, and evaluated for visible light-induced CO
release reactivity. Zinc coordination of each flavonolato anion results in a redshift of the lowest energy absorption feature and in some cases enhanced molar
absorptivity relative to the free flavonol. The zinc-coordinated flavonolato ligands
undergo visible light-induced CO release producing 2 equivalents of CO per
equivalent of compound. Most notable is the discovery that zinc flavonolato
derivatives undergo similar visible light-induced CO release reactivity in solution
and in the solid state. A solid film of a Zn(flavonolato)2 derivative was evaluated
as an in situ CO release agent for aerobic oxidative palladium-catalyzed
alkoxycarbonylation to produce esters in ethanol. The CO release product was
found to undergo ester alcolysis under the conditions of the carbonylation
reaction.

Introduction
Delivery of controlled amounts of carbon monoxide (CO) is of
significant current interest both in biology and synthetic chemistry. In
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humans, CO is produced endogenously via the enzyme-catalyzed
breakdown of heme.1 Studies of the effects of CO have demonstrated its
potential to produce a variety of beneficial health outcomes including antiinflammatory, anti-apoptotic, vasodilation, and anti-bacterial effects.2-3 To
explore the biology of CO and its possible uses as a therapeutic, COreleasing molecules (CORMs) have been developed for the delivery of
controlled amounts of CO.4 To date, the majority of CORMs investigated
have been metal carbonyl compounds (MCCs), with the most extensively
studied being [Ru(CO)3(glycinate)Cl] (CORM-3).5 This compound
coordinated to histidine residues of proteins and spontaneously releases
CO via ligand exchange.6-8 Other MCC CORMs release CO via enzymeinduced reactivity9,10, magnetic heating11, or via visible light-induced
reactivity (photoCORMs).12-14 CORMs that can be easily controlled in terms
of their CO release reactivity are especially attractive as they offer the
opportunity for localized release of CO at specific sites for biological
studies or therapeutic purposes.
To address issues of solubility and concerns regarding the use of
redox-active and heavy metals in MCCs, efforts to encapsulate these
compounds in micelles, dendrimers, and solid supports have been
reported.11, 15-19 Efforts to develop metal-free organic photoCORMs have
also advanced.20-23 The development of organic photoCORMs holds
significant promise as standard approaches employed in medical chemistry
for tuning and targeting could be possible.24-26
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CO-releasing molecules are also of significant current interest for
applications in synthetic organic chemistry. Due to the health hazards of
handling CO gas, efforts in recent years have focused on the development
of molecules that release CO on demand for synthetic applications, such
as palladium-catalyzed carbonylation reactions.27-32 The majority of the CO
release compounds currently being used in synthetic organic application
wither are used in an ex situ fashion or are used in situ but require the
introduction of additional reagents, microwave irradiation, or heating to
induce CO release. Ex situ approaches require either the use of
specialized two-chamber glassware to separate the CO-generation process
from the substrate reaction chamber27-31-, or manual transfer of the gas
(e.g. via a balloon).32 In situ sources for CO have also been previously
reported. These include metal carbonyls (e.g. Mo(CO)6), which can serve
as in situ CO release agents for palladium-catalyzed carbonylations, albeit
not at a stoichiometric level with respect to CO.33-43 When metal carbonyls
are used, additional reagents, high temperatures and/or microwave
assistance are generally needed for CO release. It is also important to note
that low-valent metal carbonyls typically cannot be used in situ for
substrates containing functional groups that can be reduced (e.g. –NO2
derivatives) due to the reducing nature of the low-valent metal complex.3440, 44

Two chamber systems can be used to address this issue.45

Formamides46 (including N-formylsaccharin47,48), formats, and formic
acid49,50 derivatives, as well as CHCl351, and diethylpyrocarbonate52,53 have
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been recently investigated as in situ CO release agents at near
stoichiometric levels. However, all of these CO release compounds require
either significant heat (formamides and formic acids, diethylpyrocarbonate),
or the presence of additional reagents (e.g. N-formylsaccharin (mild base
or KF); formats (mild base); formic acid (strongly acidic conditions); CHCl3
(metal hydroxide) to induce CO release.
An area that has seen little development is that of solid compounds
capable of visible light-induced CO release. Such compounds could offer
the possibility of CO release materials that could have tremendous
advantages for both biological and synthetic applications. Mascharak
recently reported two visible light-induced MCC photoCORMs that undergo
solid-state CO release.54 However, the quantity of CO released and the
byproducts of this reactivity have not been reported.
Our laboratory is developing visible light-induced CO release
compounds based on the 3-hydroxy-4-flavone moiety found in naturally
occurring flavonols. Prior to our work, metal flavonolato species were well
known to undergo dioxygenase-type degradation to release CO via either
enzyme catalysis55 or thermal reactivity56 involving O2 activation. However,
reports of light-driven CO release reactivity involving O2 activation with
either free or metal-coordinated flavonols were scarce.57 We recently
reported a new family of neutral flavonol derivatives (1-4, Figure 5-1) that
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Fig 5-1 Structure of flavonol-based CO releasing molecules

undergo dioxygenase-type visible light-induced quantitative CO release
when dissolved in organic solvents or organic/aqueous mixtures.58 As
shown in Table 5-1, this class of compounds can be tuned to undergo
quantitative CO release under aerobic or anaerobic conditions. These
flavonol derivatives are fluorescent and therefore trackable in cells.
Compound 1 has been demonstrated to penetrate cells and then undergo
quantitative CO release upon exposure to visible light. The structural
framework in 1-4 also offers the opportunity for chelation to a metal center
as a means of tuning the reactivity of the CO-releasing moiety. In the
studies reported herein, we have identified key findings related to zinc
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Table 5-1 Properties of 1-4.
λmax (nm)a
Compound
1
2
3
4

-1

-1

ε (M cm )
409
16,600
442
51,000
478
36,700
544
85,500

Aerobic
CO
Release

Φ

Anaerobic
CO
Release

Yes

0.007(3)

No

Yes

0.006(1)

No

Yes

0.43(3)

No

Yes

d

Yes

c

a

Most red-shifted absorption feature. bMeasured in acetonitrile in the
presence of air. c Average of three independent trials; values in parenthesis
represent standard error. dQuantum yield for CO release not reported due
to concurrent aerobic and anaerobic CO release reactions.

coordination. The absorption spectral features of the compounds red shift
with some being in the therapeutic window (>650 nm) and solid-state CO
release activity can occur that is identical to the reactivity seen in solution.
The discovery of light-induced solid-state CO release reactivity is
particularly significant as it suggests that CO release materials based on a
zinc flavonolato motif could be developed. Building on this discovery, we
sought to design zinc flavonolato derivatives that are insoluble in organic
solvents, which could facilitate their use as in situ light-driven CO release
agents in synthetic organic processes. Our experience with simple Zn(II)
bis-flavonolato compounds (Zn(flavonolato)2) suggested that such
compounds could exhibit the desired minimal solubility.59 Therefore
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derivatives of this type using 1-4 were synthesized, characterized, and
evaluated as solid-state CO release agents. As outlined herein, we have
found that a member of this family can be used in aerobic oxidative
palladium-catalyzed carbonylation processes that employ O2 as the sole
oxidant and are performed under very mild conditions.62 Overall, our results
suggest that the structural motif in 1-4 is a highly versatile CO release unit
that can be developed for various CO release applications.

Experimental Section
General

Chemicals and Reagents
All chemicals and reagents were obtained from commercial sources
and used as received unless otherwise noted. The synthesis of the
extended flavonols 1-4 proceeded as previously reported.58

Physical Methods
Anaerobic procedures were performed in a Vacuum Atmospheres
glovebox under N2. Solvents for glovebox use were dried according to
published methods and distilled under N2.64 UV-vis spectra were recorded
at room temperature using a Hewlett-Packard 8453A diode array
spectrophotometer. Fluorescence emission spectra were collected using a
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Shimadzu RF-530XPC spectrometer in the range of 400-800 nm with the
excitation wavelength corresponding to the most red-shifted absorption
maximum of the compound. Infrared spectra were recorded using a
Shimadzu FTIR-8400 as KBr pellets. 1H NMR spectra (in ppm) are
referenced to the residual solvent peaks in pyridine-d5 (1H: 7.22 (singlet)
ppm). J values are given in Hz. Mass spectral data was collected at the
Mass Spectrometry Facility, University of California, Riverside. Elemental
analyses were performed by Atlantic Microlab, Inc., Norcross, GA, or by
Robertson Microlit Laboratories, Ledgewood, NJ. Photochemical
experiments were performed using a Luzchem photoreactor equipped with
RPR-4190A, RPR5750A, or Sylvania cool white lamps. Carbon monoxide
quantification were performed by gas chromatography as previously
described.61
General Synthetic Method for Zinc Bis(flavonolato) Compounds.
A 500 mL round bottom flask, protected from light with aluminium foil, was
charged with the flavonol (21 mmol), Me4NOH·5H2O (21 mmol), and MeOH
(50 mL) and the resulting mixture was stirred at room temperature for 2
hours. Zinc triflate (10.3 mmol) was then transferred to the flask using
MeOH (15 mL). The mixture was stirred overnight after which time the
product was collected by filtration, washed with water and dried in vacuo.
Zn(1-)2·4H2O (5). 88% yield. Orange solid. 1H NMR (pyridine-d5, 300
MHz)

9.35 (d, J = 7.8 Hz, 4H), 8.86 (s, 2H), 8.07 (s, 2H), 7.89 (d, J = 8.4

Hz, 2H), 7.80-7.77 (m, 6H), 7.54-7.39 (m, 4H), 7.27 (t, J = 7.2 Hz, 2H) ppm.
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UV-vis (pyridine), nm ( , M-1cm-1) 483 (23,300), 375 (7,600), 306 (25,700).
LIFDI-MS, m/z (relative intensity) 638.0710, calc. 638.0702 ([M]+, 100%).
Anal. Calc. C38H22O6Zn·4H2O: C, 64.10; H, 4.25. Found: C, 63.48; H, 4.08.
The presence and quantity of water present in the solid sample was
confirmed through integration of the water peak in the 1H NMR spectrum.
Zn(2-)2·2H2O (6). 86% yield. Red Solid. 1H NMR (pyridine-d5, 300
MHz)

9.37 (d, J = 8.7 Hz, 4H), 9.03 (s, 2H), 8.10 (s, 2H), 7.91 (d, J = 8.1

Hz, 2H), 7.88 (d, J = 8.7 Hz, 2H), 7.46 (t, J = 8.7 Hz, 2H), 7.34 (t, J = 8.1
Hz, 2H), 6.94 (d, J = 8.7 Hz, 4H), 3.30 (q, J = 7.2 Hz, 8H), 1.08 (t, J = 7.2
Hz, 12H) ppm. UV-vis (pyridine), nm ( , M-1cm-1) 525 (92,500), 402
(17,600), 305 (47,800). LIFDI-MS, m/z (relative intensity) 780.2163, calc.
780.2172 ([M+], 100%). Anal. Calc. C46H40N2O6Zn·2H2O: C, 67.52; H, 5.42;
N, 3.42. Found: C, 67.30; H, 5.29; N, 3.50. The presence and quantity of
water present in the solid sample was confirmed through integration of the
water peak in the 1H NMR spectrum.
Zn(3-)2·2H2O (7). 92% yield. Purple solid. 1H NMR (pyridine-d5, 300
MHz)

9.48 (d, J = 7.5 Hz, 4H), 9.45 (s, 2H), 8.26 (s, 2H), 8.10 (d, J = 8.7

Hz, 2H), 8.01 (d, J = 8.4 Hz, 2H), 7.70 (t, J = 7.5 Hz, 4H), 7.56-7.43 (m, 6H)
ppm. UV-vis (pyridine), nm ( , M-1cm-1) 564 (31,700), 405 (27,500), 306
(22,800). LIFDI-MS, m/z (relative intensity) 670.0259, calc. 670.0246 ([M+],
72%). Anal. Calc. C38H22O4S2Zn·2H2O: C, 64.45; H, 3.70. Found: C, 64.21;
H, 3.73. The presence and quantity of water present in the solid sample
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was confirmed through integration of the water peak in the 1H NMR
spectrum.
Zn(4-)2·2H2O (8). 91% yield. Blue solid. 1H NMR (pyridine-d5, 300
MHz)

9.55 (d, J = 9.3 Hz, 4H), 9.44 (s, 2H), 8.16 (s, 2H), 8.05 (d, J = 8.1

Hz, 2H), 7.95 (d, J = 8.7 Hz, 2H), 7.55-7.37 (m, 4H), 6.91 (d, J = 6.9 Hz,
4H), 3.33 (q, J = 6.9 Hz, 8H), 1.09 (t, J = 6.9 Hz, 12H) ppm. UV-vis
(pyridine), nm ( , M-1cm-1) 609 (143,300), 303 (52,200). LIFDI-MS, m/z
(relative intensity) 812.1711, calc. 812.1715 ([M+], 100%). Anal. Calc.
C46H40N2O4S2Zn·2H2O: C, 64.97; H, 5.22; N, 3.29. Found: C, 64.75; H,
5.08; N, 3.27. The presence and quantity of water present in the solid
sample was confirmed through integration of the water peak in the 1H NMR
spectrum.
Photoinduced Reactivity of 5-8 in Pyridine. Solutions of 5-8
(~0.01 mmol) in pyridine-d5 (~0.7 mL) were placed in NMR tubes under air.
Each tube was then placed in a Luzchem photoreactor equipped with 419
nm or white light lamps and illuminated until the reaction was determined to
be complete by 1H NMR. The solvent was then removed under reduced
pressure and an FT-IR spectrum was obtained.
Zinc bis(3-benzoyloxy)-2-naphthoate) (9). Beige solid. 1H NMR
(pyridine-d5, 300 MHz)

9.14 (s, 2H), 8.48 (d, J = 6.9 Hz, 4H), 1H NMR

(pyridine-d5, 300 MHz) 7.94-7.82 (m, 6H), 7.56-7.37 (m, 10H) ppm. FT-IR
(KBr, cm-1) 1728 (nC=O).
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Zinc bis(3-((4-(diethylamino)benzoyl)oxy)-2-naphthoate) (10).
Beige solid. 1H NMR (pyridine-d5, 300 MHz)

9.11 (s, 2H), 8.47 (d, J = 7.2

Hz, 4H), 8.00-7.75 (m, 6H), 7.51-7.26 (m, 4H), 6.71 (d, J = 7.2 Hz, 4H),
3.19 (q, J = 6.9 Hz, 8H), 0.99 (t, J = 6.9 Hz, 12H) ppm. FT-IR (KBr, cm-1)
1714 (nC=O)
Zinc bis(3-(benzoyloxy)naphthalene-2-carbothiolate (11). Beige
solid. 1H NMR (pyridine-d5, MHz)

9.14 (s, 2H), 8.36 (d, J = 8.6 Hz, 4H),

7.97 (d, J = 8.1 Hz, 2H), 7.84 (d, J = 8.1 Hz, 2H), 7.79 (s, 2H), 7.55-7.35
(m, 10H) ppm. FT-IR (KBr, cm-1) 1739 (nC=O).
Zinc bis(3-(4-(diethylamino)benzoyl)oxy)naphthalene-2carbothiolate (12). Beige solid. 1H NMR (pyridine-d5, 300 MHz)

9.06 (s,

2H), 8.36 (d, J = 7.5 Hz, 4H), 8.00-7.65 (m, 6H), 7.57-7.29 (m, 4H), 6.73 (d,
J = 7.5 Hz, 4H), 3.26 (q, J = 6.9 Hz, 8H), 1.04 (t, J = 6.9 Hz, 12H) ppm. FTIR (KBr, cm-1) 1713 (nC=O).
Dark control reactions of 5-8. Solutions of 5-8 (~2 mM) in pyridined5 were prepared in air under minimal red light and each was placed in a
NMR tube. Each NMR tube was then covered in foil, placed in a
photoreactor, and illuminated using 419 nm (5 and 6) or white light lamps
(5-8) for 24 hours. Evaluation of each solution by 1H NMR indicated that no
reaction had occurred.
Anaerobic control reaction. Solutions of 5-8 in pyridine-d5 were
prepared, each was placed in a NMR tube, and N2 was bubbled through
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each solution for ~5 minutes. Each NMR tube was then placed in a
photoreactor and illuminated with 419 nm (5 and 6) or white light lamps (58) for 24 hours. Evaluation of each solution by 1H NMR indicated that no
reaction had occurred.
CO release quantification of 5-8 in solution. 50 mL round bottom
flasks were loaded with 5-8 (ca. 10 mg) dissolved in pyridine (5 mL). Each
flask was then sealed with a septum, purged with O2 for 45 seconds, and
illuminated with white light for 24 hours, which resulted in the bleaching of
each solution to colorless. A sample (10 mL) of headspace gas was then
analyzed by gas chromatography and the area of the peak associated with
CO applied to a calibration curve created specifically for reactions
performed in pyridine. The solvent was then removed under reduced
pressure and the residual solid was analyzed by 1H NMR for completeness
of reaction.
Photoreactivity fo 5-8 as powdered solids. Compounds 5-8 were
placed in 50 mL round bottom flasks as powdered solids. Each flask was
then sealed with a septum, gently purged with O2 for 1 minute, and placed
in a photoreactor with 419 nm (5 and 6) or white light lamps (5-8) for 72
hours. The headspace gas of the flask was then analyzed by gas
chromatography for the production of CO. Compounds 5 and 6 as
powdered solids produced 2 equivalents of CO per equivalent of compound
when illuminated 419 nm or white light lamps. Compounds 7 and 8 did not
produce CO upon illumination with white light lamps. The residual solid in
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the flask was then dissolved in pyridine-d5 and the solution evaluated by 1H
NMR, indicating 5 and 6 had fully converted to the photoproducts 9 and 10,
while no reaction occurred for 7 and 8.
Photoreactivity of 5 as a film deposit. Compound 5 (52.6

mol,

33.7 mg) was deposited in a round bottom flask and dissolved in pyridine
(~ 10 mL). The solvent was then removed via rotary evaporator using the
highest rpm setting to deposit the compound on the vessel walls. The flask
was sealed with a septum and placed in a photoreactor with 419 nm or
white light lamps and illuminated for 48 hours. Reactions were determined
to be complete by 1H NMR.
CO quantification for solid samples 5 and 6. A GC calibration
curve for the quantification of CO was created using sodium bicarbonate as
an inert solid in a 50 mL round bottom flask. Each flask was sealed with a
septum, evacuated, and varying volumes of O2 and CO were injected. For
each mixture, GC analysis was performed using the number of moles of
CO calculated to be in the flask based on volume.
Aerobic oxidative palladium-catalyzed carbonylation reactions.
The general reaction conditions were as follows. Compound 5 was
deposited as a film in a 50 mL round bottom flask as described above. The
flask was then loaded with phenyl boronic ester (52.6
PdCl2(PPh3)2 (2.63

mol, 1.8 mg), NEt3 (105.2

mol, 10 mg),

mol, 15

L) and ethanol

(5 mL, 190 proof). The flask was then sealed with a septum and placed in
an oil bath pre-heated to 40 °C. Each reaction mixture was illuminated with
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two CFL blue bulbs set at an average distance of 5 cm from the flask for 24
hours. The flask was removed from the oil bath and allowed to cool to room
temperature. The reaction mixture was then passed through a short silica
plug (~600 mg) 1 L of the filtrate was then analyzed by GC-MS. The
remaining filtrate from the reactions was then brought to dryness under
reduced pressure and analyzed by 1H NMR.
GC-MS parameters. GC-MS spectral data was collected on a
Shimadzu GCMS-QP5000 equipped with an EC-5 column that is 5%
phenyl:95% methylpolysiloxane with a fused silica coating. The column is
30 m in length with a 0.25

m coating and 0.25 mm diameter. The injection

temperature was 185 °C with an interface temperature of 250 °C. The
column initial temperature was 70 °C with a final temperature of 250 °C
and a ramp rate of 12 °C/minute. The column inlet pressure was 43.5 kPa
with a column flow of 0.8 mL/min and a linear velocity of 32.8 cm/sec for a
total flow of 35.4 mL/min. Analysis of product mixtures was performed on 1
L of EtOH solution.
Evaluation of CO release reactivity of 5 (film deposit) in the
presence of ethanol. A film deposit of 5 in a 50 mL round bottom flask
was generated as outlined above. To this flask was added ethanol (5 mL).
The flask was then sealed with a septum and placed in an oil bath preheated to 40 °C. The flask was illuminated with two CFL blue bulbs set at
an average distance of 5 cm from the flask for 24 hours. The flask was then
removed from the oil bath and allowed to cool to room temperature. The
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ethanol solution was then passed through a short silica plug (~600 mg).
The filtrate was then analyzed by GC-MS, which revealed the formation of
ethyl benzoate. The remaining filtrate was then brought to dryness under
reduced pressure and analyzed by 1H NMR.

Results
The development of CO-releasing structural motifs that can be easily
prepared and tuned via multiple strategies (e.g. organic synthesis and/or
metal coordination) offers advantages toward the generation of compounds
that can be easily applied in biology and synthesis. Our approach focuses
on the use of extended 3-hydroxy-4-pyrone based frameworks, which are
easily structurally modified to modulate spectroscopic and CO release
properties. The presence of the 3-hydroxy-4-pyrone unit also offers the
possibility of metal coordination.
Mixing 1-4 with Zn(OTf)2 in MeOH in the presence of base yielded
precipitates of the analytical formulation [Zn(flavonolato)2·nH2O (5, n=4; 68, n=2; Scheme 5-1). All exhibit poor solubility in common organic solvents
except pyridine. Each compound was characterized as a solid using
elemental analysis and FT-IR. 1H NMR, LIFDI-MS, UV-vis, and
fluorescence spectra (Figures D-1-D-16) were obtained in pyridine. The 1H
NMR features are consistent with equivalent flavonolato ligands,
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5, X = O, R = H
6, X = O, R = NEt2
7, X = S, R = H
8, X = S, R = NEt2

Scheme 5-1 Synthesis of 5-8.

suggesting possible trans water ligands (Scheme 5-1) in a pseudooctahedral structure. As shown in Figure 5-2, the absorption features of 5-8
in pyridine (Table 5-2) span the visible region from ~400-650 nm. The NEt2containing derivatives 6 and 8 have high extinction coefficients, consistent
with the presence of two flavonolato ligands.

Photoinduced O2 reactivity of 5-8
When dissolved in pyridine and illuminated with white (5-8) or blue
light (5 and 6), the Zn(II) bis(flavonolato) compounds exhibit dioxygenasetype photoinduced release of two equivalents of CO (Table 5-2). The zinc
containing products (9-12, Scheme 5-2) are bis-carboxylate derivatives
based on 1H NMR and IR spectral features (Figures D-17-D-24). Thus,
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Compounds 5-8 dissolved in pyridine (200 µg/mL)

5

6

7

Fig 5-2 Absorption spectral features of 5-8.

Table 5-2 Absorption and CO release properties of 5-8

8
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5, X = O, R = H
6, X = O, R = NEt2

9, X = O, R = H
10, X = O, R = NEt2

7, X = S, R = H
8, X = S, R = NEt2

11, X = S, R = H
12, X = S, R = NEt2

Scheme 5-2 Visible light induced CO release reactivity of 5-8 in pyridine.

both flavonolato ligands in 5-8 undergo light-induced CO release when
dissolved in pyridine. We note than Tran and Cohen previously reported
light-induced reactivity for a zinc bis(flavonothianoato) complex in CHCl3
but did not report the nature of the products.63

Solid-state photoinduced CO-release reactivity of 5 and 6
Light induced CO release compounds offer the possibility of control
over the temporal and spatial release of CO. To date, compounds
developed for biological and in situ synthetic applications have focused on
soluble species. However, solid-state materials or compounds that release

151

CO upon introduction of visible light could also be very useful in various
applications, including in implantable systems and for CO release within
reaction mixtures. Visible and near infra-red light-driven NO-releasing solidstate materials (photoNORMs) have been previously developed for
biological applications.64-72 A current limitation in terms of development of
photoCORM materials is the almost complete lack of availability of
compounds that exhibit solid state CO release reactivity upon illumination
compounds that will release CO upon illumination of the crystals with
microscope light. However, these compounds were not characterized in
terms of the amount of CO released or the products remaining following
CO release.54
To our knowledge, solid state light-induced CO release has not been
previously reported for flavonol or metal flavonolato complexes. Notably,
we have discovered that exposure of powders of 5 and 6 to visible light in
the presence of O2 for 48 h results in quantitative CO release (Table 5-2).
Analysis of the remaining beige powders following light illumination via 1H
NMR in pyridine-d5 indicated the clean formation of 9 and 10. Thus the
same reactivity of observed for 5 and 6 both in solution and in the solid
state. The solid thiocarbonyl derivatives did not exhibit CO release even
after extensive periods of illumination (1 week). These results demonstrate
that there are factors that influence solid-state CO release within this family
of compounds that remain to be determined. It is important to note that the
neutral flavonols 1-4 are unreactive as solids upon extended illumination (1
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week) with visible light. The zinc bis(flavonolato) complexes (5 and 6) are
unreactive as solids under anaerobic conditions.

Initial evaluation of 5 as a CO source for oxidative palladium
catalyzed carbonylation in ethanol
Building on the discovery of solid-state CO release reactivity for 5,
we performed initial studies to examine the possibility of using this
compound as an in situ heterogeneous visible light-induced CO release
agent for oxidative palladium-catalyzed alkoxycarbonylation processes
such as the reactions outlined in Scheme 5-3. Liu, et al. have previously
reported that such reactions can be performed using air:CO (ratio 3:1-5:1)
to give carbonylated products in >70% yield using various alcohols as the
solvent.62 To our knowledge, CO-releasing molecules have not been
previously explored as alternatives to CO gas under this type of low
temperature, aerobic conditions. Our initial screening reactions focused on
the use of 5 at near stoichiometric level in terms of available CO in
reactions with boronic esters of varying electronic substituents (Scheme
3b). For each reaction, a 50 mL round bottom flask was coated with 1
equivalent of 5 (up to 2 eq CO) as a film via rotary evaporation of a pyridine
solution of the complex. The boronic ester, NEt3, and PdCl2(PPh3)2 were
then added along with ethanol (5 mL). Each reaction mixture was heated
under air at 40 °C using an oil bath and was illuminated with two blue CFL
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Scheme 5-3 Aerobic palladium catalyzed alkoxycarbonylation reactions.
The relative yields of the products generated for R” = -NO2 in b) could not
be determined due to peak overlap in the GC-MS trace.

bulbs to initiate CO release. After 24 hours of heating and illumination, the
products of the reactions were evaluated using GC-MS and 1H NMR. In the
reactions of 13a and 13b, the desired carbonylation ester products are
generated, along with phenol and biphenyl products (Scheme 5-3, Figures
D-25 and D-26). Generally similar results were obtained for the nitro
derivative 13c albeit no biphenyl product was identified (Figure D-27). The
production of significant amounts of phenyl and biphenyl byproducts

154

indicates that the CO flux in the reaction mixture needs to be further
optimized to limit the formation of these oxidation byproducts. However,
this was not pursued in these reactions due to the additional identification
of the formation of ethyl benzoate in each reaction mixture. This ester is
generated via the breakdown of the flavonol-based CO-release product by
ester alcoholysis (Scheme 5-4). Compound 5 releases ~1 eq of CO after

5

5

Scheme 5-4 Proposed ester alcoholysis reactivity of CO release product.
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24 hours of illumination of the deposited film (Figure D-28). Quantification
(via GC-MS) of the ethyl benzoate generated in reaction mixtures shown in
Scheme 5-4 after 24 hours indicated that ~60-80% of the expected COrelease product (1 eq) has undergone ethanolysis to produce ethyl
benzoate. Overall, these results indicate that while the starting
heterogeneous zinc bis(flavonolato) complex is a viable source of CO for
carbonylation reactivity, the CO-release product is reactive with alcohols.
Minimizing this background alcoholysis reactivity of the CO release agent
so as to obtain cleaner carbonylation reaction product mixtures is the
subject of ongoing studies. We believe that such studies are justified by the
combination of the mild reaction conditions and safe CO-handling present
in these reactions.

Conclusions
The dioxygenase-type CO-release chemistry of metal complexes of
3-hydroxy-4-pyrone derivatives (flavonols) has received considerable
attention due to its relevance to quercetin dioxygenase enzymes.56,73-79 Our
discovery of light-induced CO-release chemistry for divalent metal
flavonolato compounds60,61,67 has spurred us to further evaluate the lightinduced CO release reactivity of flavonols and flavonolato species for
applications as photoCORMs. Construction of the extended 3-hydroxy-4pyrone derivatives 1-4 led to the discovery that unlike neutral 3hydroxyflavone57, which undergoes multiple types of reactions upon
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illumination with UV light, the neutral extended flavonols undergo clean
dioxygenase-type visible-light induced CO release in the presence of O2.58
In this contribution we have evaluated how stabilizing the flavonolato anion
of 1-4 via zinc coordination affects the CO release chemistry. Importantly,
we have discovered that zinc coordination results in a red-shift of the
absorption features, with 8 exhibiting a large absorption feature that
extends into the therapeutic window (>650 nm). Perhaps most importantly,
the flavonolato derivatives exhibit CO release both in solution and in the
solid state. Overall, these results demonstrate that 3-hydroxy-4-pyrone
(flavonol) derivatives are tunable using both organic and inorganic
approaches for the development of light-driven CO-releasing molecules.
The ease with which structural modifications can be made positions this
family of CO-releasing molecules to contribute to various current goals in
the biology and chemistry of carbon monoxide. The discovery of lightinduced solid-state CO release reactivity in 5 and 6 also opens up the
opportunity for the development of metal flavonolato-based solid-state COreleasing materials that can be triggered using visible light. As
demonstrated herein, solid zinc bis(flavonolato) compounds can be used
as in situ CO-release compounds in oxidative palladium-catalyzed
carbonylation reactions albeit with some degradation of the CO release
product. Further studies of the applications of these solids in carbonylation
processes are currently in progress.
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CHAPTER 6

SUMMARY

Supplied in large enough doses, carbon monoxide is toxic. This has been
known since antiquity. It is only relatively recently that carbon monoxide has
been recognized as an incredibly useful compound with roles in chemical
reactions and human health. However, the risk associated with using gaseous
CO has precluded its wide spread application. In order to overcome this difficulty,
the research community has been developing compounds that are essentially
storage devises for carbon monoxide that are safe-to-handle and eliminate the
safety risk associated with the gas. Great strides have been made in this area,
with numerous compounds earning the moniker of CO-releasing molecules
(CORMs) having been reported. These compounds have demonstrated the
feasibility of storing and releasing CO from a compound. Unfortunately, the
CORMs reported thus far all exhibit significant drawbacks that have hindered the
further development of this field. In the Berreau Lab, we are interested in the
development of novel extended flavonols that act as visible light-induced
CORMs. These compounds, based on a naturally occurring framework, display
numerous characteristics desirable in a CORM. Couple these characteristics with
the ease of synthesis and their unprecedented ability to be modified (Figure 6-1)
and we have identified a class of compounds that has the potential to
revolutionize the field of CORMs. The research described in this dissertation
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Figure 6-1. The ease of synthesis and potential for analogs of the extended
flavonol class of compounds.

outlines the means by which modifications to the core structure of flavonols affect
the visible light-induced CO-releasing properties of this class of compounds.
The use of visible light to activate CO-releasing molecules was an
important milestone. UV-light is higher in energy than visible light and therefore
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light-driven CO release from CORMs is typically easier when performed with UVlight. However, UV-light is also extremely damaging and lacks penetration depth
into tissue. Therefore, researchers sought to develop CORMs capable of
triggered CO release using less damaging visible light that also has better tissue
penetration. A significant number of compounds have been reported that have
this capability. However, none of these reported compounds can be tuned in
terms of the wavelength of visible light utilized for the CO release reaction.
Through simple modifications to the core flavonol structure, we have developed
CORMs that have absorption features encompassing almost the entire visible
spectrum (Figure 6-2). Additionally, neutral extended flavonols display numerous
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Figure 6-2. Ranges of the lowest energy absorption features for the flavonol
compounds described herein.

168

features desirable in a CO-releasing molecule. For example, the parent
compound of the neutral extended flavonols displays low toxicity and,
importantly, the photoremnant is non-toxic and the fluorescence properties of
these compounds enable tracking of the localization and the CO-release
reactivity within cells. The ease with which these compounds can be modified to
absorb across the visible spectrum means that they have significant potential for
future commercial development.
The role of carbon monoxide has been implicated in the regulation of a
wide range of physiological processes. It therefore seems logical that different
biological processes would require CO at different rates. For light-triggered
CORMs, the efficiency of the CO release photoreaction is measured in terms of a
quantum yield, with compounds typically falling somewhere between 0 and 1. A
compound with a quantum yield of 1 displays 100% photochemical efficiency. We
have demonstrated that flavonols can be modified to achieve many different
quantum yields (Figure 6-3). Not only have we developed photoCORMs with the
highest quantum yields reported to date, we have compounds that display a
range of different quantum yields. I believe that the principles used to modulate
the quantum yields of these compounds will have a significant role in their future
use and development.
The usefulness of carbon monoxide goes beyond its potential as a
therapeutic. It is routinely used in numerous synthetic processes as a carbonyl
source, such as in the synthesis of ibuprofen and acetic acid. However, the
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toxicity of the gas required a significant investment in infrastructure in order to
ensure the safety of workers. Small-scale chemical companies and academic
institutions lack the capital to ensure its safe usage. In coordinating the extended
flavonols to zinc, we discovered that the compounds would undergo
photoinduced CO-release as solids. The discovery of this type of reactivity has
the potential to expand the use of photoCORMs into the realm of CO sources for
synthetic reactions. It was with this in mind that the zinc(bis(flavonolato))
compounds were developed. Zn(bis(flavonolato)) compounds are notoriously
insoluble in almost all solvents and the compounds that we developed are no
different, the exception being pyridine. These compounds were used as a
heterogeneous in situ CO source for oxidative palladium-catalyzed carbonylation
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reactions. The discovery of solid-state photoinduced CO-release in these
compounds has the potential to develop a new use for photoCORMs.
The future of this work consists of two distinct pathways: (1) the further
creation of analogs to enhance the biological properties of the compounds (i.e.
targeting); and (2) the development of different applications for the solid state
CO-releasing compounds. The results of these future studies will only serve to
enhance the already tremendous potential of this class of compounds.
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Table A-1. Summary of X-ray data collection and refinement.

empirical formula
formula weight
crystal system
space group
a (Å)
b (Å)
x (Å)
a (deg)
b (deg)
g (deg)
V (Å3)
Z
density (calcd), Mg m-3
temp (K)
crystal size (mm3)
diffractometer
Abs. coeff. (mm-1)
2q max (deg)
Reflections collected
indep. reflections
variable parameters
R1 / wR2b
goodness-of-fit (F2)
largest diff. (e Å-3)
CCDC number

a

3×CH3CN
C35H30ClN5O7Zn
733.46
Monoclinic
P21/n
10.7484(2)
17.7387(3)
17.7291(2)
90
105.7229(10)
90
3253.80(9)
4
1.497
150(1)
0.38 x 0.23 x 0.08
Nonius Kappa CCD
0.896
54.96
14263
7433
443
0.0405/0.0962
1.037
0.919; -0.530
1006160

4×CHCl3
C44H50Cl4N6O7Zn
982.07
Triclinic
P-1
11.8486(3)
12.4945(4)
16.2785(5)
88.8622(12)
75.3891(15)
81.2326(16)
2304.29(12)
2
1.415
150(1)
0.35 x 0.28 x 0.10
Nonius Kappa CCD
0.821
50.68
15983
8410
588
0.0490/0.1235
1.027
1.106; -0.664
1006159

Radiation used: Mo Ka (l = 0.71073 Å). bR1 = ∑ | |Fo| - |Fc| | / ∑ |Fo|;

wR2 = [∑[w(Fo2-Fc2)2]/[∑(Fo2)2]]1/2 where w = 1/[

2

(Fo2) + (aP)2 + bP].
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Table A-2. Selected Bond Distances (Å) and Angles (deg) for 3·CH3CN
and 4·CHCl3a
3×CH3CN
Zn(1)-O(1)
Zn(1)-O(2)
Zn(1)-N(1)
Zn(1)-N(2)
Zn(1)-N(3)
Zn(1)-N(4)
O(1)-C(19)
O(2)-C(20)
C(19)-C(20)
O(1)-Zn(1)N(3)-Zn(1)N(4)-Zn(1)N(2)
N(2)
×CHCl3
4
N(1)
Zn(1)-O(1)
Zn(1)-O(2)
Zn(1)-N(2)
Zn(1)-N(3)
Zn(1)-N(4)
Zn(1)-N(6)
O(1)-C(29)
O(2)-C(30)
C(29)-C(30)
N(6)-Zn(1)N(3)-Zn(1)N(4)-Zn(1)N(2)
N(2)
N(2)
a

1.9834(17)
2.1373(17)
2.186(2)
2.2116(18)
2.1179(19)
2.171(2)
1.334(3)
1.249(3)
1.439(3)
172.64(7)
81.23(7)
153.95(8)

O(1)-Zn(1)-O(2)
O(1)-Zn(1)-N(3)
N(3)-Zn(1)-O(2)
O(1)-Zn(1)-N(4)
N(3)-Zn(1)-N(4)
O(2)-Zn(1)-N(4)
O(2)-Zn(1)-N(2)
N(4)-Zn(1)-N(2)
N(1)-Zn(1)-N(2)
O(1)-Zn(1)-N(1)
N(3)-Zn(1)-N(1)
O(2)-Zn(1)-N(1)

81.57(7)
103.21(7)
174.39(7)
108.68(7)
87.76(7)
87.90(7)
94.34(6)
77.13(7)
76.83(7)
97.19(7)
89.31(7)
93.04(7)

2.020(2)
2.159(2)
2.200(3)
2.144(3)
2.181(3)
2.124(3)
1.320(4)
1.254(4)
1.460(4)
95.04(11)
77.30(10)
157.35(10)

O(1)-Zn(1)-N(6)
O(1)-Zn(1)-N(3)
N(6)-Zn(1)-N(3)
O(1)-Zn(1)-O(2)
N(6)-Zn(1)-O(2)
N(3)-Zn(1)-O(2)
N(3)-Zn(1)-N(4)
O(2)-Zn(1)-N(4)
O(1)-Zn(1)-N(2)
O(1)-Zn(1)-N(4)
N(6)-Zn(1)-N(4)
O(2)-Zn(1)-N(4)

106.46(9)
171.00(10)
82.28(11)
80.24(8)
172.05(9)
91.21(10)
80.08(10)
91.51(9)
99.41(9)
102.80(9)
82.91(11)
91.51(9)

Estimated standard deviations in the last significant figure are given

in parentheses.
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Figure A-1. 1H NMR spectrum of [(6-Ph2TPA)Zn(3-Hfl)]ClO4 (1) in CD3CN at 25
o

C. * denotes residual Et2O; ** denotes residual CH2Cl2 in the sample.

176

Figure A-2. 1H NMR spectrum of [(TPA)Zn(3-Hfl)]ClO4 (3) in CD3CN at 25 oC.
Note: The grouping of resonances at ~8.5-9.0 ppm integrates to 6 H’s. This
indicates that one of the H’s listed for the other aromatic group is located here.
However, we are unable to assign which hydrogen this may be.
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a

b
c
d
e
f
g
h

Figure A-3. 1H NMR spectra of [(TPA)Zn(3-Hfl)]ClO4 (3) at various temperatures
in CD2Cl2.
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Figure A-4. 1H NMR spectrum of [(bnpapa)Zn(3-Hfl)]ClO4 (4) in CD3CN at 25 oC.
* denotes residual Et2O; ** denotes residual CH2Cl2 in the sample.
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Figure A-5. 1H NMR spectrum of [(TPA)Zn(O-bs)]ClO4 (5) in CD3CN at 25 oC.
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Figure A-6. 1H NMR spectrum of [(bnpapa)Zn(O-bs)]ClO4 (6) in CD3CN at 25 oC.
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Figure A-7. MALDI mass spectrum of [(TPA)Zn(3-Hfl)]ClO4 (3).
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Figure A-8. MALDI mass spectrum of [(bnpapa)Zn(3-Hfl)]ClO4 (4).
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Figure A-9. MALDI mass spectrum of [(TPA)Zn(O-bs)]ClO4 (5).
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Figure A-10. MALDI mass spectrum of [(bnpapa)Zn(O-bs)]ClO4 (6).
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Figure A-11. MALDI mass spectrum of [(TPA)Zn(O-bs-18O2)]ClO4 (5-18O2).

186

Figure A-12. MALDI mass spectrum of [(bnpapa)Zn(O-bs-18O2)]ClO4 (6-18O2)

187

APPENDIX B

CHAPTER 3 SUPPLEMENTARY MATERIAL

188

*

Figure B-1. 1H NMR spectrum of 4 in CDCl3. The * indicates the residual signal
of the solvent (CHCl3).

189

Figure B-2. ESI/APCI-MS of 4.

190

Figure B-3. Absorption spectra of 4 in dry CH3CN and 1:1 H2O:DMSO, and 3hydroxyflavone in CH3CN.

191

Figure B-4. Absorption and emission spectra of 4 in dry CH3CN.

192

Figure B-5. Absorption and emission spectra of 4 in 1:1 H2O:DMSO.

193

Figure B-6. 1H NMR spectrum of 5 in CDCl3. The * indicates the residual signal
of the solvent (CHCl3).

194

Figure B-7. a) 1H NMR spectrum of 4 in CD3CN at ambient temperature. b) 1H
NMR spectrum obtained after irradiation of the sample at 419 nm for 24 h. The
results indicate clean conversion to 5.

195

Figure B-8. a) 1H NMR spectrum of 4 in CD3OD at ambient temperature. b) 1H
NMR spectrum obtained after irradiation of the sample at 419 nm for 24 h. The
results indicate conversion to 5. The * indicates the residual signals of the solvent
(CHD2OH).

196

Figure B-9. ESI/APCI-MS of 5.

197

Figure B-10. Emission spectra of 4 and 5 in CH3CN under N2 generated upon
excitation into the lowest energy absorption maximum (4: 409 nm; 5: 323 nm).

198

Figure B-11. Plots of human leukemia (Jurkat) and non-small cell lung
carcinoma (A549) cell viability versus complex concentration for 4 and its
photoinduced reaction product (5). IC50 values were determined using a fourparameter nonlinear regression for assays wherein at least a 50% reduction in
cell viability was observed, in this case only for A549 cells treated with compound
4 (IC50 = 41.5 μM). Values shown represent the average ± SEM of three
independently replicated experiments.
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Figure B-12. Fluorescence microscopy of human lung cancer (A549) cells
treated with compound 4 and then exposed to visible light. Detection of
compound 4 (shown above as green) was performed using Zeiss filter set 38:
excitation λ of 450-490 nm (BP 470/40 filter) and emission λ of 500-550 nm (BP
525/50 filter). Following a 1 hr incubation with compound 4, cells were excited
with visible light for 30 sec, 3 min and 10 min. For localization of the Hoechst
dye, a single fluorescence image was acquired at excitation λ at 365 nm;
emission λ of 420-470nm (BP 445/50 filter), shown in blue above (repeated down
rows for visual comparison). Overlay images indicated that compound 4 was cell
permeable, was present in most cells in the field of view, and was localized
primarily to the cytoplasm. The apparent loss of fluorescence with increasing
length of exposure to visible light suggested photoinduced CO release.
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*

Figure B-13. 1H NMR spectrum of 6 in CDCl3. The * indicates the residual signal
of the solvent (CHCl3).

201

Figure B-14. ESI/APCI-MS of 6.

202

Figure B-15. Absorption and emission spectra of 6 in dry CH3CN.

203

Figure B-16. 1H NMR spectrum of 7 in CDCl3. The * indicates the residual signal
of the solvent (CHCl3).

204

Figure B-17. ESI/APCI-MS of 7.

205

Figure B-18. Absorption and emission spectra of 7 in dry CH3CN.

206

Figure B-19. 1H NMR spectrum of 8 in CDCl3. The * indicates the residual signal
of the solvent (CHCl3).

207

Figure B-20. ESI/APCI-MS of 8.

208

Figure B-21. Absorption and emission spectra of 8 in dry CH3CN.

209

Figure B-22. 1H NMR spectrum of 9 in CDCl3. The * indicates the residual signal
of the solvent (CHCl3).

210

Figure B-23. ESI/APCI-MS of 9.

211

*

Figure B-24. 1H NMR spectrum of 10 in CDCl3. The * indicates the residual
signal of the solvent (CHCl3).

212

Figure B-25. ESI/APCI-MS of 10. The results provide evidence for the oxidized
disulfide form of 10 (see drawing below).

213

Figure B-26. Proposed structure of oxidized disulfide form of 10.

Figure B-27. 1H NMR spectra of 8 demonstrating anaerobic
photoreactivity. a) Aromatic region of the 1H NMR spectrum of 8 in CD3CN.
b) 1H NMR spectrum after 24 h of irradiation ( l

max

> 546 nm) of 8 in

CD3CN under anaerobic conditions. c) 1H NMR spectrum after 24 h of
irradiation ( l

max

> 546 nm) of 8 in CD3CN under aerobic conditions.

214

Figure B-28. ESI/APCI-MS of the reaction mixture produced upon irradiation of 8
in CH3CN (lmax > 546 nm) under anaerobic conditions. The observed ions
suggest an isomerization pathway leading to CO release. Under aerobic
conditions, the m/z 376 is observed, along with an insoluble precipitate.
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CH2Cl2

Figure C-1. 1H NMR of 5 in CD3CN.
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Figure C-2. FT-IR of 5 in KBr.
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Figure C-3. Absorption spectrum of 5 in acetonitrile.

Figure C-4. Overlay of the lowest energy absorption feature of 5 with the
emission spectrum of 5 in acetonitrile.
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Figure C-5. ESI/APCI MS of 5.
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Figure C-8. Absorption spectrum of 6 in acetonitrile.
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Figure C-10. ESI/APCI MS of 6.
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Figure C-11. 1H NMR of 7 in CD3CN.
65

55
50
45
40
-

ClO4

35
30

3900

3400

2900

2400
1900
Wavenumber (cm-1)

Figure C-12. FT-IR of 7 in KBr.

1400

900

400

% Transmittance

60

223

Molar Absorptivity (M-1cm-1)

20000
18000
16000
14000
12000
10000
8000
6000
4000
2000
0
300

400

500
600
Wavelength (nm)

700

800

Figure C-13. Absorption spectrum of 7 in acetonitrile
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Figure C-14. Overlay of the lowest energy absorption feature of 7 with the
emission spectrum in acetonitrile.
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Figure C-15. ESI/APCI MS of 7.
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Figure C-16. 1H NMR of 8 in CD3CN. (* denotes residual solvent)
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Figure C-17. FT-IR of 8 in KBr.
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Figure C-18. Absorption spectrum of 8 in acetonitrile.

Figure C-19. Overlay of the lowest energy absorption feature of 8 with the
emission spectrum in acetonitrile
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Figure C-20. ESI/APCI MS of 8.
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Figure C-21. 1H NMR of 9 in CD3CN.
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Figure C-22. FT-IR of 9 in KBr.
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Figure C-23. ESI/APCI MS of 9.
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Figure C-24. ESI/APCI MS of 9 demonstrating 18O2 incorporation.
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Figure C-25. 1H NMR of 10 in CD3CN. (* denotes residual solvent)
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Figure C-26. FT-IR of 10 in KBr.
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Figure C-27. ESI/APCI MS of 10.
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Figure C-28. 1H NMR of 11 in CD3CN.
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Figure C-29. FT-IR of 11 in KBr.
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Figure C-30. ESI/APCI MS of 11.
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Figure C-32. FT-IR of 12 in KBr.
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Figure C-31. 1H NMR of 12 in CD3CN. (* denotes residual solvent)
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Figure C-33. ESI/APCI MS of 12.
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Figure D-1. 1H NMR of 5 in pyridine-d5 (* indicates solvent peaks).

Figure D-2. FTIR spectrum of 5.
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Figure D-3. Absorption (black) and emission (red) spectra of 5.
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Figure D-4. LIFDI-MS of 5.
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Figure D-5. 1H NMR of 6 in pyridine-d5 (* denotes residual solvent peaks).

Figure D-6. FTIR spectrum of 6.
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Figure D-7. Absorption (black) and emission (red) spectra of 6.
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Figure D-8. LIFDI-MS of 6.
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Figure D-9. 1H NMR of 7 in pyridine-d5 (* denotes residual solvent peaks).

-

Wavenumber (cm
1

)
Figure D-10. FTIR spectrum of 7.
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Figure D-11. Absorption (black) and emission (red) spectra of 7.
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Figure D-12. LIFDI-MS of 7.
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Figure D-13. 1H NMR of 8 in pyridine-d5 (* denotes residual solvent peaks).
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Figure D-14. FTIR spectrum of 8.
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Figure D-15. Absorption (black) and emission (red) spectra of 8.
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Figure D-16. LIFDI-MS of 8.
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Figure D-17. 1H NMR spectrum of 9 in pyridine-d5. (* denotes residual solvent
peaks)
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Figure D-18. FT-IR spectrum of 9.

1000

500

% Tansmittance

100

251

H2
O

Figure D-19. 1H NMR spectrum of 10 in pyridine-d5 (* denotes residual solvent
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Figure D-20. FT-IR spectrum of 10.

%
Transmittance

peaks).

252

νC=

Wavenumber (cm1
)
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Figure D-21. 1H NMR spectrum of 11 in pyridine-d5 (* denotes residual solvent).
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Figure D-24. FT-IR spectrum of 12.
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Figure D-23. 1H NMR spectrum of 12 in pyridine-d5. (* denotes residual solvent)

254

Figure D-25. GC-MS results for the carbonylation reaction of 13a using a film of
5 as the light-induced CO source.
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Figure D-26. GC-MS results for the carbonylation reaction of 13b using a film of
5 as the light-induced CO source.
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Figure D-27. GC-MS results for the carbonylation reaction of 13c using a film of
5 as the light-induced CO source.
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Figure D-28. 1H NMR spectrum of 5 in pyridine-d5 (top). 1H NMR spectrum of
remaining solid following illumination of 5 (film) with two blue CFL bulbs for 24
hours (middle). 1H NMR spectrum of 9 in pyridine-d5 (bottom) (* denotes residual
solvent).
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work as a whole in situ and does not involve the separate exploitation of the
permitted figures or extracts, You may not alter, remove or suppress in any
manner any copyright, trademark or other notices displayed by the Wiley
Materials. You may not license, rent, sell, loan, lease, pledge, offer as security,
transfer or assign the Wiley Materials on a stand-alone basis, or any of the rights
granted to you hereunder to any other person.
The Wiley Materials and all of the intellectual property rights therein shall at all
times remain the exclusive property of John Wiley & Sons Inc, the Wiley
Companies, or their respective licensors, and your interest therein is only that of
having possession of and the right to reproduce the Wiley Materials pursuant to
Section 2 herein during the continuance of this Agreement. You agree that you
own no right, title or interest in or to the Wiley Materials or any of the intellectual
property rights therein. You shall have no rights hereunder other than the license
as provided for above in Section 2. No right, license or interest to any trademark,
trade name, service mark or other branding ("Marks") of WILEY or its licensors is
granted hereunder, and you agree that you shall not assert any such right,
license or interest with respect thereto
NEITHER WILEY NOR ITS LICENSORS MAKES ANY WARRANTY OR
REPRESENTATION OF ANY KIND TO YOU OR ANY THIRD PARTY,
EXPRESS, IMPLIED OR STATUTORY, WITH RESPECT TO THE MATERIALS
OR THE ACCURACY OF ANY INFORMATION CONTAINED IN THE
MATERIALS, INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTY
OF MERCHANTABILITY, ACCURACY, SATISFACTORY QUALITY, FITNESS
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FOR A PARTICULAR PURPOSE, USABILITY, INTEGRATION OR NONINFRINGEMENT AND ALL SUCH WARRANTIES ARE HEREBY EXCLUDED
BY WILEY AND ITS LICENSORS AND WAIVED BY YOU.
WILEY shall have the right to terminate this Agreement immediately upon breach
of this Agreement by you.
You shall indemnify, defend and hold harmless WILEY, its Licensors and their
respective directors, officers, agents and employees, from and against any actual
or threatened claims, demands, causes of action or proceedings arising from any
breach of this Agreement by you.
IN NO EVENT SHALL WILEY OR ITS LICENSORS BE LIABLE TO YOU OR
ANY OTHER PARTY OR ANY OTHER PERSON OR ENTITY FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL, INDIRECT, EXEMPLARY OR
PUNITIVE DAMAGES, HOWEVER CAUSED, ARISING OUT OF OR IN
CONNECTION WITH THE DOWNLOADING, PROVISIONING, VIEWING OR
USE OF THE MATERIALS REGARDLESS OF THE FORM OF ACTION,
WHETHER FOR BREACH OF CONTRACT, BREACH OF WARRANTY, TORT,
NEGLIGENCE, INFRINGEMENT OR OTHERWISE (INCLUDING, WITHOUT
LIMITATION, DAMAGES BASED ON LOSS OF PROFITS, DATA, FILES, USE,
BUSINESS OPPORTUNITY OR CLAIMS OF THIRD PARTIES), AND
WHETHER OR NOT THE PARTY HAS BEEN ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES. THIS LIMITATION SHALL APPLY NOTWITHSTANDING
ANY FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY
PROVIDED HEREIN.
Should any provision of this Agreement be held by a court of competent
jurisdiction to be illegal, invalid, or unenforceable, that provision shall be deemed
amended to achieve as nearly as possible the same economic effect as the
original provision, and the legality, validity and enforceability of the remaining
provisions of this Agreement shall not be affected or impaired thereby.
The failure of either party to enforce any term or condition of this Agreement shall
not constitute a waiver of either party's right to enforce each and every term and
condition of this Agreement. No breach under this agreement shall be deemed
waived or excused by either party unless such waiver or consent is in writing
signed by the party granting such waiver or consent. The waiver by or consent of
a party to a breach of any provision of this Agreement shall not operate or be
construed as a waiver of or consent to any other or subsequent breach by such
other party.
This Agreement may not be assigned (including by operation of law or otherwise)
by you without WILEY's prior written consent.
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Any fee required for this permission shall be non-refundable after thirty (30) days
from receipt by the CCC.
These terms and conditions together with CCC's Billing and Payment terms and
conditions (which are incorporated herein) form the entire agreement between
you and WILEY concerning this licensing transaction and (in the absence of
fraud) supersedes all prior agreements and representations of the parties, oral or
written. This Agreement may not be amended except in writing signed by both
parties. This Agreement shall be binding upon and inure to the benefit of the
parties' successors, legal representatives, and authorized assigns.
In the event of any conflict between your obligations established by these terms
and conditions and those established by CCC's Billing and Payment terms and
conditions, these terms and conditions shall prevail.
WILEY expressly reserves all rights not specifically granted in the combination of
(i) the license details provided by you and accepted in the course of this licensing
transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment
terms and conditions.
This Agreement will be void if the Type of Use, Format, Circulation, or Requestor
Type was misrepresented during the licensing process.
This Agreement shall be governed by and construed in accordance with the laws
of the State of New York, USA, without regards to such state's conflict of law
rules. Any legal action, suit or proceeding arising out of or relating to these Terms
and Conditions or the breach thereof shall be instituted in a court of competent
jurisdiction in New York County in the State of New York in the United States of
America and each party hereby consents and submits to the personal jurisdiction
of such court, waives any objection to venue in such court and consents to
service of process by registered or certified mail, return receipt requested, at the
last known address of such party.
WILEY OPEN ACCESS TERMS AND CONDITIONS
Wiley Publishes Open Access Articles in fully Open Access Journals and in
Subscription journals offering Online Open. Although most of the fully Open
Access journals publish open access articles under the terms of the Creative
Commons Attribution (CC BY) License only, the subscription journals and a few
of the Open Access Journals offer a choice of Creative Commons Licenses. The
license type is clearly identified on the article.
The Creative Commons Attribution License
The Creative Commons Attribution License (CC-BY) allows users to copy,
distribute and transmit an article, adapt the article and make commercial use of
the article. The CC-BY license permits commercial and nonCreative Commons Attribution Non-Commercial License
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The Creative Commons Attribution Non-Commercial (CC-BY-NC)License permits
use, distribution and reproduction in any medium, provided the original work is
properly cited and is not used for commercial purposes.(see below)
Creative Commons Attribution-Non-Commercial-NoDerivs License
The Creative Commons Attribution Non-Commercial-NoDerivs License (CC-BYNC-ND) permits use, distribution and reproduction in any medium, provided the
original work is properly cited, is not used for commercial purposes and no
modifications or adaptations are made. (see below)
Use by commercial "for-profit" organizations
Use of Wiley Open Access articles for commercial, promotional, or marketing
purposes requires further explicit permission from Wiley and will be subject to a
fee.
Further details can be found on Wiley Online Library
http://olabout.wiley.com/WileyCDA/Section/id-410895.html
Other Terms and Conditions:

v1.10 Last updated September 2015
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the
US) or +1-978-646-2777.
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NATURE PUBLISHING GROUP LICENSE
TERMS AND CONDITIONS
Apr 03, 2016
This is an Agreement between Stacey N Anderson ("You") and Nature Publishing
Group ("Nature Publishing Group"). It consists of your order details, the terms
and conditions provided by Nature Publishing Group, and the payment terms and
conditions.
All payments must be made in full to CCC. For payment instructions, please see
information listed at the bottom of this form.
License Number
3817201389217
License date
Feb 27, 2016
Licensed Content Publisher
Nature Publishing Group
Licensed Content Publication
Nature Reviews Drug Discovery
Licensed Content Title
The therapeutic potential of carbon monoxide
Licensed Content Author
Roberto Motterlini and Leo E. Otterbein
Licensed Content Date
Sep 1, 2010
Volume number
9
Issue number
9
Type of Use
reuse in a dissertation / thesis
Requestor type
academic/educational
Format
print and electronic
Portion
figures/tables/illustrations
Number of figures/tables/illustrations
1
High-res required
no
Figures
Table 1
Author of this NPG article
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no
Your reference number
None
Title of your thesis / dissertation
SYNTHESIS, CHARACTERIZATION, AND EVALUATION OF FLAVONOL
COMPOUNDS AS PHOTOINDUCED CARBON MONOXIDE RELEASING
MOLECULES
Expected completion date
Apr 2016
Estimated size (number of pages)
400
Total
0.00 USD
Terms and Conditions
Terms and Conditions for Permissions
Nature Publishing Group hereby grants you a non-exclusive license to reproduce
this material for this purpose, and for no other use,subject to the conditions
below:
NPG warrants that it has, to the best of its knowledge, the rights to license reuse
of this material. However, you should ensure that the material you are requesting
is original to Nature Publishing Group and does not carry the copyright of another
entity (as credited in the published version). If the credit line on any part of the
material you have requested indicates that it was reprinted or adapted by NPG
with permission from another source, then you should also seek permission from
that source to reuse the material.
Permission granted free of charge for material in print is also usually granted for
any electronic version of that work, provided that the material is incidental to the
work as a whole and that the electronic version is essentially equivalent to, or
substitutes for, the print version.Where print permission has been granted for a
fee, separate permission must be obtained for any additional, electronic re-use
(unless, as in the case of a full paper, this has already been accounted for during
your initial request in the calculation of a print run).NB: In all cases, web-based
use of full-text articles must be authorized separately through the 'Use on a Web
Site' option when requesting permission.
Permission granted for a first edition does not apply to second and subsequent
editions and for editions in other languages (except for signatories to the STM
Permissions Guidelines, or where the first edition permission was granted for
free).
Nature Publishing Group's permission must be acknowledged next to the figure,
table or abstract in print. In electronic form, this acknowledgement must be
visible at the same time as the figure/table/abstract, and must be hyperlinked to
the journal's homepage.
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The credit line should read:
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME]
(reference citation), copyright (year of publication)
For AOP papers, the credit line should read:
Reprinted by permission from Macmillan Publishers Ltd: [JOURNAL NAME],
advance online publication, day month year (doi: 10.1038/sj.[JOURNAL
ACRONYM].XXXXX)
Note: For republication from the British Journal of Cancer, the following credit
lines apply.
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer
Research UK: [JOURNAL NAME] (reference citation), copyright (year of
publication)For AOP papers, the credit line should read:
Reprinted by permission from Macmillan Publishers Ltd on behalf of Cancer
Research UK: [JOURNAL NAME], advance online publication, day month year
(doi: 10.1038/sj.[JOURNAL ACRONYM].XXXXX)
Adaptations of single figures do not require NPG approval. However, the
adaptation should be credited as follows:
Adapted by permission from Macmillan Publishers Ltd: [JOURNAL NAME]
(reference citation), copyright (year of publication)
Note: For adaptation from the British Journal of Cancer, the following credit line
applies.
Adapted by permission from Macmillan Publishers Ltd on behalf of Cancer
Research UK: [JOURNAL NAME] (reference citation), copyright (year of
publication)
Translations of 401 words up to a whole article require NPG approval. Please
visit http://www.macmillanmedicalcommunications.com for more
information.Translations of up to a 400 words do not require NPG approval. The
translation should be credited as follows:
Translated by permission from Macmillan Publishers Ltd: [JOURNAL NAME]
(reference citation), copyright (year of publication).
Note: For translation from the British Journal of Cancer, the following credit line
applies.
Translated by permission from Macmillan Publishers Ltd on behalf of Cancer
Research UK: [JOURNAL NAME] (reference citation), copyright (year of
publication)
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We are certain that all parties will benefit from this agreement and wish you the
best in the use of this material. Thank you.
Special Terms:
v1.1
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the
US) or +1-978-646-2777.
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ROYAL SOCIETY OF CHEMISTRY LICENSE
TERMS AND CONDITIONS
Apr 03, 2016
This Agreement between Stacey N Anderson ("You") and Royal Society of
Chemistry ("Royal Society of Chemistry") consists of your license details and the
terms and conditions provided by Royal Society of Chemistry and Copyright
Clearance Center.
License Number
3817200480675
License date
Feb 27, 2016
Licensed Content Publisher
Royal Society of Chemistry
Licensed Content Publication
Natural Product Reports
Licensed Content Title
Structure and catalytic mechanism of heme oxygenase
Licensed Content Author
Masaki Unno,Toshitaka Matsui,Masao Ikeda-Saito
Licensed Content Date
Mar 8, 2007
Licensed Content Volume Number
24
Licensed Content Issue Number
3
Type of Use
Thesis/Dissertation
Requestor type
academic/educational
Portion
figures/tables/images
Number of figures/tables/images
1
Format
print and electronic
Distribution quantity
100
Will you be translating?
no
Order reference number
None
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Title of the thesis/dissertation
SYNTHESIS, CHARACTERIZATION, AND EVALUATION OF FLAVONOL
COMPOUNDS AS PHOTOINDUCED CARBON MONOXIDE RELEASING
MOLECULES
Expected completion date
Apr 2016
Estimated size
400
Requestor Location
Stacey N Anderson
780 E. 275 N. Apt. #3
None
None
LOGAN, UT 84321
United States
Attn: Stacey N Anderson
Billing Type
Invoice
Billing Address
Stacey N Anderson
780 E. 275 N. Apt. #3
None
None
LOGAN, UT 84321
United States
Attn: Stacey N Anderson
Total
0.00 USD
Terms and Conditions
This License Agreement is between {Requestor Name} (“You”) and The Royal
Society of Chemistry (“RSC”) provided by the Copyright Clearance Center
(“CCC”). The license consists of your order details, the terms and conditions
provided by the Royal Society of Chemistry, and the payment terms and
conditions.
RSC / TERMS AND CONDITIONS
INTRODUCTION
The publisher for this copyrighted material is The Royal Society of Chemistry. By
clicking “accept” in connection with completing this licensing transaction, you
agree that the following terms and conditions apply to this transaction (along with
the Billing and Payment terms and conditions established by CCC, at the time
that you opened your RightsLink account and that are available at any time at .
LICENSE GRANTED
The RSC hereby grants you a non-exclusive license to use the aforementioned
material anywhere in the world subject to the terms and conditions indicated
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herein. Reproduction of the material is confined to the purpose and/or media for
which permission is hereby given.
RESERVATION OF RIGHTS
The RSC reserves all rights not specifically granted in the combination of (i) the
license details provided by your and accepted in the course of this licensing
transaction; (ii) these terms and conditions; and (iii) CCC’s Billing and Payment
terms and conditions.
REVOCATION
The RSC reserves the right to revoke this license for any reason, including, but
not limited to, advertising and promotional uses of RSC content, third party
usage, and incorrect source figure attribution.
THIRD-PARTY MATERIAL DISCLAIMER
If part of the material to be used (for example, a figure) has appeared in the RSC
publication with credit to another source, permission must also be sought from
that source. If the other source is another RSC publication these details should
be included in your RightsLink request. If the other source is a third party,
permission must be obtained from the third party. The RSC disclaims any
responsibility for the reproduction you make of items owned by a third party.
PAYMENT OF FEE
If the permission fee for the requested material is waived in this instance, please
be advised that any future requests for the reproduction of RSC materials may
attract a fee.
ACKNOWLEDGEMENT
The reproduction of the licensed material must be accompanied by the following
acknowledgement:
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with
permission of The Royal Society of Chemistry.
If the licensed material is being reproduced from New Journal of Chemistry
(NJC), Photochemical & Photobiological Sciences (PPS) or Physical Chemistry
Chemical Physics (PCCP) you must include one of the following
acknowledgements:
For figures originally published in NJC:
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with
permission of The Royal Society of Chemistry (RSC) on behalf of the European
Society for Photobiology, the European Photochemistry Association and the
RSC.
For figures originally published in PPS:
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with
permission of The Royal Society of Chemistry (RSC) on behalf of the Centre
National de la Recherche Scientifique (CNRS) and the RSC.
For figures originally published in PCCP:
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with
permission of the PCCP Owner Societies.
HYPERTEXT LINKS
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With any material which is being reproduced in electronic form, you must include
a hypertext link to the original RSC article on the RSC’s website. The
recommended form for the hyperlink is http://dx.doi.org/10.1039/DOI suffix, for
example in the link http://dx.doi.org/10.1039/b110420a the DOI suffix is
‘b110420a’. To find the relevant DOI suffix for the RSC article in question, go to
the Journals section of the website and locate the article in the list of papers for
the volume and issue of your specific journal. You will find the DOI suffix quoted
there.
LICENSE CONTINGENT ON PAYMENT
While you may exercise the rights licensed immediately upon issuance of the
license at the end of the licensing process for the transaction, provided that you
have disclosed complete and accurate details of your proposed use, no license is
finally effective unless and until full payment is received from you (by CCC) as
provided in CCC's Billing and Payment terms and conditions. If full payment is
not received on a timely basis, then any license preliminarily granted shall be
deemed automatically revoked and shall be void as if never granted. Further, in
the event that you breach any of these terms and conditions or any of CCC's
Billing and Payment terms and conditions, the license is automatically revoked
and shall be void as if never granted. Use of materials as described in a revoked
license, as well as any use of the materials beyond the scope of an unrevoked
license, may constitute copyright infringement and the RSC reserves the right to
take any and all action to protect its copyright in the materials.
WARRANTIES
The RSC makes no representations or warranties with respect to the licensed
material.
INDEMNITY
You hereby indemnify and agree to hold harmless the RSC and the CCC, and
their respective officers, directors, trustees, employees and agents, from and
against any and all claims arising out of your use of the licensed material other
than as specifically authorized pursuant to this licence.
NO TRANSFER OF LICENSE
This license is personal to you or your publisher and may not be sublicensed,
assigned, or transferred by you to any other person without the RSC's written
permission.
NO AMENDMENT EXCEPT IN WRITING
This license may not be amended except in a writing signed by both parties (or,
in the case of “Other Conditions, v1.2”, by CCC on the RSC's behalf).
OBJECTION TO CONTRARY TERMS
You hereby acknowledge and agree that these terms and conditions, together
with CCC's Billing and Payment terms and conditions (which are incorporated
herein), comprise the entire agreement between you and the RSC (and CCC)
concerning this licensing transaction, to the exclusion of all other terms and
conditions, written or verbal, express or implied (including any terms contained in
any purchase order, acknowledgment, check endorsement or other writing
prepared by you). In the event of any conflict between your obligations
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established by these terms and conditions and those established by CCC's
Billing and Payment terms and conditions, these terms and conditions shall
control.
JURISDICTION
This license transaction shall be governed by and construed in accordance with
the laws of the District of Columbia. You hereby agree to submit to the
jurisdiction of the courts located in the District of Columbia for purposes of
resolving any disputes that may arise in connection with this licensing
transaction.
LIMITED LICENSE
The following terms and conditions apply to specific license types:
Translation
This permission is granted for non-exclusive world English rights only unless your
license was granted for translation rights. If you licensed translation rights you
may only translate this content into the languages you requested. A professional
translator must perform all translations and reproduce the content word for word
preserving the integrity of the article.
Intranet
If the licensed material is being posted on an Intranet, the Intranet is to be
password-protected and made available only to bona fide students or employees
only. All content posted to the Intranet must maintain the copyright information
line on the bottom of each image. You must also fully reference the material and
include a hypertext link as specified above.
Copies of Whole Articles
All copies of whole articles must maintain, if available, the copyright information
line on the bottom of each page.
Other Conditions
v1.2
Gratis licenses (referencing $0 in the Total field) are free. Please retain this
printable license for your reference. No payment is required.
If you would like to pay for this license now, please remit this license along with
yourpayment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise
you will be invoiced within 48 hours of the license date. Payment should be in the
form of a check or money order referencing your account number and this
invoice number {Invoice Number}.
Once you receive your invoice for this order, you may pay your invoice by credit
card.
Please follow instructions provided at that time.
Make Payment To:
Copyright Clearance Center
Dept 001
P.O. Box 843006
Boston, MA 02284-3006
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For suggestions or comments regarding this order, contact Rightslink Customer
Support: customercare@copyright.com or +1-855-239-3415 (toll free in the US)
or +1-978-646-2777.
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the
US) or +1-978-646-2777.
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ROYAL SOCIETY OF CHEMISTRY LICENSE
TERMS AND CONDITIONS
Apr 03, 2016
This Agreement between Stacey N Anderson ("You") and Royal Society of
Chemistry ("Royal Society of Chemistry") consists of your license details and the
terms and conditions provided by Royal Society of Chemistry and Copyright
Clearance Center.
License Number
3816180109842
License date
Feb 25, 2016
Licensed Content Publisher
Royal Society of Chemistry
Licensed Content Publication
Dalton Transactions
Licensed Content Title
Metal carbonyls as pharmaceuticals? [Ru(CO)3Cl(glycinate)], a CO-releasing
molecule with an extensive aqueous solution chemistry
Licensed Content Author
Tony R. Johnson,Brian E. Mann,Ian P. Teasdale,Harry Adams,Roberta
Foresti,Colin J. Green,Roberto Motterlini
Licensed Content Date
Mar 8, 2007
Licensed Content Issue Number
15
Type of Use
Thesis/Dissertation
Requestor type
academic/educational
Portion
figures/tables/images
Number of figures/tables/images
1
Format
print and electronic
Distribution quantity
7
Will you be translating?
no
Order reference number
None
Title of the thesis/dissertation
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SYNTHESIS, CHARACTERIZATION, AND EVALUATION OF FLAVONOL
COMPOUNDS AS PHOTOINDUCED CARBON MONOXIDE RELEASING
MOLECULES
Expected completion date
Apr 2016
Estimated size
400
Requestor Location
Stacey N Anderson
780 E. 275 N. Apt. #3
None
None
LOGAN, UT 84321
United States
Attn: Stacey N Anderson
Billing Type
Invoice
Billing Address
Stacey N Anderson
780 E. 275 N. Apt. #3
None
None
LOGAN, UT 84321
United States
Attn: Stacey N Anderson
Total
0.00 USD
Terms and Conditions
This License Agreement is between {Requestor Name} (“You”) and The Royal
Society of Chemistry (“RSC”) provided by the Copyright Clearance Center
(“CCC”). The license consists of your order details, the terms and conditions
provided by the Royal Society of Chemistry, and the payment terms and
conditions.
RSC / TERMS AND CONDITIONS
INTRODUCTION
The publisher for this copyrighted material is The Royal Society of Chemistry. By
clicking “accept” in connection with completing this licensing transaction, you
agree that the following terms and conditions apply to this transaction (along with
the Billing and Payment terms and conditions established by CCC, at the time
that you opened your RightsLink account and that are available at any time at .
LICENSE GRANTED
The RSC hereby grants you a non-exclusive license to use the aforementioned
material anywhere in the world subject to the terms and conditions indicated
herein. Reproduction of the material is confined to the purpose and/or media for
which permission is hereby given.
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RESERVATION OF RIGHTS
The RSC reserves all rights not specifically granted in the combination of (i) the
license details provided by your and accepted in the course of this licensing
transaction; (ii) these terms and conditions; and (iii) CCC’s Billing and Payment
terms and conditions.
REVOCATION
The RSC reserves the right to revoke this license for any reason, including, but
not limited to, advertising and promotional uses of RSC content, third party
usage, and incorrect source figure attribution.
THIRD-PARTY MATERIAL DISCLAIMER
If part of the material to be used (for example, a figure) has appeared in the RSC
publication with credit to another source, permission must also be sought from
that source. If the other source is another RSC publication these details should
be included in your RightsLink request. If the other source is a third party,
permission must be obtained from the third party. The RSC disclaims any
responsibility for the reproduction you make of items owned by a third party.
PAYMENT OF FEE
If the permission fee for the requested material is waived in this instance, please
be advised that any future requests for the reproduction of RSC materials may
attract a fee.
ACKNOWLEDGEMENT
The reproduction of the licensed material must be accompanied by the following
acknowledgement:
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with
permission of The Royal Society of Chemistry.
If the licensed material is being reproduced from New Journal of Chemistry
(NJC), Photochemical & Photobiological Sciences (PPS) or Physical Chemistry
Chemical Physics (PCCP) you must include one of the following
acknowledgements:
For figures originally published in NJC:
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with
permission of The Royal Society of Chemistry (RSC) on behalf of the European
Society for Photobiology, the European Photochemistry Association and the
RSC.
For figures originally published in PPS:
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with
permission of The Royal Society of Chemistry (RSC) on behalf of the Centre
National de la Recherche Scientifique (CNRS) and the RSC.
For figures originally published in PCCP:
Reproduced (“Adapted” or “in part”) from {Reference Citation} (or Ref XX) with
permission of the PCCP Owner Societies.
HYPERTEXT LINKS
With any material which is being reproduced in electronic form, you must include
a hypertext link to the original RSC article on the RSC’s website. The
recommended form for the hyperlink is http://dx.doi.org/10.1039/DOI suffix, for
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example in the link http://dx.doi.org/10.1039/b110420a the DOI suffix is
‘b110420a’. To find the relevant DOI suffix for the RSC article in question, go to
the Journals section of the website and locate the article in the list of papers for
the volume and issue of your specific journal. You will find the DOI suffix quoted
there.
LICENSE CONTINGENT ON PAYMENT
While you may exercise the rights licensed immediately upon issuance of the
license at the end of the licensing process for the transaction, provided that you
have disclosed complete and accurate details of your proposed use, no license is
finally effective unless and until full payment is received from you (by CCC) as
provided in CCC's Billing and Payment terms and conditions. If full payment is
not received on a timely basis, then any license preliminarily granted shall be
deemed automatically revoked and shall be void as if never granted. Further, in
the event that you breach any of these terms and conditions or any of CCC's
Billing and Payment terms and conditions, the license is automatically revoked
and shall be void as if never granted. Use of materials as described in a revoked
license, as well as any use of the materials beyond the scope of an unrevoked
license, may constitute copyright infringement and the RSC reserves the right to
take any and all action to protect its copyright in the materials.
WARRANTIES
The RSC makes no representations or warranties with respect to the licensed
material.
INDEMNITY
You hereby indemnify and agree to hold harmless the RSC and the CCC, and
their respective officers, directors, trustees, employees and agents, from and
against any and all claims arising out of your use of the licensed material other
than as specifically authorized pursuant to this licence.
NO TRANSFER OF LICENSE
This license is personal to you or your publisher and may not be sublicensed,
assigned, or transferred by you to any other person without the RSC's written
permission.
NO AMENDMENT EXCEPT IN WRITING
This license may not be amended except in a writing signed by both parties (or,
in the case of “Other Conditions, v1.2”, by CCC on the RSC's behalf).
OBJECTION TO CONTRARY TERMS
You hereby acknowledge and agree that these terms and conditions, together
with CCC's Billing and Payment terms and conditions (which are incorporated
herein), comprise the entire agreement between you and the RSC (and CCC)
concerning this licensing transaction, to the exclusion of all other terms and
conditions, written or verbal, express or implied (including any terms contained in
any purchase order, acknowledgment, check endorsement or other writing
prepared by you). In the event of any conflict between your obligations
established by these terms and conditions and those established by CCC's
Billing and Payment terms and conditions, these terms and conditions shall
control.
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JURISDICTION
This license transaction shall be governed by and construed in accordance with
the laws of the District of Columbia. You hereby agree to submit to the
jurisdiction of the courts located in the District of Columbia for purposes of
resolving any disputes that may arise in connection with this licensing
transaction.
LIMITED LICENSE
The following terms and conditions apply to specific license types:
Translation
This permission is granted for non-exclusive world English rights only unless your
license was granted for translation rights. If you licensed translation rights you
may only translate this content into the languages you requested. A professional
translator must perform all translations and reproduce the content word for word
preserving the integrity of the article.
Intranet
If the licensed material is being posted on an Intranet, the Intranet is to be
password-protected and made available only to bona fide students or employees
only. All content posted to the Intranet must maintain the copyright information
line on the bottom of each image. You must also fully reference the material and
include a hypertext link as specified above.
Copies of Whole Articles
All copies of whole articles must maintain, if available, the copyright information
line on the bottom of each page.
Other Conditions
v1.2
Gratis licenses (referencing $0 in the Total field) are free. Please retain this
printable license for your reference. No payment is required.
If you would like to pay for this license now, please remit this license along with
yourpayment made payable to "COPYRIGHT CLEARANCE CENTER" otherwise
you will be invoiced within 48 hours of the license date. Payment should be in the
form of a check or money order referencing your account number and this
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